



LUND UNIVERSITY

Application of chemical oxidation processes for the removal of pharmaceuticals in biologically treated wastewater

Hey, Gerly

2013

[Link to publication](#)

Citation for published version (APA):

Hey, G. (2013). *Application of chemical oxidation processes for the removal of pharmaceuticals in biologically treated wastewater*. [Doctoral Thesis (compilation), Division of Chemical Engineering].

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Application of Chemical Oxidation Processes for the Removal of Pharmaceuticals in Biologically Treated Wastewater



Gerly Hey

Water and Environmental Engineering
Department of Chemical Engineering
Lund University



Application of chemical oxidation processes for the removal of pharmaceuticals in biologically treated wastewater

Gerly Hey



LUND
UNIVERSITY

Water and Environmental Engineering
Department of Chemical Engineering
Lund University, Sweden
2013

Academic thesis which, by due permission of the Faculty of Engineering of Lund University, will be publicly defended on 21 February 2013 at 10:15 am in lecture hall K:G at the Center for Chemistry and Chemical Engineering, Getingevägen 60, Lund, for the degree of Doctor of Philosophy in Engineering. The Faculty opponent is Research Professor (1st Class) Marie-Noëlle Pons, Université de Lorraine, France.



Copyright © Gerly Hey

Water and Environmental Engineering
Department of Chemical Engineering
Lund University, Sweden

ISBN 978-91-7473-453-9

Printed in Sweden by Media-Tryck, Lund University
Lund 2013

Abstract

The discharge of effluents from wastewater treatment plants (WWTPs) is considered to be the major source of residual pharmaceuticals frequently found in aquatic environments. The complex nature of such compounds tends to make conventional biological treatments aimed at their removal ineffective. The present thesis concerns the removal of 62 different active pharmaceutical ingredients commonly detected in Swedish wastewater effluents by means of chemical oxidation techniques. Techniques with potential to be effective are in particular peracetic acid (PAA), chlorine dioxide (ClO_2), ozone (O_3) and a combination of ozone and hydrogen peroxide ($\text{O}_3/\text{H}_2\text{O}_2$), which all were included in this study. The performance of a given treatment was evaluated in terms of the degree of pharmaceutical removal achieved and the oxidant demand of the wastewater. The effects of the characteristics of the wastewater have on the degree of removal efficiency of different pharmaceuticals were also evaluated.

Ozone is considered to be the most efficient chemical oxidant for reducing the concentrations of a large number of different pharmaceuticals, the ozone dose required for this being fairly low (5-10 mg/L), depending upon the characteristics of the effluent. Over 90% of the pharmaceuticals investigated in most of the effluents could be eliminated to 90-100% by use of ozone, while several of the pharmaceuticals being observed to be recalcitrant to chlorine dioxide treatment. The addition of small amounts of hydrogen peroxide during wastewater ozonation, although not enhancing the removal of pharmaceuticals, was found to increase ozone decomposition, presumably resulting in the formation of hydroxyl (OH) radicals as secondary oxidants. The addition of small amounts of H_2O_2 in this way is seen as being advantageous in terms of its reducing both the treatment time and the reaction tank volume which is needed.

Of the various water quality parameters investigated, the organic carbon content was found to have a particularly strong effect on the removal of pharmaceuticals, due to its competitive behavior towards the oxidant. PAA appears to have the lowest degree of pharmaceutical removal, making it not a suitable treatment option for removing pharmaceuticals in the effluents. Although chlorine dioxide and ozone appeared quite similar in their manner of removing pharmaceuticals, both of them reacting with electron-rich functional groups such as those of the phenolic and amino type, some of the pharmaceuticals reacted more slowly with chlorine dioxide than with ozone, given the same reactive substituent and structural similarities. Thus, a decision regarding the possible use of chlorine dioxide for tertiary treatment should take account of how strongly the pollutant or pollutants in question are affected by it. The use of chlorine dioxide appeared to be particularly beneficial when a small-scale WWTP is involved or when treatment is required for only a limited period of time. Although ClO_2 is slightly more expensive to produce than ozone, the preparation system and the reaction chamber

for treatment that are required are far simpler and less expensive to build than those needed for ozone treatment. It was noted that energy costs connected with ozonation are a function both of the ozone demand of the wastewater and the contaminant or contaminants to be removed. It appeared that, in view of the high degree of reactivity of ozone to a broad range of the pharmaceuticals that were investigated, ozonation of secondary effluent is the most suitable alternative for most WWTPs.

Populärvetenskaplig sammanfattning

Den största källan till läkemedelsrester i vattenmiljön är utgående renat avloppsvatten från våra kommunala reningsverk. Läkemedel är utvecklade för att ha olika typer av biologiska effekter. Vilka dessa är i människan är relativt välkänt, medan effekterna på vattenlevande organismer och andra djur till stor del är okända. Detta i kombination med deras resistens mot de kemiska och biologiska nedbrytningsprocesser som pågår i reningsverken gör att de utgör en potentiell risk för miljön eftersom de inte avlägsnas i reningsverken utan följer med utgående vatten till miljön.

I denna avhandling undersöks om läkemedelsrester som finns i renat avloppsvatten från olika typer av avloppsreningsverk i Sverige kan avlägsnas med hjälp av några olika kemiska oxidationsmedel. De som ingick i studien var klordioxid, perättiksyra och ozon. Den senare enskilt och i kombination med väteperoxid. Bland de undersökta läkemedelsresterna ingick antiinflammatoriska, analgetiska, anti epileptiska och antidepressiva preparat, hormonstyrande substanser och betablockerare. Reningseffektiviteten kvantifierades genom hur mycket av läkemedlen som kunde nedbrytas vid en viss dos, definierat som att hur mycket av ursprungssubstansen som försvann. Ska dock noteras att detta inte säger något om hur långt nedbrytningen går, dvs om endast en del av molekylerna förändras eller om omvandling sker ända ned till koldioxid och vatten.

Resultaten av experimenten, som genomfördes som batch experiment i laboratoriet, visade att användning av ozon är det mest effektiva sättet att genom kemisk oxidation bryta ned (>90%) de flesta av de studerade läkemedelsresterna i utgående avloppsvatten. För att uppnå >90% reduktion krävdes en ozon dos på 5 - 10 mg/L. Där dosen både var beroende av vilken substans som studerades och vilken kvalitet som vattnet hade (primärt innehåll av organiskt kol (DOC) och graden av aromatisitet hos detta). Det kunde inte fastställas att en ökad effektivitet kan uppnås genom tillsättning av små mängder väteperoxid tillsammans med ozon. Däremot visades dessa experiment att en sådan tillsättning innebar en ökad reaktionshastighet vilket i sin tur innebär minskad behandlingstid och därmed också minskad volym av reaktionsbehållaren. Något som kan ha stor betydelse vid implementering av tekniken i praktiken.

Användning av klordioxid kan jämföras med ozon då båda reagerar med elektronrika funktionella fenol- och amino grupper. Emellertid visade experimenten att för vissa av de studerade läkemedelsresterna att reaktionen med klordioxid är långsammare än motsvarande reaktion med ozon. Detta betyder att potentialen för användning av klordioxid som behandlingsmetod kommer att bero på vilka läkemedelsrester som är i fokus och på om det kan vara fördelaktigt ut andra aspekter. Här kan nämnas att klordioxidtekniken skulle kunna vara fördelaktig för småskaliga avloppsreningsverk eller vid reningsverk där behandling endast krävs under en begränsad tid. Anledningen är att

anläggningarna för klordioxid är enklare och billigare att bygga både med avseende på klordioxidgeneratoren som reaktionskammaren, jämfört med motsvarande anläggningar för ozonbehandling.

List of publications

- Paper I** Hey, G., Ledin, A., la Cour Jansen, J., Andersen, H.R. 2012. Removal of pharmaceuticals in biologically treated wastewater by chlorine dioxide or peracetic acid. *Environmental Technology* 3(9), 1041-1047.
- Paper II** Hey, G., Grabic, R., Ledin, A., la Cour Jansen, J., Andersen, H.R. 2012. Oxidation of pharmaceuticals by chlorine dioxide in biologically treated wastewater. *Chemical Engineering Journal* 185-186, 236-242.
- Paper III** Antoniou, M.G., Hey, G., Vega, S.R., Spiliotopoulou, A., Fick, J., Tysklind, M., Ledin, A., la Cour Jansen, J., Andersen, H.R. Required ozone doses for removing pharmaceuticals from wastewater effluents. Manuscript.
- Paper IV** Hey, G., Vega, S.R., Fick, J., Tysklind, M., Ledin, A., la Cour Jansen, J., Andersen, H.R. Removal of pharmaceuticals in WWTP effluents by ozone and hydrogen peroxide. Submitted for publication.

My contribution to the publications

- Paper I** I planned the experiment together with my supervisors. I carried out the laboratory work at the Department of Environmental Engineering of the Technical University of Denmark (DTU). I wrote the paper and was provided comments by my supervisors and co-authors. The analysis of pharmaceuticals was performed by the Department of Environmental Engineering of DTU.
- Paper II** I planned the experiment together with my supervisors. I did the laboratory work at the Department of Environmental Engineering of DTU. I wrote the paper, receiving comments from my supervisors and co-authors. The analysis of pharmaceuticals was performed by the Department of Chemistry of Umeå University (UMU).
- Paper III** I helped conducting the experiments at the Department of Environmental Engineering of DTU. I wrote parts of the manuscript. The analysis of pharmaceuticals was performed by the Department of Chemistry of UMU.
- Paper IV** I planned the experiment together with my co-author and supervisor and carried out the laboratory work at the Department of Environmental Engineering of DTU. I wrote the paper and received comments from my supervisors and co-authors. The analysis of pharmaceuticals was performed by the Department of Chemistry of UMU.

Other related publication

Moradas, G. (Now Hey, G.), Auresenia, J., Gallardo, S., Guieysse, B. 2008. Biodegradability and toxicity assessment of trans-chlordane photochemical treatment. *Chemosphere* 73(9), 1512-1517.

Acknowledgements

This PhD studies I carried out were made possible through the help and support of my supervisors, colleagues, research collaborators and industrial contacts. Especially, I would like to express my deep gratitude to the following persons:

My main supervisor, Jes la Cour Jansen for accepting me as a PhD student and for all of the guidance he provided me throughout my PhD studies.

My second supervisors: Anna Ledin for her encouragement and support, especially during the writing of the articles and of my thesis and Henrik Rasmus Andersen for his advice and valuable supervision during my laboratory work at DTU.

Our technical staff, Gertrud Persson and Ylva Persson, for all of their help in the laboratory.

My officemates and colleagues, Per Falås and Maritha Hörsing, for their kindness and for their constructive suggestions and inputs that contributed to my research work.

Our analytical laboratory contacts both at DTU, especially Christina Maj Hagberg (with the supervision of Henrik Rasmus Andersen), and at UMU, especially Roman Grabic and Jerker Fick (with the supervision of Mats Tysklind), for doing the analysis of pharmaceuticals.

The DTU researchers Maria Antoniou, Sergio Rodriguez Vega and Aikaterini Spiliotopoulou for the good times we spent together during the ozone experiments.

The process engineers at Källby WWTP, Sjölunda WWTP, Björnstorp WWTP, Öresundsverket WWTP, Klagshamn WWTP, Nykvarnsverket WWTP, Käppala WWTP, and Uppsala WWTP for the wastewater samples you kindly provided.

The Swedish Foundation for Strategic Environmental Research that through the MistraPharma programme provided financial support of my PhD studies.

To my precious family here in Sweden and in the Philippines for all of the inspiration you have given me.

Contents

| | |
|--|----|
| 1. Introduction | 1 |
| 1.1 Background | 1 |
| 1.2 Hypothesis and objectives | 3 |
| 1.3 Thesis outline | 4 |
| 2. Chemical oxidation for water and wastewater treatment | 5 |
| 3. Methodology | 11 |
| 4. Removal of pharmaceuticals by chemical oxidation | 21 |
| 4.1 Comparison of different chemical oxidants | 21 |
| 4.2 Removal of pharmaceuticals by ozonation: reactivity of the functional groups | 23 |
| 4.3 Effects of the water matrix on the removal of pharmaceuticals by ozonation | 24 |
| 5. Discussions | 29 |
| 6. Conclusions | 31 |
| 7. Suggestions for further work | 33 |
| References | 35 |

1. Introduction

1.1 Background

Pharmaceuticals in the environment

The high standard of living, in highly developed countries in particular, and the increasing availability and affordability of medical treatment in many countries, has led to an increased production and consumption of different classes of pharmaceuticals, both those that require a prescription and those that do not. In recent years, a number of pharmaceuticals have been reported to be potentially toxic substances often found rather widely in the environment (Singh et al., 2011; Albrecht et al., 2012). Hundreds of pharmaceutical substances of differing therapeutic class, together with their metabolic by-products, have been detected in different environmental matrices (Ternes et al., 1998; Kolpin et al., 2002; Kinney et al., 2006; Snyder, 2008; Lubick, 2010; Fick et al., 2010; Al-Odaini et al., 2010; Kassinos et al., 2011; Fram and Belitz, 2011), these threatening the health of many sensitive living organisms including, including humans (Pomati et al., 2006; Filby et al., 2007; Pomati et al., 2008; Schultz et al., 2010; Albrecht, 2012).

The major sources of pharmaceuticals in aquatic environments are discharges of WWTP effluents, the pharmaceuticals these contain stemming mainly from their use in households and in hospitals, and from discharges of wastewater from drug producers (Figure 1.1) (Kolpin et al., 2002; Ternes and Joss (eds), 2006; Wu et al., 2009; Albrecht, 2012). Pharmaceuticals of up to levels of several $\mu\text{g/L}$ have been detected in WWTP effluents globally (Ternes, 1998; Bendz et al., 2005; Batt et al., 2006; Zorita et al., 2009; Zhang and Geissen, 2010; Falås et al., 2012; Lacey et al., 2012). These pharmaceuticals, often referred to as 'emerging pollutants', are not yet regulated in terms of their occurrence in water bodies and wastewater effluents (Bell et al., 2011). It has been proposed by the European Commission, however, that certain pharmaceuticals, such as diclofenac and the hormones ethinyl estradiol (EE2) and estradiol (E2), be regarded as priority substances in terms of the water policies established in accordance with the EU Water Framework Directive (EC, 2012).

Removal of pharmaceuticals during wastewater treatment

The majority of WWTPs in Europe operate with use of physical and biological treatments alone, due to high investment costs associated with the introduction of an additional, more advanced tertiary step (Zorita et al., 2009; Bolong et al., 2009). In Sweden, the introduction of biological wastewater treatment began 60 years ago, and nowadays the majority of the municipal WWTPs operated with use of the following processes: *i*) mechanical treatment, *ii*) biological treatment, *iii*) chemical treatment (mainly for phosphorus removal), and *iv*) filtration as a final step (Swedish EPA Naturvårdsverket Report, 2009; Rudén et al. (eds), 2010). Biological treatment comes in different process configurations involving activated sludge (with and without extended nitrogen removal), biofilm, and a combination of activated sludge and biofilm (Falås et al., 2012). The efficiency of the removal of pharmaceuticals varies, depending upon the treatment process involved. In most cases, use of activated sludge with extended nitrogen removal provides the highest level of efficiency (Falås et al., 2012). The possibilities for operating with extended biological nitrogen removal depends upon the size and location of the plant (Falås et al., 2012). Generally, WWTPs located in the northern part of the country operate without extended nitrogen removal, due to the low temperatures.

A number of studies have confirmed conventional biological methods not being effective enough to provide for the complete removal of residual pharmaceuticals in wastewaters (Ternes and Hirsch, 2000; Kimura et al., 2005; Vieno et al., 2005; Suarez et al., 2008; Hollender et al., 2009), due to the recalcitrance of the pharmaceuticals to biodegradation or to the limited biological activity taking place, especially in cold climates. Accordingly, new treatment approaches aimed at improving the process efficiency of wastewater treatment need to be employed.

The addition of a tertiary step such as chemical oxidation, following secondary biological treatment (Figure 1.1), is a suitable treatment alternative. This additional step can be followed by another process, such as a polishing step, if the effluent quality desired calls for it. The potential of this process for treating organic micropollutants, pharmaceuticals included, that both water generally and wastewaters can contain has been investigated on a worldwide basis. Chemical oxidation following biological treatment has been found to be an appropriate option for eliminating to large extent pharmaceuticals of ecotoxicological concern and reducing the probability of their occurrence in the environment.

The various observations just referred to represent the basis for the major hypothesis of the thesis and its main objectives as presented below.




Figure 1.1 - Sources and flow of pharmaceuticals in a wastewater treatment plant.

1.2 Hypothesis and objectives

The main hypothesis tested in the thesis is the following: *Chemical oxidation is an efficient method for the removal of residual pharmaceuticals in WWTP effluents.* “Efficient” as conceived here is efficiency in decreasing the concentration of the target compounds to an acceptable level, without increasing the costs and the use of other resources (such as energy and various chemicals) for the wastewater treatment, above that can be regarded as acceptable levels. For testing this hypothesis, a number of questions were posed:

1. What oxidation method is the most efficient here?
2. How much of the oxidant is needed to effectively remove the pharmaceuticals?
3. How are the pharmaceuticals removed during chemical oxidation?
4. What factors affect the removal efficiency?

5. Which treatment method is most appropriate under the conditions present, taking into account in particular the climate, the location within the country and the size of the WWTP?

These questions led to the formulation of what is regarded as the major objective:

To develop an appropriate treatment technology for the removal of pharmaceuticals in biologically-treated wastewater by means of chemical oxidation.

In addition, a number of more specific objectives, related to the main objective, were formulated. These include the following:

- to compare the efficiency of several quite promising appearing methods involving use of peracetic acid (PAA), chlorine dioxide (ClO_2) and ozone-based processes (O_3) as oxidants for removing pharmaceuticals,
- to determine the most suitable dose of an oxidant, one resulting in >90% removal of the pharmaceuticals,
- to examine the effects of the chemical structure of the pharmaceuticals on their reactivity towards the oxidants, and
- to assess variations in the removal efficiency of different WWTP effluents in terms of the degree to which they are affected by the wastewater characteristics such as the amount of organic matter they contain, and their alkalinity, UV absorbance and pH.

1.3 Thesis Outline

The present work is based on four papers that are appended to the thesis.

A brief presentation of state-of-the-art within chemical oxidation of waters of various types is presented in Chapter 2, followed by a brief description of the methodologies employed (Chapter 3). The relevant results obtained are presented in the various sections included in Chapter 4 (with reference to the specific papers involved): *i*) Chapter 4.1 – Comparison of different chemical oxidants, *ii*) Chapter 4.2 – Removal of pharmaceuticals by ozonation: reactivity of the functional groups, and *iii*) Chapter 4.3 – Effects of the water matrix on the removal of pharmaceuticals by ozonation. Chapter 5 presents a discussion of the results obtained. The major conclusions are presented in Chapter 6, and what appear to be future research needs in relation to this work are taken up in Chapter 7.

2. Chemical Oxidation for water and wastewater treatment

In recent years, the potential of chemical oxidation for removing organic micropollutants in water and wastewater that cannot be degraded efficiently by conventional biological methods has been widely recognized (Ternes et al., 2003; Buffle et al., 2006; Kosjek et al., 2009; Lee and von Gunten, 2010; Benitez et al., 2011). Oxidation can be an efficient treatment option employing a variety of chemical oxidants, such as chlorine, chlorine dioxide, peracetic acid, ozone, fenton and hydrogen peroxide, its efficiency depending upon the target pollutants, the water matrix and the effluent quality aimed at. Chemical oxidants are known to react preferentially with electron-rich organic functional groups such as aromatic compounds (phenol, aniline, and polycyclic aromatics, for example), organosulfur compounds, and deprotonated amines (Hoigne and Bader, 1994; Huber et al., 2005a; Lee and von Gunten, 2010).

Chlorine has for many years been one of the most commonly used disinfectants for both water and wastewater treatment, due to its strong bactericidal effects and its cost-effectiveness (Aieta et al., 1980; Lee and von Gunten, 2010). Various studies have shown however, that use of chlorine can lead to the formation of chlorinated by-products that can be of concern in terms of public health (Isacson et al., 1985; Pehlivanoglu-Mantas et al., 2006; Watson et al., 2012). Therefore, treatment with chlorine may not be an appropriate option here.

It appears that *chlorine dioxide*, which is comparable to chlorine in its disinfection efficiency, is a better alternative, since it limits the formation of unwanted disinfection by-products (Aieta et al., 1980). ClO_2 can be used either alone or in combination with other oxidants, such as ozone. It has been employed for water disinfection and for oxidation to remove taste- and odor-causing compounds (Danielescu, 2007; EPA). The potential of ClO_2 as an oxidant makes it particularly suitable for the treatment of drinking water, surface water and wastewater for the removal of pharmaceuticals, due to its high reactivity. For example, the anti-inflammatory drug diclofenac, reported as being one of the most frequently detected compounds in water at concentrations of up to the $\mu\text{g/L}$ level (Ternes, 1998), is among the pharmaceuticals completely degraded during drinking and surface water treatment at the lowest ClO_2 dose employed (Huber et al., 2005b). Additional studies have shown the effectiveness of low doses of ClO_2 in removing

pharmaceuticals in wastewater (Andersen et al., 2007; Andersen, 2010; Lee and von Gunten, 2010).

Peracetic acid (PAA) has often been employed for wastewater disinfection due to its high degree of efficiency in the inactivation of disease-causing microorganisms such as bacteria, viruses and spores (Baldry and French, 1989; Gehr et al., 2003; Dell'Erba et al., 2007). Aside from its common use as a disinfectant, PAA can be regarded as a potential oxidant for the removal of pharmaceuticals, due to its strong oxidation potential, which is greater than that of chlorine and of chlorine dioxide (Kitis et al., 2004; Koivunen and Heinonen-Tanski, 2005). In contrast to other oxidants, PAA is not known to produce any harmful by-products in being used to treat water (Erba et al., 2007).

Ozonation is considered to function efficiently in the disinfection and oxidation of pollutants in water. Traditionally, ozone has been used for treating drinking water for disinfection purposes and for the removal of odor and taste. In WWTPs, ozonation has been used as a pretreatment step for biological processes of different types or as a final disinfection step. Ozonation used for post-treatment purposes has been shown to be effective in removing trace organics, including a number of different pharmaceuticals (Ternes et al., 2003; Huber et al., 2005a; Bahr et al., 2007; Hansen et al., 2010). An advantage of the use of ozone is the production of hydroxyl (OH) radicals that occurs through the self-decomposition of ozone, usually at pH values above 7 (Hoigne and Bader, 1981; Klavarioti et al., 2009). OH radicals are known to react non-selectively with a number of organic compounds in water (Lee and von Gunten, 2010). The addition of hydrogen peroxide also catalyzes the decomposition of ozone to produce OH radicals (von Gunten, 2003), termed a peroxone process, which is an advanced oxidation process (AOP). This technique provides non-selective oxidation that leads to an enhancement of the rate of oxidation of O₃-resistant compounds and to a reduction in treatment time (Prado and Esplugas, 1999; Zwiener and Frimmel, 2000; Huber et al., 2003). The efficiency of ozone-based processes has also been confirmed by the high degree of TOC reduction they can achieve (Rosal et al., 2008). In addition, ozone can be employed for wastewater treatment in combination with UV light (O₃/UV, also an AOP) such that at a UV radiation of 254nm ozone decomposes to produce OH radicals. This combined technique leads to such reactions as photolysis, direct ozonation and radical oxidation (Kim and Tanaka, 2010). It has been employed for the removal of various organic compounds in water and wastewater (Chen et al., 2007; Zou and Zhu, 2008; Kim and Tanaka, 2010).

Another method in which hydroxyl radicals play a central role is the combined use of *UV and H₂O₂*, a method found able to remove both naproxen and TOC from wastewater (Felis et al., 2007).

Fenton oxidation, a catalytic process involving the combined use of hydrogen peroxide and ferrous ions (Fe²⁺), is an AOP that has been studied very extensively.

Its use for the removal of organics and improvement in their biodegradability has been tested in different wastewaters (Bautista et al., 2008; Trapido et al., 2009). The main disadvantage in the use of this method, however, is the high costs of the peroxide and of the additional treatment required for removing the iron sludge from the treated water (Bautista et al., 2008). Development of the photo-fenton process, which utilizes either UV or solar light, has resulted in a reduction in the amounts of the waste sludge produced and an increase in the efficiency of treatment (Kim and Vogelpohl, 1998).

UV/TiO₂ heterogeneous photocatalysis, which is also among the most widely studied water treatment processes for the removal of contaminants consisting in part of pharmaceuticals (Dimitroula et al., 2012; Rodriguez et al., 2012) offers the advantage of the photocatalyst (TiO₂) employed being low in cost and being chemically stable. The use of solar radiation as a UV source is recommended however, due to the high costs associated with the use of lamps producing artificial UV (Rodriguez et al., 2012).

Chemical oxidation methods have been tested both in pilot- and in full-scale studies in many different regions around the world (Table 2.1). This work has demonstrated the versatility of the chemical oxidants involved in the treatment of water generally and of wastewater for disinfection and/or for micropollutant oxidation purposes. Ozone's first full-scale application in the treatment of drinking water took place prior to the 1900s in the Netherlands (Langlais et al., 1991). Ozone became popular then as a disinfectant and an oxidant in wastewater treatment. Full-scale applications of chlorine dioxide have been mostly concerned with treatment of drinking water and with wastewater disinfection. Ozone in combination with hydrogen peroxide has also been employed full-scale for groundwater remediation. In addition, advanced oxidation processes involving use of TiO₂, UV and Fenton have been tested for the removal of organic pollutants, mostly on a pilot-scale.

The transformation of micropollutants during oxidation is affected by the nature and characteristics of the wastewater involved, such as the presence of dissolved organic (DOC) and inorganic species, as well as alkalinity and pH, and the reactivity of the oxidant to the target compounds (Lee and von Gunten, 2010). For example, when ozone is applied to wastewater containing a wide range of organic matter, the reactivity of the organic material affects the efficiency of ozone, especially in the case of micropollutant oxidation. Carbonate alkalinity also acts as a scavenger of OH radicals, this affecting the lifetime of ozone in water, such as through its leading to a decrease in the decomposition of ozone as alkalinity increases (Elovitz et al., 2000). Another relevant factor to consider is the pH of the wastewater. Low pH favors reaction with molecular ozone, whereas high pH levels result in an increase in ozone decomposition which favors the formation of OH radicals and allows the degradation of substances less reactive to ozone (von Sonntag and von Gunten, 2012).

Table 2.1 - Examples of oxidation technologies applied in pilot- or full-scale water and wastewater treatment.

| Treatment | Application | Size | Country | Reference |
|------------------|--------------------------------------|-------------|-------------|---|
| Chlorine dioxide | Combined sewer overflow disinfection | Pilot-scale | USA | Geisser et al., 1979 |
| Chlorine dioxide | Groundwater remediation | Pilot-scale | China | Kun et al., 1998 |
| Chlorine dioxide | Drinking water treatment | Full-scale | Israel | Limoni and Teltsch, 1985; Richardson and Thruston, 2003 |
| Chlorine dioxide | Drinking water treatment | Full-scale | USA | Volk et al., 2002 |
| Chlorine dioxide | Drinking water treatment | Full-scale | China | Tao et al., 2004 |
| Chlorine dioxide | Drinking water treatment | Full-scale | Italy | Buschini et al., 2004 |
| Chlorine dioxide | Wastewater disinfection | Pilot-scale | Italy | Veschetti et al., 2005 |
| Ozone | Wastewater disinfection | Full-scale | USA | Rakness and Hegg, 1980; Rakness et al., 1988 |
| Ozone | Drinking water treatment | Full-scale | USA | Escobar and Randall, 2001; Lee et al., 2003 |
| Ozone | Drinking water treatment | Full-scale | Netherlands | Langlais et al., 1991 |
| Ozone | Wastewater pharmaceuticals removal | Pilot-scale | Switzerland | Ternes et al., 2003; Huber et al., 2005a |
| Ozone | Drinking water treatment | Full-scale | Switzerland | Hammes et al., 2006 |
| Ozone | Wastewater pharmaceutical removal | Full-scale | Japan | Nakada et al., 2007 |
| Ozone | Wastewater micropollutant oxidation | Pilot-scale | USA | Wert et al., 2009 |
| Ozone | Municipal wastewater treatment | Pilot-scale | Italy | Ried et al., 2009 |
| Ozone | Wastewater micropollutant oxidation | Full-scale | Switzerland | Hollender et al., 2009 |
| Ozone | Drinking water treatment | Full-scale | Belgium | Audenaert et al., 2010 |

| | | | | |
|--|---|-------------|-------------|-------------------------|
| Ozone | Wastewater disinfection, Micropollutant oxidation | Full-scale | Switzerland | Zimmermann et al., 2011 |
| Ozone | Tertiary treatment of wastewater | Pilot-scale | Austria | Altmann et al., 2012 |
| Ozone/hydrogen peroxide | Groundwater remediation | Pilot-scale | USA | Zappi et al., 1998 |
| Ozone/hydrogen peroxide | Groundwater remediation for removal of organics | Full-scale | Vienna | Werderitsch, 2007 |
| Ozone/hydrogen peroxide | Wastewater pharmaceutical removal | Pilot-scale | Switzerland | Ternes et al., 2003 |
| Ozone/hydrogen peroxide | Drinking water treatment | Pilot-scale | Canada | Irabelli et al., 2008 |
| Ozone, Ozone/hydrogen peroxide | Wastewater pharmaceutical removal | Pilot-scale | Japan | Kim and Tanaka, 2010 |
| Ozone/UV | Wastewater pharmaceutical removal | Pilot-scale | Switzerland | Ternes et al., 2003 |
| Fenton | Groundwater remediation by oxidation | Pilot-scale | USA | Bergendahl et al., 2003 |
| Fenton | Wastewater pharmaceutical removal | Full-scale | Turkey | Tekin et al., 2006 |
| Photo-Fenton | Industrial wastewater treatment | Pilot-scale | Austria | Bauer and Fallman, 1997 |
| Photo-Fenton | Leachate pesticides removal | Pilot-scale | Spain | Navarro et al., 2011 |
| UV/TiO ₂ , Fenton, photo-Fenton | Pesticides treatment in water | Pilot-scale | Spain | Maldonado et al., 2007 |

To summarize, although the use of oxidation methods for the removal of pharmaceuticals appears very promising, the removal and reactivity of a number of pharmaceuticals has not been investigated extensively at all in real wastewater. It is also important to investigate matrix effects on the removal of pharmaceuticals in greater detail, since the proper dosage is dependent upon the characteristics of the water matrix, such information being highly important to evaluating the potential of the methods in question for full-scale implementation.

3. Methodology

Wastewater effluents

The WWTP effluents used in the investigation were taken after secondary treatment from different treatment plants in Sweden, which differ in the quality of the wastewater and the types of biological treatment employed. The WWTP processes are described briefly below.

Description of WWTPs

Källby WWTP in Lund receives what is mainly domestic wastewater from 80,000 inhabitants. The incoming wastewater has annual average concentrations of approximately 180 mg/L BOD₇ and 40 mg/L Total Nitrogen (TN). The wastewater is treated mechanically (screening, grit removal, and sedimentation), followed by a low-loaded activated sludge process operated with pre-denitrification. Side-stream hydrolysis is also performed so as to provide an additional carbon source and thus enhance biological phosphorous removal. Post-precipitation is used as a complementary process when biological phosphorous removal is insufficient. The samples for the present study were taken after the activated sludge process.

Sjölunda WWTP in Malmö receives wastewater from 300,000 inhabitants and from a wide range of industries. The incoming wastewater has annual average concentrations of approximately 220 mg/L BOD₇ and 40 mg/L TN. The wastewater is first treated mechanically (screening, grit removal, and pre-precipitation). The subsequent, high-loaded activated sludge process operates for BOD removal, but there is an anaerobic/anoxic zone at the inlet for denitrification of aerobically-treated or nitrified reject water from the sludge-handling facilities. Nitrification takes place in a subsequent nitrifying trickling filter, this being followed by a moving-bed biofilm reactor (MBBR) for denitrification. Flotation constitutes the final particle separation step. The samples for the present study were taken from the outflow of the high-loaded activated sludge plant.

Öresundsverket WWTP in Helsingborg receives wastewater from 120,000 inhabitants and from various industries. The incoming wastewater has annual average concentrations of approximately 180 mg/L BOD₇ and 30 mg/L TN. The wastewater is first treated mechanically (screening, grit removal, and

sedimentation). The primary sedimentation tanks are operated with primary sludge hydrolysis for the production of a carbon source for enhanced biological phosphorous removal. Nitrogen removal and enhanced biological phosphorous removal take place in a traditional UCT process. No chemicals for phosphorus removal are used at the plant. Biological sand filtration is used as the polishing step. In the present study, samples were taken after the UCT process.

Björnstorp WWTP in Lund is a very small plant that only receives domestic wastewater from about 200 persons. The incoming wastewater is diluted and has annual average concentrations of approximately 70 mg/L BOD₇ and 21 mg/L TN. The wastewater passes through a cutting pump prior to sedimentation in a pre-precipitation process, followed by passage through activated sludge for BOD removal. The treated water is then soil-infiltrated. In the present study, samples were taken following activated sludge treatment.

Nykvarnsverket WWTP in Linköping receives wastewater from about 135,000 inhabitants and from several industries. The incoming wastewater has annual average concentrations of approximately 280 mg/L BOD₇ and 45 mg/L TN. The wastewater is first treated mechanically (screening, grit removal, and pre-precipitation). Passage through a low-loaded activated sludge plant in which nitrification alone takes place follows. Part of the nitrified effluent is diverted into a post-denitrification unit (Moving Bed Biofilm Reactor), in which ethanol is used as the carbon source. Finally all of the wastewater is treated in a post-precipitation plant for final polishing. In the present study, samples were taken after the final post-precipitation stage.

Klagshamn WWTP in Malmö receives wastewater from 70,000 inhabitants. The incoming wastewater, which has annual average concentrations of 130 mg/L BOD₇ and 30 mg/L TN, was treated mechanically. This is followed by a low-loaded activated sludge process which is mainly for BOD removal and nitrification, but can also be operated for partial pre-denitrification. Denitrification takes place mainly in a moving-bed biofilm reactor process that follows the activated sludge treatment, the samples were taken from the MBBR process.

Käppala WWTP in Stockholm receives wastewater from 700,000 inhabitants. The incoming wastewater, which has annual average concentrations of approximately 230 mg/L BOD₇ and 44 mg/L TN is treated mechanically (screening, grit removal, and primary sedimentation), followed by an activated sludge process for nitrogen and enhanced biological phosphorous removal. Sand-filtration is applied as polishing step and subsequent post-precipitation with iron-sulphate as a complementary process in case of insufficient biological phosphorous removal. The samples for the present study were taken after the activated sludge process.

Uppsala (Kungsängsverket) WWTP in Uppsala receives wastewater from 200,000 inhabitants. The incoming wastewater has annual average concentrations of approximately 160 mg/L BOD₇ and 42 mg/L TN. The incoming wastewater is

treated mechanically (screening, grit removal, and primary sedimentation) with subsequent primary precipitation for carbon and phosphorous removal in the primary clarifier. Activated sludge process is applied for nitrogen removal and thereafter sand-filtration as a polishing step. Post-precipitation as a complementary process is applied in case of insufficient phosphorous removal. The samples for the present study were taken after the activated sludge process.

Chemicals

The methanol, acetonitrile, sodium hydroxide and sulfuric acid employed were purchased from Merck (Germany). The hydrogen peroxide solution (30%) was purchased from Sigma-Aldrich. All the pharmaceutical reference standards were purchased from the suppliers as analytical grade (>98%) solids. The stock solutions of the pharmaceuticals were prepared in methanol. Chlorine dioxide was synthesized using hydrochloric acid, sodium chlorite and deionized water (Figure 3.1). The ozone stock solution was prepared according to methods described in Antoniou and Andersen (2011) (Figure 3.2).




Figure 3.1 - ClO₂ (greenish yellow color) produced in the laboratory.




Figure 3.2 - Laboratory set up used in the preparation of ozone stock solution.

Oxidation Experiment

The oxidation of biologically-treated WWTP effluents was carried out using different techniques, such as chlorine dioxide, peracetic acid and ozone-based processes (Table 3.1). The pharmaceuticals selected represent different classes of pharmaceuticals commonly sold and used in Sweden, all of them likely to end up in WWTP effluents due to their low degree of sorption to sludge (Hörsing et al., 2011). The list of the pharmaceuticals investigated and the corresponding oxidation treatment employed is presented in Table 3.2.

PAA and ClO₂ treatment

The effluent samples were prepared in borosilicate glass bottles and were spiked with the pharmaceuticals to the initial concentrations desired. The oxidant (PAA or ClO₂) was then added to the samples at different concentrations. All of the samples were stored in the dark and were allowed to react overnight at room temperature, after which the pH and the oxidant concentrations in the samples were measured. The oxidant consumed by the effluent was followed the whole time and the oxidant remained after treatment was taken note of.

Table 3.1 - Effluent source and treatment(s) applied.

| WWTP | PAA | ClO ₂ | O ₃ | O ₃ /H ₂ O ₂ |
|----------------|-----|------------------|----------------|---|
| Källby | x | x | x | |
| Björnstorp | | | x | |
| Sjölunda | x | x | x | |
| Öresundsverket | | | x | |
| Nykvarnsverket | | | x | |
| Klagshamn | | | x | |
| Käppala | | | x | x |
| Uppsala | | | x | x |

O₃ and O₃/H₂O₂ treatment

The wastewater effluents were spiked with pharmaceuticals and were then transferred into glass bottles to which different volumes of O₃ stock solution were added. The bottles were covered with aluminum foil and were placed for 2 hours in a 15°C water bath. For the O₃ and H₂O₂ experiments that were conducted, the H₂O₂ was added just prior to adding the ozone.

Water quality analysis

Measurements of COD and NH₄⁺-N were conducted by use of Hach Lange test kits. Total suspended solids (SS-EN 872:2005), total P (SS-EN ISO 6878:2005) and total N (SS-EN ISO 11905-1) were analyzed using Swedish standard methods. Alkalinity was measured by titrating 25 ml sample with 0.05 M HCl to a pH of 4.5 and was calculated as mg HCO₃⁻/L. DOC was measured on the basis of wet chemical oxidation, using a Shimadzu TOC-Vwp analyzer. The UV-absorbance at 254 nm was measured using a Varian CARY50 Bio UV-Vis spectrophotometer. The specific UV absorbance (SUVA) was determined by normalizing the UV absorbance at 254 nm to the DOC concentration (Weishaar et al. 2003). The effluent water quality parameters are given in Table 3.3 below. In some of the treatment, 2 samples from the same WWTP were taken at different period (for example in Sjölunda, the samples denoted as 1 and 2).

Table 3.2 - The pharmaceuticals investigated and the treatments employed.

| Pharmaceuticals | PAA | ClO ₂ | O ₃ | O ₃ /H ₂ O ₂ |
|-------------------|-----|------------------|----------------|---|
| Alfuzosin | | x | | x |
| Alprazolam | | x | | x |
| Amitriptyline | | x | x | x |
| Atracurium | | x | x | x |
| Beclomethasone | | x | x | x |
| Bezafibrate | | x | | x |
| Biperiden | | x | x | x |
| Bisoprolol | | x | x | x |
| Budesonide | | x | | x |
| Buprenorphine | | x | | x |
| Bupropion | | x | x | x |
| Carbamazepine | | x | x | x |
| Cilazapril | | x | x | x |
| Ciprofloxacin | | x | | x |
| Citalopram | | x | x | x |
| Clindamycine | | x | | x |
| Clofibric acid | x | x | | |
| Clomipramine | | | x | x |
| Clonazepam | | x | | x |
| Codeine | | x | x | x |
| Cyproheptadine | | x | | x |
| Desloratidine | | x | | x |
| Diclofenac | x | x | x | x |
| Dicycloverin | | x | | x |
| Diltiazem | | x | x | x |
| Diphenhydramine | | x | | x |
| Dipyridamole | | x | | x |
| Eprosartan | | x | x | x |
| Estriol | | x | | x |
| Estrone | | x | | x |
| Ethinyl estradiol | | x | x | x |
| Ezetimibe | | | x | |
| Fexofenadine | | x | x | x |
| Finasteride | | x | | x |
| Fluconazole | | x | x | x |
| Fluoxetine | | x | x | x |
| Flutamide | | x | x | x |
| Glimepiride | | | x | |
| Gemfibrozil | x | x | | x |
| Haloperidol | | x | x | x |
| Hydroxyzine | | | x | x |
| Ibuprofen | x | x | x | x |
| Irbesartan | | x | x | x |
| Ketoprofen | | x | x | x |
| Levonorgestrel | | | x | x |
| Loperamide | | | x | x |

| | | | | |
|------------------|---|---|---|---|
| Maprotiline | | x | x | x |
| Mefenamic acid | x | x | | |
| Memantine | | x | x | x |
| Metoprolol | | x | x | x |
| Mianserin | | x | | x |
| Mirtazapine | | x | | x |
| Naloxone | | x | | x |
| Naproxen | x | x | x | x |
| Orphenadrine | | x | x | x |
| Oxazepam | | | x | x |
| Paroxetine | | x | | x |
| Pizotifen | | x | | x |
| Promethazine | | x | | x |
| Repaglinide | | x | x | x |
| Risperidone | | x | x | x |
| Rosuvastatin | | | x | x |
| Sertraline | | | x | x |
| Sotalol | | x | | x |
| Sulfamethoxazole | | x | x | x |
| Telmisartan | | x | | x |
| Tramadol | | x | x | x |
| Trihexyphenidyl | | x | | x |
| Trimethoprim | | x | x | x |
| Venlafaxine | | x | x | x |
| Verapamil | | | x | |
| Zolpidem | | x | | x |

Analysis of the oxidants: chlorine dioxide, peracetic acid and ozone

The concentration of ClO₂ in each of the samples was quantified on the basis of its reaction with DPD (N,N-diethyl-p-phenylenediamine) using a spectrophotometer with a built-in calibration line for ClO₂ (**Paper I and Paper II**). PAA was also analysed on the basis of its reaction with DPD at a neutral pH value that prevented its oxidation by H₂O₂ in contrast to the normal use of DPD, which is based on its reaction with the oxidants at low pH. PAA was quantified on the basis of the photometric standard curve for total chlorine (Cl₂), the values obtained being recalculated to the PAA concentrations by multiplying by a factor of 1.07, which is based on the relative masses of the two oxidants (**Paper I**).

The O₃ doses delivered were analyzed by use of the colorimetric method of indigo ($\lambda = 600 \text{ nm}$), using a UV spectrophotometer, preparing bottles of indigo trisulfonate solution in Milli-Q water in parallel with the treatment samples (Bader and Hoigne, 1981; Antoniou and Andersen, 2012) (**Paper III and Paper IV**).

Table 3.3 - Quality parameters of the effluent wastewaters studied. (TP = total phosphorus; TN = total nitrogen; Alk = alkalinity as HCO₃⁻; UVA = UV absorbance at 254nm)

| Parameters | pH | COD | TSS | TP | TN | DOC | Alk | NH ₄ ⁺ -N | UVA | SUVA |
|---|-----|--------------------|-----|------|-----|------|-----|---------------------------------|-----------------|--------|
| | | ----- in mg/L----- | | | | | | | m ⁻¹ | L/mg.m |
| WWTP | | | | | | | | | | |
| PAA and ClO ₂ | | | | | | | | | | |
| Källby | 6.7 | 31 | - | - | - | - | - | - | - | - |
| Sjölunda 1 | 7.0 | 49 | - | - | - | - | - | - | - | - |
| Sjölunda 2 | 7.0 | 60 | - | - | - | - | - | - | - | - |
| ClO ₂ | | | | | | | | | | |
| Källby | 6.8 | 35 | 5 | 0.26 | 7.5 | 6.8 | - | - | - | - |
| Sjölunda | 7.2 | 55 | 8 | 0.28 | 8.0 | 9.9 | - | - | - | - |
| O ₃ | | | | | | | | | | |
| Källby 1 | 6.6 | 29 | - | - | - | 7.5 | 244 | 1.36 | - | - |
| Källby 2 | 6.7 | 51 | - | - | - | 6.5 | 154 | 2.98 | - | - |
| Sjölunda | 6.7 | 90 | - | - | - | 13.7 | 256 | 1.86 | - | - |
| Björnstorp | 7.0 | 30 | - | - | - | 5.2 | 185 | 0.77 | - | - |
| Öresundsv | 7.2 | 36 | - | - | - | 8.1 | 229 | 4.93 | - | - |
| Nykvarnsv | 6.8 | 44 | - | - | - | 8.4 | 164 | 5.98 | - | - |
| O ₃ or O ₃ /H ₂ O ₂ | | | | | | | | | | |
| Öresundsv | 7.2 | 42 | - | - | - | 9.2 | 348 | 0.04 | 16.4 | 1.78 |
| Klagshamn | 7.6 | 32 | - | - | - | 9.0 | 427 | 0.29 | 24.8 | 1.78 |
| Uppsala | 6.6 | 18 | - | - | - | 6.9 | 80 | 0.02 | 16.0 | 2.31 |
| Käppala | 6.3 | 35 | - | - | - | 12.5 | 65 | 3.60 | 29.5 | 2.36 |

Analysis of pharmaceuticals

Prior to pharmaceutical analysis, solid-phase extractions (SPE) of the samples were conducted. For the PAA and ClO₂ tests, the samples were filtered through a glass microfiber filter (GFC, Whatman) and were then acidified to pH 3, using a phosphate acid buffer. An internal standard, Mecoprop, was then added. The SPE columns (Oasis® HLB 3 cc/60 mg, Waters) were conditioned serially by use of 5 ml each of methanol, ethyl acetate and acidified water. The samples were extracted at a rate of 2 ml/min. The SPE columns were dried completely by drawing air through the columns for at least 30 min (**Paper I and Paper II**). For O₃ experiments, the frozen samples were sent directly to a laboratory partner for SPE extraction prior to pharmaceutical analysis.

Two different analytical procedures for pharmaceutical analysis were employed. In **Paper I**, the analytical method used was based on Kosjek et al, 2009. After SPE extraction of the samples, analyses were carried out by gas chromatography-mass spectrometry (GC-MS), using an Agilent 5973N Mass Selective Detector. The

pharmaceuticals were quantified based on standard calibration curves, the retention times, the target and qualifier ions, and the qualifier-to-target ratios determined have to be within 20% range.

In **Paper II, Paper III, and Paper IV** the analytical method employed was one based on Grabic et al. (2012). After SPE extraction, LC/MS/MS (liquid chromatography-tandem mass spectrometry) analysis of the extracts was carried out, using a triple-stage quadrupole MS/MS TSQ Quantum Ultra EMR (Thermo Fisher Scientific, San Jose, CA, USA) coupled with an Accela LC pump (Thermo Fisher Scientific, San Jose, CA, USA) and a PAL HTC autosampler (CTC Analytics AG, Zwingen, Switzerland) having a Hypersil GOLD aQTM column (50 mm x 2.1 mm ID x 5 µm particles, Thermo Fisher Scientific, San Jose, CA, USA). Both heated electrospray (HESI) and atmospheric pressure photoionization (APPI) in the positive and the negative ion modes were employed for ionization of the target compounds. The method of analysing the pharmaceuticals employed was also used earlier by Hörsing et al. (2011) and Hey et al. (2012). A detailed description and a full method evaluation of it are presented in Grabic et al. (2012).

4. Removal of pharmaceuticals by chemical oxidation

4.1 Comparison of different chemical oxidants

As presented in Figure 4.1 and in **Paper I, Paper II and Paper III**, the removal of pharmaceuticals in real wastewater effluents can be carried out by employing any of the chemical oxidants, such as peracetic acid, chlorine dioxide or ozone. However, their efficiency was dependent upon the pharmaceutical in question. The selected pharmaceuticals shown in Figure 4.1 are the nonsteroidal anti-inflammatory drugs (NSAID) diclofenac, naproxen and ibuprofen, these are frequently found at high levels in Swedish WWTP effluents (Falås et al., 2012). Figure 4.1 shows the degree of removal of these compounds from the wastewater effluent of Källby WWTP, which has a COD content of around 30 mg/L. In comparing their removal efficiencies, both diclofenac and naproxen were found to show a high degree of removal (>90%) using ClO₂. While at low doses of ClO₂ (between 1 to 4 mg/L), a high degree of diclofenac removal was achieved as compared to O₃ in this effluent. In contrast, ibuprofen did not show any removal using ClO₂ of up to 20 mg/L. A significant improvement in the removal of both naproxen and ibuprofen was observed when they were treated with ozone.




Figure 4.1 - Removal of NSAID pharmaceuticals after treatment with different doses of PAA, ClO₂ and O₃.

Based on these results, it appears that PAA is not an option for removing these pharmaceuticals from the wastewater effluent due to its low reactivity. For some of the pharmaceuticals investigated, however, PAA was found to be an effective oxidant, when high doses are employed (>25 mg/L) (**Paper I**).

Ozone was found in general to be a more efficient oxidant than chlorine dioxide for removing a large number of pharmaceuticals. As shown in Figure 4.2, over 90% of the pharmaceuticals in the effluent that were investigated could be eliminated to up to 90-100% by ozone dose of ~10 mg/L, which is equivalent to 1.3 g O₃/g DOC. The compounds carbamazepine (antiepileptic drug), metoprolol (beta-blocker), irbesartan (angiotensin receptor blocker) and bupropion (antidepressant), which have been shown to be recalcitrant to ClO₂ (**Paper II**), are among those that were eliminated to over 90% by ozone treatment (**Paper III**). With use of ClO₂, about half of the pharmaceuticals investigated could not be removed effectively even when the oxidant dose was increased to 20 mg/L, suggesting there to be only a low degree of reactivity between these compounds and ClO₂ (**Paper II**).




Figure 4.2 - Removal of pharmaceuticals at different ozone doses.

4.2 Removal of pharmaceuticals by ozonation: reactivity of the functional groups

In general, the efficiency of mono- and polyaromatic pharmaceutical removal by chemical oxidation, through ozonation, has been found to be affected by the nature of the compound involved, particularly as concerns the functional groups attached to the aromatic ring. For example, ozone reacts very rapidly with compounds bearing phenolic functions (von Sonntag and von Gunten, 2012). Tertiary amines and C=C functionalities are also known to be ozone-reactive sites (Huber et al., 2005a; Nakada et al., 2007; Hollender et al., 2009). In contrast, for compounds that react slowly with ozone, hydroxyl (OH) radicals can be important for mediating removal mechanisms (von Sonntag and von Gunten, 2012). The outcome of the ozone experiments carried out in the present work (**Paper III**) is considered here in discussing the impact of the chemical structure of the pharmaceuticals involved on the removal efficiencies.

One of the most reactive pharmaceuticals (see Figure 4.2), the calcium channel blocker verapamil (see chemical structure, Figure 4.3), possesses 4 electron-rich methoxy groups on its benzene rings, making it react, very readily with ozone. The tertiary amine function can also be considered as an additional ozone-reactive site. The antidiarrheal drug loperamide was likewise found to react quickly with ozone, this being presumably due to ozone attack on either the amine or the two benzene rings or both. The third benzene ring is deactivated in the presence of the chlorine substituent, in which an ozone attack is unlikely to occur. For carbamazepine, there can also be expected to be a high degree of ozone reactivity, due to its possessing a C=C double bond (Nakada et al., 2007).




Figure 4.3 – Chemical structures of some of the pharmaceuticals investigated.

Electron-withdrawing groups (EWG) reduce the electron density of pharmaceuticals and affect their reactivity towards ozone negatively (von Sonntag and von Gunten, 2012). For example, the antiandrogen drug flutamide has two EWGs, its trifluoromethyl (-CF₃) and its nitro (-NO₂) substituents, these contributing to the extremely low ozone reactivity of this compound. The electron-withdrawing carbonyl group of the nonsteroidal anti-inflammatory drug ketoprofen in conjunction with its two benzene rings can be thought to be the basis for the low ozone reactivity found.

On the basis of the results discussed above, the rates of reaction of ozone with the different pharmaceuticals can vary widely, depending upon the nature of the substituents. For less reactive compounds having no electron-donating functional groups, it has been found that efficient elimination can be achieved by reactions involving hydroxyl radicals (von Sonntag and von Gunten, 2012).

4.3 Effects of the water matrix on the removal of pharmaceuticals by ozonation

Table 4.3 shows the estimated ozone dose necessary to remove to at least 90% some of the most commonly detected pharmaceuticals (together with the therapeutic class to which each of them belongs) in two Swedish WWTP effluents. The pharmaceuticals can be ranked from easily- to poorly-oxidizable based on the ozone dose required. The two effluents involved showed a high degree of variation in terms of DOC and alkalinity content, one with low DOC and low alkalinity levels and one with high DOC and high alkalinity levels. A low COD level reduces the competition for ozone between the pharmaceuticals and the organic components of the water matrix.

Table 4.3 shows clearly that a lesser ozone dose is needed for pharmaceutical removal when the effluent contains relatively low levels of COD and of alkalinity (Effluent 1). As observed in other effluents that were investigated (**Paper III**), however, the alkalinity content did not seem to have any negative effect, as compared with the DOC content, on removal of the pharmaceuticals. This also provides an indication that most of the pharmaceuticals studied were oxidized by ozone directly. In addition, due to the low pH level of the effluents (between pH 6.6 to 7.2), a high degree of production of OH radicals could not be expected; otherwise these could have resulted in the increased removal of ozone-refractory pharmaceuticals. Thus, for ozone-refractory compounds present in these effluents, a much higher ozone dose would be needed for their complete elimination.

Table 4.3 - Estimated ozone dose for 90% removal of pharmaceuticals in the wastewater effluent. (NA = not available)

| | | O ₃ dose, mg/L | |
|--|--------------------|---------------------------|------------|
| | | Effluent 1 | Effluent 2 |
| DOC, mg/L | | 5.2 | 13.7 |
| Alkalinity, mg/L HCO ₃ ⁻ | | 185 | 256 |
| pH | | 7.0 | 6.7 |
| Pharmaceuticals | Class | | |
| Risperidone | antipsychotic | 0.9 | 12.1 |
| Codeine | narcotic analgesic | 2.4 | 9.2 |
| Carbamazepine | antiepileptic | 2.2 | 10.8 |
| Naproxen | NSAID | 2.5 | 10.0 |
| Diclofenac | NSAID | NA | 10.0 |
| Tramadol | narcotic analgesic | 3.4 | 13.0 |
| Citalopram | antidepressant | 2.0 | 15.0 |
| Sertraline | antidepressant | 1.7 | 12.0 |
| Metoprolol | β-blocker | 3.8 | 18.2 |
| Fluoxetine | antidepressant | 3.1 | 20.0 |
| Oxazepam | anxiolytic | 7.1 | 18.4 |
| Ketoprofen | NSAID | 5.5 | 23.9 |
| Ibuprofen | NSAID | 7.3 | 27.0 |

The effects of different pH levels as well as of the addition of H₂O₂ on the ozone lifetime and on the removal of pharmaceuticals were likewise investigated. Two effluents of relatively high pH (pH 8.0) were treated with ozone, whereas two other effluents, of low pH (pH 6.0), were treated with ozone in combination with H₂O₂ (at a H₂O₂/O₃ ratio of 0.10). Treatment was carried out at these pH levels since they correspond to the upper and the lower part of the typical range of pH values found in Swedish WWTP effluents. The effluents also differed in the origin of the potable water and in such chemical characteristics as those of alkalinity, and ammonium ion and organic matter content (**Paper IV**).

As can be expected (Figure 4.4), a rapid decomposition of ozone was observed in both the high pH and the low pH effluents, where small amounts of H₂O₂ were added, indicating an enhanced production of OH radicals to occur. On the other hand, as shown for the two effluents at different pH (Figure 4.5), the degree of removal of pharmaceuticals was higher in the effluent at pH 6.0 (without H₂O₂) than in the one at pH 8.0, especially at low ozone doses. This can be explained on the basis of the low degree of DOC content of the low pH effluent, which results in there being less competition for ozone between the water matrix and pharmaceuticals. In addition, the pH 8.0 effluent has a relatively high level of alkalinity which could increase the scavenging of the OH radicals available for pharmaceutical oxidation. In comparing those effluents (at pH 8.0), the DOC levels of which were about the same, the effect of the specific UV absorbance (SUVA) on the pharmaceutical removal efficiency was found to be significant

(Paper IV). The effluent, for which SUVA content is higher, showed to have poor removal of pharmaceuticals even when the O₃ dose was increased (Paper IV).




Figure 4.4 – Ozone consumption in WWTP effluents at pH 8.0 (O₃ only) and at pH 6.0 (O₃ and O₃/H₂O₂); pH 8.0 effluent: DOC 9.2 mg/L, SUVA 1.8 L/mg·m; pH 6.0 effluent: DOC 6.9 mg/L, SUVA 2.3 L/mg·m.




Figure 4.5 – Comparison of the pharmaceutical removal efficiency of pH 6.0 (right bar) and pH 8.0 (left bar) effluents in response to different levels of ozone dosage (for the pH 6.0 effluent: DOC 6.9 mg/L; for the pH 8.0 effluent: DOC 9.2 mg/L).

The addition of small amounts of H₂O₂ did not have any significant effect on the removal of pharmaceuticals, especially those less reactive to ozone. For certain of the pharmaceuticals- levonorgestrel, sulfamethoxazole and ketoprofen- only a slight increase in removal (<20%) was observed under such conditions (**Paper IV**).

5. Discussions

Of the 3 oxidants investigated, PAA appears to have the lowest efficiency to remove pharmaceuticals, making it not a suitable treatment option (**Paper I**). On the other hand, the oxidation of pharmaceuticals by chlorine dioxide was found to be comparable to the oxidation by molecular ozone, since both of these are selective oxidants, their capability of transforming pharmaceuticals depending upon their reactivity and the characteristics of the effluent (**Paper II and Paper III**). However, even for pharmaceuticals of the same functional group, the reaction between ClO_2 and certain of the pharmaceuticals was much slower than their reaction with ozone. Thus, it appears that ozone is the most efficient chemical oxidant of those that were investigated, its being shown to be capable of removing a large fraction of the pharmaceuticals present in most of the wastewater effluents, doing so at fairly low ozone doses (of 5-10 mg/L), and the size of the fraction removed depending upon the quality of the effluent. In employing ozonation, it is important to investigate the initial ozone demand of the wastewater in question, due to matrix effects (**Paper III and Paper IV**).

Although the addition of H_2O_2 (at a $\text{H}_2\text{O}_2/\text{O}_3$ ratio of 0.08-0.13) to an initial ozone dose of 10 mg/L cannot be expected to have any appreciable impact on pharmaceutical removal, the overall findings suggest that the reaction time can be reduced through combining ozone, at low pH, with small amounts of H_2O_2 , which would clearly be advantageous when the technology is implemented in practice. This allows the size of the reaction tank employed for treatment to be reduced (**Paper IV**).

When chlorine dioxide is employed for tertiary treatment, there can be doubts about its use, due to the inherent toxicity of produced by-products such as chlorite. This can be controlled by minimizing the dose of ClO_2 or by employing a post-treatment step such as using ferrous iron (Fe^{2+}) or sulfite (SO_3^{2-}) (Griese et al., 1991; Katz and Narkis, 2001) (**Paper II**). This method can reduce the ClO_2 and chlorite residuals to chloride, allowing higher levels of ClO_2 to be used for treatment and providing for more effective pharmaceutical removal. The use of ClO_2 in WWTP effluents also depends upon whether the target pharmaceuticals are sensitive to ClO_2 . In addition, running costs need to be taken account of, since ClO_2 is slightly more expensive to produce than ozone, whereas it is much simpler and less expensive to build both the preparation system and the reaction chamber for ClO_2 than those for ozone. Thus, it would appear best for treatment purposes to

make use of ClO_2 mainly in small-scale WWTPs (<2,000 person equivalent) or when treatment is required for only a limited period of time (**Paper II**).

Treatment with ozone requires more energy, such as the energy needed for ozone production, for a destruction unit and for on-site oxygen generation, the installation costs and maintenance costs required also being higher (Hollender et al., 2009). The energy costs can be seen as roughly proportional to the ozone demand of the wastewater and of the contaminant which is to be removed. In fact, according to Hollender et al. (2009), the total energy consumption of a secondary-treated wastewater (~5mg/L DOC) subjected to ozone can be estimated to be around 0.04 kWh/m³ wastewater, equivalent to 12% of the energy required to operate a typical nutrient removal plant. Yet given the high degree of reactivity of ozone to a wide range of pharmaceuticals, the ozonation of a secondary effluent can be seen as probably being the most suitable alternative for most WWTPs while at the same time improving the microbiological quality of the effluent.

During chemical oxidation, the pharmaceuticals are not expected to be fully mineralized, but partly degraded and therefore transformed into so called transformation products. These products may have lower or higher toxicity than the parent compound. As they are expected to be more easily degraded biologically, an additional treatment step such as a polishing step in a biologically active sand filter could be a good option.

6. Conclusions

The following conclusions can be drawn on the basis of the results of the present study:

Of the chemical oxidants investigated, PAA appears to have the lowest potential for pharmaceutical efficient removal, making it not a suitable treatment option for removing pharmaceuticals in the effluents.

The oxidation of pharmaceuticals by chlorine dioxide was found to be comparable to the oxidation by molecular ozone, since both are selective oxidants, their capability of transforming pharmaceuticals depending upon their reactivity and the characteristics of the effluent.

Ozone was found to be the most efficient chemical oxidant for removing most pharmaceuticals commonly found in Swedish wastewater effluents.

Ozone decomposition to OH radicals can be stimulated by the addition of small amounts of hydrogen peroxide at low pH. This reduces the treatment time and, accordingly, the reaction volume needed. Since the addition of hydrogen peroxide has only a limited impact on the removal of pharmaceuticals, it has no appreciable negative effects in terms of reducing the reactor volume needed.

Of the various water quality parameters, the organic carbon content was found to have a particularly strong influence on the removal of pharmaceuticals, due to its competitive behavior towards the oxidant.

The decision of whether to use either chlorine dioxide or ozone can be considered as depending upon the sensitivity of the target compounds to be removed. Chlorine dioxide treatment can be particularly appropriate for small-scale wastewater treatment plants or in cases in which treatment is needed for only a short period of time.

The energy costs associated with ozone treatment are dependent upon the ozone demand of the wastewater (matrix effects) and on the contaminants to be removed. The high level of reactivity of ozone to a wide range of the pharmaceuticals that were investigated suggests that the ozonation of secondary effluents is the most suitable alternative for WWTPs.

7. Suggestions for further work

It would be of interest in future investigations to assess the applicability of ozone to full-scale tertiary treatment for the removal of pharmaceuticals from wastewaters, with the aim of better understanding the impact of ozone oxidation on the quality of the effluent, so as to ensure in so far as possible, the safety of the water that has been treated prior to its discharge. The addition of a polishing step, such as one involving biological filtration, can be employed to reduce the possible toxicity caused by oxidation by-products.

It would be of interest to develop a simple approach to performing a toxicity assay of the treatment as a whole, since it is almost impossible to identify either the types of toxic transformation products that have occurred or oxidation by-products that have been created when the wastewater contains a large number of different micropollutants.

References

- Aieta, E.M., Berg, J.D., Roberts, P.V. and Cooper, R.C., 1980. Comparison of chlorine dioxide and chlorine in wastewater disinfection. *Journal of Water Pollution Control Federation* 52(4), 810-822.
- Albrecht, R.J., 2012. Pharmaceuticals in the environment: Looking to green governance for a remedy. *Journal of Energy and Environmental Law*, 182-203.
- Al-Odaini, N.A., Zakaria, M.P., Yaziz, M.I. and Surif, S., 2010. Multi-residue analytical method for human pharmaceuticals and synthetic hormones in river water and sewage effluents by solid-phase extraction and liquid chromatography–tandem mass spectrometry. *Journal of Chromatography A* 1217(44), 6791-6806.
- Altmann, D., Schaar, H., Bartel, C., Schorkopf, D., Miller, I., Kreuzinger, N., Möstl, E. and Grillitsch, B., 2012. Impact of ozonation on ecotoxicity and endocrine activity of tertiary treated wastewater effluent. *Water Research* 46, 3693-3702.
- Andersen, H.R., Lundsbye, M., Vedel, H.W., Eriksson, E. and Ledin, A., 2007. Estrogenic personal care products in a greywater reuse System. *Water Science and Technology* 56, 45-49.
- Andersen, H.R., 2010. Use of ClO₂ for removal of estrogenic substances in wastewater, Patent WO2010/023311.
- Audenaert, W., Callewaert, M., Nopens, I., Cromphout, J., Vanhoucke, R., Dumoulin, A., Dejans, P. and Hulle, S., 2010. Full-scale modelling of an ozone reactor for drinking water treatment. *Chemical Engineering Journal* 157, 551-557.
- Bader, H. and Hoigne, J., 1981. Determination of ozone in water by the indigo method. *Water Research* 15(4), 449-456.
- Bahr, C., Schumacher, J., Ernst, M., Luck, F., Heinzmann, B. and Jekel, M., 2007. SUVA as control parameter for the effective ozonation of organic pollutants in secondary effluent. *Water Science and Technology* 55(12), 267-274.
- Baldry, M.G.C. and French, M.S., 1989. Disinfection of sewage effluent with peracetic acid. *Water Science and Technology* 21(3), 203-206.
- Batt, A.L., Snow, D.D. and Aga, D.S., 2006. Occurrence of sulfonamide antimicrobials in private water wells in Washington County, Idaho, USA. *Chemosphere* 64, 1963-1971.
- Bauer, R. and Fallmann, H., 1997. The photo-fenton oxidation- A cheap and efficient wastewater treatment method. *Research on Chemical Intermediates* 23(4), 341-354.
- Bautista, P., Mohedano, A.F., Casas, J.A., Zazo, J.A. and Rodriguez, J.J., 2008. Review: An overview of the application of Fenton oxidation to industrial wastewaters treatment. *Journal of Chemical Technology and Biotechnology* 83, 1323-1338.

- Bell, K.Y., Wells, M.J.M., Traexler, K.A., Pellegrin, M.L., Morse, A. and Bandy, J., 2011. Emerging pollutants. *Water Environment Research* 83(10), 1906-1984.
- Bendz, D., Paxéus, N.A., Ginn, T.R. and Loge, F.J., 2005. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Høje River in Sweden. *Journal of Hazardous Materials* 122, 195-204.
- Benitez, F.J., Acero, J.L., Real, F.J., Roldan, G. and Casas, F., 2011. Comparison of different chemical oxidation treatments for the removal of selected pharmaceuticals in water matrices, *Chemical Engineering Journal* 168, 1149-1156.
- Bergendahl, J., Hubbard, S. and Grasso, D., 2003. Pilot-scale Fenton's oxidation of organic contaminants in groundwater using autochthonous iron. *Journal of Hazardous Materials B99*, 43-56.
- Bolong, N., Ismail, A.F., Salim, M.R. and Matsuura, T., 2009. A review of the effects of emerging contaminants in wastewater and options for their removal. *Desalination* 239, 229-246.
- Buffle, M.O., Schumacher, J., Salhi, E., Jekel, M. and Von Gunten, U., 2006. Measurement of the initial phase of ozone decomposition in water and wastewater by means of a continuous quench-flow system: Application to disinfection and pharmaceutical oxidation. *Water Research* 40(9), 1884-1894.
- Buschini, A., Carboni, P., Frigeriol, S., Furlini, M., Marabini, L., Monarca, S., Poli, P., Radicel, S. And Rossi, C., 2004. Genotoxicity and cytotoxicity assessment in lake drinking water produced in a treatment plant. *Mutagenesis* 19(5), 341-347.
- Danielescu, D.C. and Bogatu, C., 2007. The use of chlorine dioxide for organic compounds oxidation and prevention of THM formation in surface waters. Conference Proceedings: The IX Internation Symposium "Young People and Multidisciplinary Research" *Annals of West University of Timisoara Series of Chemistry* 16(4), 113-118.
- EC (European Commission), 2012. Proposal for a Directive of the European Parliament and the Council, amending Directives 2000/60/EC and 2008/105/EC as regards priority substances in the field of water policy (Com (2011) 876).
- Dell'Erba, A., Falsanisi, D., Liberti, L., Notarnicola, M. and Santoro, D. 2007. Disinfection by-products formation during wastewater disinfection with peracetic acid. *Desalination* 215, 177-186.
- Dimitroula, H., Daskalaki, V., Frontistis, Z., Kondarides, D., Panagiotopoulou, P., Xekoukoulotakis, N. and Mantzavinos, D., 2012. Solar photocatalysis for the abatement of emerging micro-contaminants in wastewater: Synthesis, characterization and testing of various TiO₂ samples. *Applied Catalysis B: Environmental* 117- 118, 283- 291.
- Elovitz, M., von Gunten, U. and Kaiser, H.P., 2000. Hydroxyl radicals/ozone ratios during ozonation processes. II. The effect of temperature, pH, alkalinity, and DOM properties. *Ozone Science and Engineering* 22, 123-150.
- Escobar, I. and Randall, A., 2001. Case study: ozonation and distribution biostability. *American Water Works Association* 93(10), 77-89.
- Falås, P., Andersen, H.R., Ledin, A. and la Cour Jansen, J., 2012. Occurrence and reduction of pharmaceuticals in the water phase at Swedish wastewater treatment plants. *Water Science and Technology* 66(4), 783-791.

- Fatta-Kassinos, D., Meric, S. and Nikolaou, A., 2011. Review: Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research. *Analytical and Bioanalytical Chemistry* 399, 251-275.
- Felis, E., Marciocha, D., Sumacz-Gorska, J. And Miksch, K., 2007. Photochemical degradation of naproxen in the aquatic environment. *Water Science and Technology* 55(12), 281-286.
- Fick, J., Lindberg, R.H., Tysklind, M. and Larsson, D.G., 2010. Predicted critical environmental concentrations for 500 pharmaceuticals. *Regulatory toxicology and pharmacology: RTP* 58(3), 516-523.
- Filby, A., Neuparth, T., Thorpe, K., Owen, R., Galloway, S. and Tyler, C., 2007. Health impacts of estrogens in the environment, considering complex mixture effects. *Environmental Health Perspectives* 115(12), 1704-1710.
- Fram, M.S. and Belitz, K., 2011. Occurrence and concentrations of pharmaceutical compounds in groundwater used for public drinking-water supply in California. *Science of the Total Environment* 409, 3409-3417.
- Gehr, R., Wagner, M., Veerasubramanian, P. and Payment, P., 2003. Disinfection efficiency of peracetic acid, UV and ozone after enhanced primary treatment of municipal wastewater. *Water Research* 37, 4573-4586.
- Geisser, D.F., Garver, S.R. and Murphy, C.B., 1979. Design optimization of high-rate disinfection using chlorine and chlorine dioxide. *Water Control Federation* 51(2), 351-357.
- Grabic, R., Fick, J., Lindberg, R.H., Fedorova, G. and Tysklind, M., 2012. Multi-residue method for trace level determination of pharmaceuticals in environmental samples using liquid chromatography coupled to triple quadrupole mass spectrometry. *Talanta* 100, 183-195.
- Griese, M.H., Hauser, K., Berkemeier, M. and Gordon, G., 1991. Using reducing agents to eliminate chlorine dioxide and chlorite ion residuals in drinking water. *Journal of American Water Works Association* 83(5), 56-61.
- Hammes, F., Salhi, E., Köster, O., Kaiser, H.P., Egli, T. and von Gunten, U., 2006. Mechanistic and kinetic evaluation of organic disinfection by-product and assimilable organic carbon (AOC) formation during the ozonation of drinking water. *Water Research* 40, 2275-2286.
- Hansen, K.M.S., Andersen, H.R. and Ledin, A., 2010. Ozonation of estrogenic chemicals in biologically treated sewage. *Water Science and Technology* 62(3), 649-657.
- Hey, G., Grabic, R., Ledin, A., la Cour Jansen, J. and Andersen, H.R., 2012. Oxidation of pharmaceuticals by chlorine dioxide in biologically treated wastewater. *Chemical Engineering Journal* 185-186, 236-242.
- Hoigné, J. and Bader, H., 1994. Kinetics of reaction of chlorine dioxide (OCIO) in water – i. rate constants for inorganic and organic compounds. *Water Research* 28(1), 45-55.
- Hollender, J., Zimmermann, S.G., Koepke, S., Krauss, M., McArdell, C.S., Ort, C., Singer, H., von Gunten, U. and Siegrist, H., 2009. Elimination of organic micropollutants in a municipal wastewater treatment plant upgraded with a full-scale post-ozonation followed by sand filtration. *Environmental Science and Technology* 43(20), 7862-7869.

- Huber, M.M., Canonica, S., Park, G.Y. and von Gunten, U., 2003. Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. *Environmental Science and Technology* 37(5), 1016-1024.
- Huber, M. M., Göbel, A., Joss, A., Hermann, N., Löffler, D., Mcardell, C.S., Ried, A., Siegrist, H., Ternes, T. A. and von Gunten, U., 2005a. Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: a pilot study. *Environmental Science and Technology* 39, 4290-4299.
- Huber, M.M., Korhonen, S., Ternes, T.A. and von Gunten, U., 2005b. Oxidation of pharmaceuticals during water treatment with chlorine dioxide. *Water Research* 39, 3607-3617.
- Hörsing, M., Ledin, A., Grabic, R., Fick, J., Tysklind, M., la Cour Jansen, J. and Andersen, H.R., 2011. Determination of sorption of seventy-five pharmaceuticals in sewage sludge. *Water Research* 45, 4470-4482.
- Irabelli, A., Jasim, S. and Biswas, N., 2008. Pilot-scale evaluation of ozone vs. peroxone for trihalomethane formation. *Ozone: Science & Engineering* 30(5), 356-366.
- Isacson, P., Bean, J., Splinter, R., Olson, D. and Kohler, J., 1985. Drinking water and cancer incidence in Iowa III. Association of cancer with indices of contamination. *American Journal of Epidemiology* 121(6), 856-869
- Katz, A. and Narkis, N., 2001. Removal of chlorine dioxide disinfection by-products by ferrous salts. *Water Research* 35(1), 101-108.
- Kim, S.M. and Vogelpohl, A., 1998. Degradation of organic pollutants by the photo-fenton process. *Chemical Engineering and Technology* 21, 187-191.
- Kim, I. and Tanaka, H., 2010. Use of ozone-based processes for the removal of pharmaceuticals detected in a wastewater treatment plant. *Water Environment Research* 82(4), 294-301.
- Kimura, K., Hara, H. and Watanabe, Y., 2005. Removal of pharmaceutical compounds by submerged membrane bioreactors (MBRs). *Desalination* 178, 135-140.
- Kinney, C., Furlong, E., Zaugg, S., Burkhardt., Werner, S., Cahill, J. and Jorgensen, G., 2006. Survey of organic wastewater contaminants in biosolids destined for land application. *Environmental Science and Technology* 40(23), 7207-7215.
- Kitis, M., 2004. Disinfection of wastewater with peracetic acid: a review. *Environment International* 30, 47-55.
- Klavarioti, M., Mantzavinos, D. and Kassinos, D., 2009. Removal of residual pharmaceuticals from aqueous systems by advanced oxidation processes. *Environment International* 35, 402-417.
- Koivunen, J. and Heinonen-Tanski, H., 2005. Peracetic acid (PAA) disinfection of primary, secondary and tertiary treated municipal wastewaters. *Water Research* 39, 4445-4453.
- Kolpin, D.W., Furlong, E.T., Meyer, M.T., Thurman, E.M., Zaugg, S.D., Barber, L.B. and Buxton, H.T., 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. *Environmental Science and Technology* 36, 1202-1211.
- Kosjek, T., Andersen, H.R., Kompare, B., Ledin, A. and Heath, E., 2009. Fate of carbamazepine during water treatment. *Environmental Science and Technology* 43, 6256-6261.

- Kun, Z., Hui, C., Guanghe, L. and Zhaochang, L., 1998. In situ remediation of petroleum compounds in groundwater aquifer with chlorine dioxide. *Water Research* 32(5), 1471-1480.
- Lacey, C., Basha, S., Morrissey, A. and Tobin, J.M., 2012. Occurrence of pharmaceutical compounds in wastewater process streams in Dublin, Ireland. *Environmental Monitoring and Assessment* 184, 1049-1062.
- Langlais, B., Reckhow, D.A. and Brink, D.R. (eds), 1991. *Ozone in water treatment: application and engineering* (1st ed.). American Water Works Association Research Foundation, ISBN 0-87371-474-1.
- Lee, J.Y. and Deiniger, R.A., 2003. Microbial responses after disinfectant change to ozone in a full-scale distribution system. *Ozone: Science and Engineering* 25(6), 473-484.
- Lee, Y. and von Gunten, U., 2010. Oxidative transformation of micropollutants during municipal wastewater treatment: comparison of kinetic aspects of selective (chlorine, chlorine dioxide, ferrate VI, and ozone) and non-selective oxidants (hydroxyl radical). *Water Research* 44, 555-566.
- Limoni, B. and Telsch, B., 1985. Chlorine dioxide disinfection of drinking water- an evaluation of a treatment plant. *Water Research* 19(12), 1489-1495.
- Lubick, N., 2010. Drugs in the environment: Do pharmaceutical take-back programs make a difference? *Environmental Health Perspectives* 118(5), 210-214. <http://dx.doi.org/10.1289/ehp.118-a210>.
- Maldonado, M.I., Pasarinho, P.C., Oller, I., Gernjak, W., Fernandez, P., Blanco, J. and Malato, S., 2007. Photocatalytic degradation of EU priority substances: A comparison between TiO₂ and Fenton plus photo-Fenton in a solar pilot plant. *Journal of Photochemistry and Photobiology A: Chemistry* 185, 354-363.
- Nakada, N., Shinohara, H., Murata, A., Kiri, K., Managaki, S., Sato, N. and Takada, H., 2007. Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. *Water Research* 41, 4373-4382.
- Navarro, S., Fenoll, J., Vela, N., Ruiz, E. and Navarro, G., 2011. Removal of ten pesticides from leaching water at pilot plant scale by photo-Fenton treatment. *Chemical Engineering Journal* 167, 42-49.
- Pehlivanoglu-Mantas, E., Hawley, E.L., Deeb, R.A. and Sedlak, D.L., 2006. Formation of nitrosodimethylamine (NDMA) during chlorine disinfection of wastewater effluents prior to use in irrigation systems. *Water Research* 40(2), 341-347.
- Pomati, F., Castiglioni, S., Zuccatto, E., Fanelli, R., Vigetti, D., Rosetti, C. and Calamari, D., 2006. Effects of a Complex Mixture of Therapeutic Drugs at Environmental Levels on Human Embryonic Cells. *Environmental Science and Technology* 40(7), 2442-2447.
- Pomati, F., Orlandi, C., Clerici, M., Luciani, F. and Zuccato, E., 2008. Effects and interactions in an environmentally relevant mixture of pharmaceuticals. *Toxicological Sciences* 102(1), 129-137.
- Prado, J. and Esplugas, S., 1999. Comparison of different advanced oxidation processes involving ozone to eliminate atrazine. *Ozone: Science and Engineering* 21, 39-52.

- Rakness, K. and Hegg, B., 1980. Full-Scale Ozone Disinfection of Wastewater. *Water Pollution Control Federation* 52(3), 502-511.
- Richardson, S. and Thruston, A., 2003. Tribromopyrrole, brominated acids, and other disinfection byproducts produced by disinfection of drinking water rich in bromated. *Environmental Science and Technology* 37, 3782-3793.
- Ried, A., Mielcke, J. and Wieland, A., 2009. The potential use of ozone in municipal wastewater. *Ozone: Science & Engineering* 31, 415-421.
- Rodriguez, L.P., Miralles-Cuevas, S., Oller, I., Agüera, A., Puma, G. and Malato, S., 2012. Treatment of emerging contaminants in wastewater treatment plants (WWTP) effluents by solar photocatalysis using low TiO₂ concentrations. *Journal of Hazardous Materials* 211–212, 131–137.
- Rosal, R., Rodriguez, A., Perdigon-Melon, J.A., Mezcua, M., Hernando, M.D., Leton, P., Garcia-Calvo, E., Agüera, A. and Fernandez-Alba, A.R., 2008. Removal of pharmaceuticals and kinetics of mineralization by O₃/H₂O₂ in a biotreated municipal wastewater. *Water Research* 42, 3719-3728.
- Rudén, C., Liljelund, K. and Hagerman, H. (eds), 2010. Towards sustainable pharmaceuticals in a healthy society. *Mistrapharma*.
- Schultz, M., Furlong, E., Kolpin, D., Werner, S., Schoenfuss, H., Barber, L., Blazer, V., Norris, D. and Vajda, A., 2010. Antidepressant pharmaceuticals in two U.S. effluent-impacted streams: Occurrence and fate in water and sediment, and selective uptake in fish neural tissue. *Environmental Science and Technology* 44(6), 1918-1925.
- Singh, P., Rani, B. and Maheshwari, R., 2011. Pharmaceutical pollution: A short communication. *International Journal of Pharmacy and Biological Sciences (ISSN: 2230-7605)* 1 (2), 26-30. Available online through www.ijbps.com.
- Snyder, S.A., 2008. Occurrence, treatment, and toxicological relevance of EDCs and pharmaceuticals in water. *Ozone: Science and Engineering* 30, 65-69.
- Suarez, S., Carballa, M., Omil, F. and Lema, J., 2008. How are pharmaceutical and personal care products (PPCPs) removed from urban wastewaters? *Reviews in Environmental Science and Biotechnology* 7, 125-138.
- Swedish EPA, 2009. Swedish EPA Naturvårdsverket Report. ISBN: 978-91-620-8416-5.
- Tao, L., Fu-yi, C., Dong-mei, L. and Don, A., 2004. Full-scale study of removal effect on cyclops of zooplankton with chlorine dioxide. *Journal of Environmental Sciences* 16(5), 746-750.
- Tekin, H., Bilkay, O., Ataberk, S., Baltacı, T., Cerbasi, I.H., Sanin, D., Dilek, F. and Yetis, U., 2006. Use of Fenton oxidation to improve the biodegradability of a pharmaceutical wastewater. *Journal of Hazardous Materials B136*, 258-265.
- Ternes, T.A., 1998. Occurrence of drugs in German sewage treatment plants and rivers. *Water Research* 32, 3245-3260.
- Ternes, T.A. and Hirsch, R., 2000. Occurrence and behavior of x-ray contrast media in sewage facilities and the aquatic environment. *Environmental Science and Technology* 34, 2741-2748.
- Ternes, T.A., Stuber, J., Herrmann, N., McDowell, D., Ried, A., Kampmann, M. and Teiser, B., 2003. Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater? *Water Research* 37, 1976-1982.

- Ternes, T.A. and Joss, A. (eds), 2006. Human pharmaceuticals, hormones and fragrances: The challenge of micropollutants in urban water management. IWA Publishing, London.
- Trapido, M., Kulik, N., Goi, A., Veressinina, Y. and Muntern, R., 2009. Fenton treatment efficacy for the purification of different kinds of wastewater. *Water Science and Technology* 60(7), 1795-1801.
- USEPA, 1999. Alternative disinfectants and oxidants guidance manual. EPA 815-R-99-014.
- Veschetti, E., Cittadini, B., Maresca, D., Citti, G. and Ottavini, M., 2005. Inorganic by-products in waters disinfected with chlorine dioxide. *Microchemical Journal* 79, 165-170.
- Vieno, N.M. Tuhkanen, T. and Kronberg, L., 2005. Seasonal variation in the occurrence of pharmaceuticals in effluents from a sewage treatment plant and in the recipient water. *Environmental Science and Technology* 39, 8220-8226.
- Volk, C.J., Hofmann, R., Chauvet, C., Gagnon, G.A., Ranger, G. and Andrews, R.C., 2002. Implementation of chlorine dioxide disinfection: effects of the treatment change on drinking water quality in a full-scale distribution system. *Journal of Environmental Engineering and Science* 1, 323-330.
- Von Gunten, U., 2003. Ozonation of drinking water: Part I. Oxidation kinetics and product formation. *Water Research* 37, 1443-1467.
- Von Sonntag, C. and von Gunten, U., 2012. Chemistry of ozone in water and wastewater treatment. IWA Publishing, UK.
- Watson, K., Shaw, G., Leusch, F.D.L. and Knight, N.L., 2012. Chlorine disinfection by-products in wastewater effluent: Bioassay-based assessment of toxicological impact. *Water Research* 46(18), 6069-6083.
- Wert, E., Rosario-Ortiz, F. and Snyder, S., 2009. Effect of ozone exposure on the oxidation of trace organic contaminants in wastewater. *Water Research* 43, 1005-1014.
- Werderitsch, M., Personal Communication. First full scale advanced oxidation treatment plant for groundwater in Austria. Article is published in *Water Practice and Technology*.
- Wu, M., Atchley, D., Greer, L., Janssen, S., Rosenberg, D. and Sass, J., 2009. Dosed without prescription: Preventing pharmaceutical contamination of our nation's drinking water. Natural Resources Defense Council White Paper, 60 pages.
- Zappi, M., Fleming, E.C., Miller, T., Ragan, F., Swindle, R., Morgan, R. and Harvey, S., 1998. A pilot-scale assessment of peroxone oxidation for potential treatment of three contaminated groundwaters at the Rocky Mountain Arsenal, Commerce City, Colorado. Strategic Environmental Research and Development Program (SERDP). Technical Report.
- Zhao, J.L., Ying, G.G., Liu, Y.S., Chen, F., Yang, J.F., Wang, L., Yang, X.B., Stauber, J.L. and Warne, M.S.J., 2010. Occurrence and a Screening-Level Risk Assessment of Human Pharmaceuticals in the Pearl River System, South China. *Environmental Toxicology and Chemistry* 29(6), 1377-1384.
- Zhang, Y. and Geissen, S.U., 2010. Prediction of carbamazepine in sewage treatment plant effluents and its implications for control strategies of pharmaceutical aquatic contamination. *Chemosphere* 80, 1345-1352.

- Zimmermann, S.G., Wittenwiler, M., Hollender, J., Krauss, M., Ort, C., Siegrist, H. and von Gunten, U., 2011. Kinetic assessment and modeling of an ozonation step for full-scale municipal wastewater treatment: Micropollutant oxidation, by-product formation and disinfection. *Water Research* 45(2), 605-617.
- Zorita, S., Martensson, L. and Matthiasson, L., 2009. Occurrence and removal of pharmaceuticals in a municipal sewage treatment system in the south of Sweden. *Science of the Total Environment* 407, 2760-2770.
- Zou, L. and Zhu, B., 2008. The synergistic effect of ozonation and photocatalysis on color removal from reused water. *Journal of Photochemistry and Photobiology A: Chemistry* 196, 24-32.
- Zwiener, C. and Frimmel, F.H., 2000. Oxidative treatment of pharmaceuticals in water. *Water Research* 34(6), 1881-1885.

Paper I

Removal of pharmaceuticals in biologically treated wastewater by chlorine dioxide or peracetic acid

G. Hey^{a*}, A. Ledin^b, J. la Cour Jansen^a and H.R. Andersen^b

^aWater and Environmental Engineering at Department of Chemical Engineering, Lund University, P.O. Box 124, 221 00 Lund, Sweden;

^bDepartment of Environmental Engineering, Technical University of Denmark, Miljøvej, Building 113, 2800 Kongens Lyngby, Denmark

(Received 14 April 2011; final version received 14 July 2011)

Removal of six active pharmaceutical ingredients in wastewater was investigated using chlorine dioxide (ClO₂) or peracetic acid (PAA) as chemical oxidants. Four non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac and mefenamic acid) and two lipid-regulating agents (gemfibrozil and clofibrac acid, a metabolite of clofibrate) were used as target substances at 40 µg/L initial concentration. Three different wastewaters types originating from two wastewater treatment plants (WWTPs) were used. One wastewater was collected after extended nitrogen removal in activated sludge, one after treatment with high-loaded activated sludge without nitrification, and one from the final effluent from the same plant where nitrogen removal was made in trickling filters for nitrification and moving-bed biofilm reactors for denitrification following the high-loaded plant. Of the six investigated compounds, only clofibrac acid and ibuprofen were not removed when treated with ClO₂ up to 20 mg/L. With increasing PAA dose up to 50 mg/L, significant removal of most of the pharmaceuticals was observed except for the wastewater with the highest chemical oxygen demand (COD). This indicates that chemical oxidation with ClO₂ could be used for tertiary treatment at WWTPs for active pharmaceutical ingredients, whereas PAA was not sufficiently efficient.

Keywords: pharmaceuticals; chlorine dioxide; peracetic acid; wastewater effluent

Introduction

The presence of active pharmaceutical ingredients (APIs) in effluents from wastewater treatment plants (WWTPs) has raised awareness as a result of the increasing usage of human pharmaceuticals and improved analytical ability to detect their occurrence in the effluents of WWTPs and receiving surface waters [1–3]. Insufficient treatment may lead to surface and groundwater contamination, compromising the health of the aquatic ecosystems and the surrounding environment [4, 5].

In cases where APIs are not sufficiently degraded by biological processes during wastewater treatment, either because of a high persistence to biodegradation or limited biological activity during treatment, as can be found in cold areas, e.g. northern Scandinavia, improvement at the WWTPs by addition of further treatment technology such as chemical oxidation is a probable solution [6–8]. Oxidation techniques have proven effective to quantitatively remove potential pollutants in wastewater that cannot be degraded biologically. An added benefit of oxidative treatment is the disinfection effect [9, 10].

Currently, chemical oxidation is widely employed in the treatment of drinking water and wastewater, for disinfection and oxidation, involving the use of oxidants such as ozone

(O₃), chlorine, chlorine dioxide (ClO₂) and peracetic acid (PAA). Among these four oxidants, ozone has been considered to be the most promising oxidation method for removal of micropollutants [2,8,11]. Unlike ozonation, ClO₂ as well as PAA, has not been extensively studied for the removal of pharmaceuticals in wastewater effluents. So far, a study on drinking and surface water using chlorine dioxide showed promising results for removal of pharmaceuticals, where for example diclofenac was completely degraded even at the lowest ClO₂ dose [12]. Navalon *et al.* [13] also demonstrated the reactivity of ClO₂ to remove several antibiotics in artificial raw water. Andersen *et al.* [14, 15] found that estrogens and xenoestrogens could be removed quickly and with a high selectivity from wastewater effluents by very small doses of ClO₂ in the order of 2–4 mg/L, which was consumed by the wastewater constituents in less than 30 seconds, leaving no ClO₂ residues. This is interpreted as being due to very fast oxidation of the phenolic groups, which nearly all estrogens contain, compared with slower reactions with the general matrix in wastewater effluents.

Although PAA has not been applied in wastewater treatment to remove pharmaceuticals, it is believed to have a strong oxidizing power, with an oxidation potential ranking next to ozone [16], and it is used for disinfection of

*Corresponding author. Email: gerly.moradas@chemeng.lth.se

wastewater [17]. Thus, aside from its disinfection effect, PAA has the potential to be an alternative technique to treat pharmaceuticals in wastewater.

When used for treatment, ClO_2 is mainly reduced to chlorite by reaction with organic matter. Chlorite reacts more slowly with organic matter, to be reduced to chlorite. Chlorite residuals can potentially be problematic for the treatment depending on the concentration and degradation rate. Chlorine dioxide differs from chlorine in that it produces very little chloro-organic by-products [9,12,14]. Peracetic acid reacts in water mainly to become acetic acid, and oxygen or hydrogen peroxide, which are all quickly degraded by bacteria in treated wastewater [16,17].

This study aims to investigate the effectiveness of ClO_2 and PAA on the removal of six anionic, active pharmaceutical ingredients (APIs) in biologically treated wastewater. The APIs were the non-steroidal anti-inflammatory drugs (NSAIDs) ibuprofen, naproxen, diclofenac and mefenamic acid, and the lipid-regulating agents gemfibrozil and clofibric acid (the pharmaceutically active form of the drug clofibrate). The oxidants' consumption of the wastewater effluent was also followed as well as the oxidant remaining after treatment of the APIs. Results were compared with those of ozonation based on previous studies on wastewater, drinking and surface water.

Materials and methods

Chemicals

All chemicals except ClO_2 were analytical grade and purchased from Sigma-Aldrich. Chlorine dioxide was synthesized by mixing 400 mL of demineralized water with 25 mL each of 9% HCl and 7.5% NaClO_2 . The reaction mixture was allowed to react overnight and was then diluted to 1000 mL with demineralized water. This resulted in an approximately 1 g/L ClO_2 solution.

Oxidation experiments

Wastewater effluents were collected from two treatment plants in Sweden, namely Källby and Sjölanda WWTPs. Effluent 1 was from Källby WWTP, operating with extended nitrogen removal in activated sludge. Effluent 2 was from Sjölanda WWTP, also operating full nitrogen removal but carried out in biofilm systems after a high-loaded activated sludge treatment plant. Nitrification is carried out in trickling filters, and denitrification in moving-bed biofilm reactors with addition of external carbon. Effluent 3 was also taken from Sjölanda WWTP after the high-loaded activated sludge plant. This wastewater is typical for many Swedish WWTPs operating without nitrogen removal owing to their location in the northern part of the country.

To characterize the wastewater, the pH and chemical oxygen demand (COD), measured spectrophotometrically by standardized Dr. Lange DR 2800 COD LCK 114

cuvette test, of the effluents were determined. Based on its respective COD value, the wastewater effluent was classified as low (effluent 1), medium (effluent 2) or high (effluent 3) COD.

An experiment was made to determine how fast PAA and ClO_2 react with a wastewater sample. An effluent from Källby WWTP with extended nitrogen removal was used.

For experiments with removal of APIs, an effluent sample of 300 mL was prepared in Schott Duran® bottles, spiked with each API to a final concentration of 40 µg/L and covered with aluminium foil. Each dose of the oxidants was added to duplicate samples in the range 0–20 mg/L and 0–50 mg/L for ClO_2 and PAA, respectively. Samples were stored in the dark without stirring and allowed to react overnight (18 h); thereafter the pH and oxidant concentration of the samples were measured. Residual oxidants were removed by addition of 50 mg/L Na_2SO_3 .

Chlorine dioxide and peracetic acid analysis

The concentration of ClO_2 or PAA residuals in all samples was quantified by reaction with DPD (N,N-diethyl-p-phenylenediamine) using an Allcon spectrophotometer (Alldos, GmbH) with a built-in calibration line for ClO_2 . The analysis of ClO_2 with DPD was performed according to the photometer manufacturer's instructions.

Peracetic acid was quantified by the photometer's standard curve for total chlorine (Cl_2), which was recalculated to PAA concentration by multiplying by a factor of 1.07, which is based on the relative masses of the two oxidants. Peracetic acid was analysed by reaction with DPD at neutral pH, which prevented oxidation by H_2O_2 contrary to the normal use of DPD, which is based on reaction with the oxidants at low pH. This was necessary since PAA is delivered as a mixture with the synthesis precursors H_2O_2 and acetic acid. The selectivity of the reaction was tested by measuring a sample spiked with 50 mg/L H_2O_2 only. The quantification of PAA was shown not to be biased by the presence of H_2O_2 in water, as a wastewater sample to which was added 50 mg/L H_2O_2 measured less than 0.05 mg/L PAA.

API analysis

The analytical procedure was based on Kosjek *et al.* [18]. Samples of 250 mL were filtered with a glass microfibre filter (GFC, Whatman) and then acidified to pH 3 using phosphate acid buffer. An internal standard (IS), mecoprop (40 µg/L), was added before solid-phase extraction (SPE). The SPE columns (Oasis® HLB 3 cc/60 mg, Waters) were conditioned serially with 5 mL each of methanol, ethyl acetate and acidified water. Samples were extracted at a maximum flow rate of 2 mL/min. The SPE columns were dried completely by drawing air through the columns for at least 30 min.

Samples were eluted with 1.5 mL of ethyl acetate and evaporated in a thermal heating block at 35°C with a

Table 1. Retention times, target ion, qualifier ion(s) and ratio of qualifier ion(s)/target ion of the APIs and the IS, and the LOD determined in a typical biologically treated wastewater.

| API | Retention time(min) | Target ion | Qualifier ion(s) | Ratio (%) | LOD ($\mu\text{g/L}$) |
|----------------|---------------------|------------|------------------|-----------|-------------------------|
| Ibuprofen | 7.02 | 143 | 271, 273 | 43, 16 | 0.8 |
| Clofibric acid | 7.40 | 263 | 117 | 10 | 0.8 |
| Mecoprop (IS) | 7.55 | 225 | 199 | 45 | NA |
| Naproxen | 11.55 | 287 | 185, 141 | 31, 13 | 1.0 |
| Gemfibrozil | 11.95 | 243 | 307 | 24 | 0.8 |
| Diclofenac | 13.55 | 214 | 352, 354 | 120, 86 | 1.1 |
| Mefenamic acid | 14.35 | 224 | 298 | 86 | 0.8 |

gentle stream of nitrogen until approximately 250 μL was left. Samples were transferred to GC vials and 25 μL of the derivatization reagent, N-(t-butyltrimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA), was added. The vials were allowed to react for 60 min at 60°C. Analyses of the samples were done with gas chromatography–mass spectrometry (GC-MS, Agilent 5973N Mass Selective Detector). The capillary column was an Agilent HP 5-MS (30.0 m \times 250 μm \times 0.25 μm) with a 1 μL injection volume in splitless mode. The GC oven temperature programme was as follows: 100°C for 1 min, 30°C/min up to 190°C, 3°C/min up to 204°C, 30°C/min up to 245°C, 5°C/min up to 265°C, and finally 30°C/min up to 300°C for 1 min. The APIs were quantified based on standard calibration curves with the retention times, the target and qualifier ions, and the determined qualifier-to-target ratios, which have to be within 20%. The limit of detection (LOD) of the method was between 0.8 and 1.1 $\mu\text{g/L}$, as determined in a representative WWTP (Table 1). The method had a linear response between the LOD and at least 50 $\mu\text{g/L}$.

Statistics

GraphPad Prism [19] was used for both graphical and statistical analyses.

Results and discussion

Effluent 1 with extended nitrogen removal has the lowest COD at 31 mg/L, followed by effluent 2 at 49 mg/L, and effluent 3 without nitrogen removal with COD at 60 mg/L. From the COD values, the effluents were classified as low, medium and high in COD, respectively. The initial pH of effluent 1 was 6.7 and effluent 2 and 3 had a pH at 7.0. The pH did not change a lot in any of the effluents after treatment even for the highest oxidant dose where pH remained slightly acidic (\sim pH 6). The decrease in pH is expected since the stock solutions of ClO_2 contain some HCl residual from their synthesis, and likewise the PAA stock solution contains acetic acid.

The profiles of consumption of the two oxidants in a biologically treated wastewater effluent (Figure 1) revealed




Figure 1. Profiles of oxidant consumption with time in a biologically treated wastewater. The fitted lines represent a one-phase exponential decay model for PAA and a two-phase exponential decay model for ClO_2 .

that ClO_2 reacts faster than PAA in wastewater effluents. About 90% of 6 mg/L ClO_2 had disappeared 30 min after addition, whereas the same removal was reached after 18 h reaction for PAA. The profile of ClO_2 decay resembled profiles shown in other investigations on biologically treated wastewater [8,14,15]. The profile of ClO_2 decay fitted ($R^2 = 0.996$) a two-phase exponential decay model, which could be explained by ClO_2 reacting fast with a minor part of the dissolved material in the effluent, which consumes about 3.5 mg/L ClO_2 within 0.5 min. After this reactive fraction of the solutes in the water is consumed, a slow reaction with the bulk of the solutes follows. Compared with this, the PAA profile fitted ($R^2 = 0.952$) a one-phase exponential decay model, which indicates that PAA reacts equally well, but more slowly, than ClO_2 , with all the solutes. The PAA degrades relatively slowly in treated wastewater, which makes it less attractive for treatment of effluents, unless the residual is removed with a chemical before it is released to surface water. Both oxidants are essentially stable ($>95\%$ remain) in distilled water at the same pH and time range (18 h; results not shown). These results show that the oxidant consumption of the wastewater alone was significant compared with that needed to oxidize the APIs in the batch experiments.

The residual concentrations of ClO_2 and PAA in the three effluents spiked with APIs and increasing oxidant doses are shown in Figure 2. Chlorine dioxide was almost completely consumed in all samples with added ClO_2 dose up to 10 mg/L. However, when the dose was doubled, the oxidant remaining in effluent 1 (low COD) was much higher than in the two other effluents. Spiked with the same amount of pharmaceuticals, the difference in ClO_2 removal could be attributed to the differences in the COD. Effluents 2 (medium COD) and 3 (high COD) contained more COD than effluent 1; therefore more oxidant was needed to remove a fraction of the COD. As shown in this test, oxidant consumption was mostly due to the presence of organic components in the wastewater rather




Figure 2. Residual concentrations of ClO₂ (left) and PAA (right) in the three effluents after treatment with different initial doses of ClO₂ or PAA.

than the pharmaceuticals. Peracetic acid oxidation followed the same trend as ClO₂ except that effluent 1 had much lower consumption of PAA in all treatment doses, which is consistent with the fact that effluent 1 has the lowest COD.

Residual concentrations of pharmaceuticals in all effluents treated with ClO₂ are shown in Figure 3. Clofibric acid and ibuprofen appeared to be recalcitrant to oxidation in wastewater and did not react with ClO₂ even at the 20 mg/L treatment dose. Gemfibrozil was removed only when treated with 20 mg/L ClO₂ in the low COD effluent 1, whereas higher removal was observed in effluents 2 and 3 at much lower ClO₂ dose. On the other hand,

more than 60% of mefenamic acid was removed with just 0.5 mg/L ClO₂, and, by treatment with a dose of 1.25 mg/L, 90–95% of mefenamic acid was removed from all effluents. More than 90% diclofenac and naproxen were removed in all effluents with 2.5 and 20 mg/L ClO₂, respectively, whereas, in the medium COD effluent, diclofenac was completely removed with 3.75 mg/L ClO₂. A similar study on drinking water by Huber *et al.* [3] showed complete oxidation of diclofenac and 50% naproxen removal at 0.95 mg/L ClO₂; ibuprofen and clofibric acid did not show reactivity up to 11.5 mg/L ClO₂, whereas gemfibrozil showed 40% removal [3]. As presented in these studies, oxidation of




Figure 3. Percentage residual concentrations of APIs in the effluents after treatment with different initial ClO₂ doses.

pharmaceuticals in drinking water normally consumes less ClO_2 than in wastewater, which could be attributed to the presence of higher concentrations of organic compounds with high ClO_2 demand in the wastewater.

Comparing this to the ozonation process, Ternes *et al.* [6] reported that, during ozone treatment of municipal sewage treatment plant effluent, diclofenac and naproxen were completely removed with 5 mg/L O_3 , while increasing the O_3 dose to 10 and 15 mg/L effectively removed ibuprofen and clofibric acid. In the study by Huber *et al.* [3], diclofenac and naproxen were also oxidized to more than 90% during ozonation of municipal wastewater effluents at O_3 dose ≥ 2 mg/L. On the other hand, ibuprofen residual of 20% was still detectable at higher O_3 dose [3]. Furthermore, ozonation of surface water with 0.2 mg/L O_3 was sufficient to completely oxidize diclofenac, whereas a much higher dose of 2 mg/L O_3 was needed to remove 40–60% of ibuprofen [11]. In contrast to wastewater, surface water typically contains lower concentrations of organic matter; therefore a much lower O_3 dose was needed to oxidize the same type of compound. In addition, the presence of other inorganic components in the wastewater may also deplete the oxidant, and this affects the removal of the target compounds [8]. Thus, for wastewaters with a high load of organic or inorganic matter, a rather high dose of oxidants is required to significantly remove the pollutant of concern.

The oxidation reaction mechanism for ClO_2 appears to be similar to the oxidation by molecular ozone. Diclofenac and naproxen, which were removed by the lowest doses of ClO_2 , were also removed by the lowest ozone doses, whereas ibuprofen and clofibric acid, which were not effectively removed by ClO_2 , required higher ozone doses. Both ozone and ClO_2 are selective oxidants that transform organic pollutants depending on their reactivity and the presence of other components in the water (i.e. the dissolved organic matter). They react with electron-rich functional groups of organic compounds such as phenolic and amino groups (i.e. aniline group for diclofenac) [3,8,20,21]. However, compared with ozonation, the reaction of ClO_2 was much slower even with the same reactive functional group, as shown previously in a number of studies.

These studies demonstrated the potential of ozonation for removing certain pharmaceuticals, such as ibuprofen and clofibric acid, that exhibit no reactivity to ClO_2 as shown in the present study. In addition to its higher oxidative capacity, ozone can react with water to create the unselective reacting hydroxyl radical, which can compete in removing the APIs, which ozone itself does not react quickly [6,11]. However, for small WWTPs where an ozonation system could be too expensive and complicated to implement, the more simple dosing of ClO_2 can be an alternative option to remove some of the most potentially problematic pharmaceuticals present in the wastewater effluents.




Figure 4. Percentage residual concentrations of APIs in the effluents after treatment with different initial PAA doses.

In the case of PAA, Figure 4 shows that mefenamic acid was most reactive at lower PAA dose in both low and medium COD effluents, as compared with the rest of the APIs, which were gradually removed with increasing PAA dose. Diclofenac was more reactive in effluent 2 at higher oxidant dose, with more than 90% removal for 25 mg/L PAA, compared with only 75% when treated with 50 mg/L PAA in effluent 1. On the other hand, in effluent 3 with high COD, no significant degradation was observed in most of the APIs investigated, even at the highest oxidant dose, except mefenamic acid, which was removed by 90% at 50 mg/L PAA. The results of this study indicated that ibuprofen and clofibrac acid are more recalcitrant to both ClO₂ and PAA oxidation compared with the other four compounds investigated. Higher doses of PAA allow removal of APIs such as diclofenac and mefenamic acid in lower COD effluents. Nevertheless, PAA showed its potential to remove some compounds in wastewater that may pose a threat to the environment, especially the aquatic ecosystem. To our knowledge, no literature references exist regarding the reaction of pharmaceuticals with PAA in wastewater.

In comparison to PAA, ClO₂ is more effective at low doses in removing pharmaceuticals, especially naproxen and diclofenac, which have low biodegradability and are of ecotoxicological concern; for instance diclofenac, tagged as among the most devastating environmental toxicants, caused the poisoning and decline of Indian vultures [22,23]. Other APIs such as ibuprofen are not so easily removed by oxidation, but they can be degraded biologically [24]. Therefore it appears that PAA is not a candidate oxidant for treatment of APIs in biologically treated sewage effluents, though it remains an interesting disinfectant chemical for both sewage effluents and combined sewer overflows [17].

Conclusions

This study showed that ClO₂ is more effective than PAA at removing pharmaceuticals in wastewater. However, removal of APIs varies between the two oxidants and the matrix of the wastewater. Some of the pharmaceuticals react selectively with ClO₂ and are therefore removed even with a low dose, almost independently of the matrix, whereas others do not react. Peroxyacetic acid generally reacts more uniformly with the APIs from effluent 1 containing low COD but requires high doses to achieve significant removal. The exception was mefenamic acid, which was degraded by low doses of PAA. Owing to its high selectivity, ClO₂ can be applied, as an alternative to ozone, during wastewater treatment to remove pharmaceuticals of ecotoxicological concern, such as diclofenac, as long as the residual ClO₂ is minimized and does not exceed the standard; this requires a minimal reaction time before contact with the receiving waters. Oxidation with ClO₂ could be a potential solution for removal of pharmaceutical at smaller treatment plants where ozonation may be too expensive and complicated to

operate. Furthermore, evaluation of the ecological toxicity of the oxidation products and the treatment by-products should be carried out, and the economic aspect of the treatment operation should be investigated.

Acknowledgements

The authors would like to thank the Swedish Foundation for Strategic Environmental Research through the MistraPharma programme for the full financial support of this study. The determination of LOD for the APIs and the selectivity test for the PAA method compared with hydrogen peroxide were performed by Nils Henning Kerlin in a parallel project.

References

- [1] T.A. Ternes, *Occurrence of drugs in German sewage treatment plants and rivers*, Water Res. 32 (1998), pp. 3245–3260.
- [2] T.A. Ternes and A. Joss, *Human Pharmaceuticals, Hormones and Fragrances: The Challenge of Micropollutants in Urban Water Management*, IWA Publishing, London, 2006.
- [3] M.M. Huber, A. Göbel, A. Joss, N. Hermann, D. Löffler, C.S. McArdell, A. Ried, H. Siegrist, T.A. Ternes, and U. von Gunten, *Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: A pilot study*, Environ. Sci. Technol. 39 (2005), pp. 4290–4299.
- [4] K. Fent, A.A. Weston, and D. Caminada, *Ecotoxicology of human pharmaceuticals*, Aquat. Toxicol. 76 (2006), pp. 122–159.
- [5] S. Zorita, L. Martensson, and L. Matthiasson, *Occurrence and removal of pharmaceuticals in a municipal sewage treatment system in the south of Sweden*, Sci. Total Environ. 407 (2009), pp. 2760–2770.
- [6] T.A. Ternes, J. Stuber, N. Herrmann, D. McDowell, A. Ried, M. Kampmann, and B. Teiser, *Ozonation: A tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?* Water Res. 37 (2003), pp. 1976–1982.
- [7] K.M.S. Hansen, H.R. Andersen, and A. Ledin, *Ozonation of estrogenic chemicals in biologically treated sewage*, Water Sci. Technol. 62(3) (2010), pp. 649–657.
- [8] Y. Lee and U. von Gunten, *Oxidative transformation of micropollutants during municipal wastewater treatment: Comparison of kinetic aspects of selective (chlorine, chlorine dioxide, ferrate^{VI}, and ozone) and non-selective oxidants (hydroxyl radical)*, Water Res. 44 (2010), pp. 555–566.
- [9] M.M. Huber, *Elimination of pharmaceuticals during oxidative treatment of drinking water and wastewater: Application of ozone and chlorine dioxide*, Ph.D. diss., Swiss Federal Institute of Technology Zurich, 2004.
- [10] O. Ayyıldız, B. Illeri, and S. Sanik, *Impacts of water organic load on chlorine dioxide disinfection efficacy*, J. Hazard. Mater. 168 (2009), pp. 1092–1097.
- [11] M.M. Huber, S. Canonica, G.Y. Park, and U. von Gunten, *Oxidation of pharmaceuticals during ozonation and advanced oxidation processes*, Environ. Sci. Technol. 37 (2003), pp. 1016–1024.
- [12] M.M. Huber, S. Korhonen, T.A. Ternes, and U. von Gunten, *Oxidation of pharmaceuticals during water treatment with chlorine dioxide*, Water Res. 39 (2005), pp. 3607–3617.
- [13] S. Navalon, M. Alvaro, and H. Garcia, *Reaction of chlorine dioxide with emergent water pollutants: Product study of the reaction of three β-lactam antibiotics with ClO₂*, Water Res. 42 (2008), pp. 1935–1942.

- [14] H.R. Andersen, M. Lundsbye, H.W. Vedel, E. Eriksson, and A. Ledin, *Estrogenic personal care products in a greywater reuse system*, *Water Sci. Technol.* 56 (12) (2007), pp. 45–49.
- [15] H.R. Andersen, *Use of ClO_2 for removal of estrogenic substances in wastewater*, WIPO Pub. No. WO/2010/023311, World Intellectual Property Organization, 2010.
- [16] J. Koivunen and H. Heinonen-Tanski, *Peracetic acid (PAA) disinfection of primary, secondary and tertiary treated municipal wastewaters*, *Water Res.* 39 (2005), pp. 4445–4453.
- [17] M. Kitis, *Disinfection of wastewater with peracetic acid: A review*, *Environ. Int.* 30 (2004), pp. 47–55.
- [18] T. Kosjek, E. Heath, and A. Krbavčič, *Determination of non-steroidal anti-inflammatory drug (NSAIDs) residues in water samples*, *Environ. Int.* 31 (2005), pp. 679–685.
- [19] *GraphPad Prism 5.03*, GraphPad Software, Inc., La Jolla, CA, USA, 2009; software available at <http://www.graphpad.com>.
- [20] D. Vogna, R. Marotta, A. Napolitano, R. Andreozzi, and M. d'Ischia, *Advanced oxidation of the pharmaceutical drug diclofenac with UV/H_2O_2 and ozone*, *Water Res.* 38 (2004), pp. 414–422.
- [21] V.K. Sharma, *Oxidative transformation of environmental pharmaceuticals by Cl_2 , ClO_2 , O_3 and $Fe(VI)$: Kinetics assessment*, *Chemosphere* 73 (2008), pp. 1379–1386.
- [22] J.L. Oaks, M. Gilbert, M.Z. Virani, R.T. Watson, C.U. Meteyer, B.A. Rideout, H.L. Shivaprasad, S. Ahmed, M.J. Chaudry, M. Arshad, S. Mahmood, A. Ali, and A.A. Khan, *Diclofenac residues as the cause of vulture population decline in Pakistan*, *Nature* 427 (2004), pp. 630–633.
- [23] V. Naidoo and G.E. Swan, *Diclofenac toxicity in Gyps vulture is associated with decreased uric acid excretion and not renal portal vasoconstriction*, *Comp. Biochem. Phys. C: Toxicol. Pharmacol.* 149 (2009), pp. 269–274.
- [24] C. Zwiener and F.H. Frimmel, *Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac*, *Sci. Total Environ.* 309 (2003), pp. 201–211.

Paper II



Oxidation of pharmaceuticals by chlorine dioxide in biologically treated wastewater

G. Hey^{a,*}, R. Grabic^b, A. Ledin^{a,c}, J. la Cour Jansen^a, H.R. Andersen^c

^a Water and Environmental Engineering, Department of Chemical Engineering, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden

^b Department of Chemistry, Umeå University, SE-901 87 Umeå, Sweden

^c Department of Environmental Engineering, Technical University of Denmark, Miljøvej, Building 113, DK-2800 Kongens Lyngby, Denmark

ARTICLE INFO

Article history:

Received 30 August 2011

Received in revised form 19 January 2012

Accepted 20 January 2012

Keywords:

Pharmaceuticals

Chlorine dioxide

Wastewater effluent

ABSTRACT

Biologically treated wastewater spiked with a mixture of 56 active pharmaceutical ingredients (APIs) was treated with 0–20 mg/L chlorine dioxide (ClO₂) solution in laboratory-scale experiments. Wastewater effluents were collected from two wastewater treatment plants in Sweden, one with extended nitrogen removal (low COD) and one without (high COD). About one third of the tested APIs resisted degradation even at the highest ClO₂ dose (20 mg/L), while others were reduced by more than 90% at the lowest ClO₂ level (0.5 mg/L). In the low COD effluent, more than half of the APIs were oxidized at 5 mg/L ClO₂, while in high COD effluent a significant increase in API oxidation was observed after treatment with 8 mg/L ClO₂. This study illustrates the successful degradation of several APIs during treatment of wastewater effluents with chlorine dioxide.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

One of the pressing problems in wastewater treatment plants (WWTPs) is the inability of conventional methods to completely remove active pharmaceutical ingredients (APIs) due to their high resistance to biodegradation and/or limited biological activity, especially in cold climates such as that in Sweden [1,2]. The extensive usage and hence release of traces of many pharmaceuticals in wastewater effluents may lead to surface and groundwater contamination compromising the aquatic ecosystem and the environment [3,4].

Where biological treatment is not sufficient, improvement in WWTPs can be achieved by an additional chemical oxidation step to remove potential pollutants that cannot be degraded biologically [5–8]. Among the chemical oxidants applied in water treatment reported in the literature, chlorine dioxide is one that merits further investigation regarding its potential to remove APIs in wastewater. As in the case of ozonation, the application of chlorine dioxide to treat drinking water, surface water and wastewater effluents has shown promising results for the removal of pharmaceuticals. The non-steroidal anti-inflammatory drug diclofenac, reported as one of the most frequently detected compounds in water at concentrations up to the µg/L level [9], is among the pharmaceuticals completely degraded during drinking and surface

water treatment at the lowest ClO₂ dose applied [10]. In wastewater effluents, steroid estrogens and industrial estrogenic chemicals, as well as personal care products, were removed by low doses of ClO₂ between 1.25 and 3.75 mg/L, and the removal of estrogenic potency was observed at the same time [11]. The removal of several antibiotics found in water has also demonstrated the ability of ClO₂ as an oxidant [12,13].

When ClO₂ was used for selective oxidation of organic micropollutants in other investigations on biologically treated wastewater, it was found that smaller doses, e.g. up to 4 mg/L (depending on the concentrations tested and the matrix) were consumed in less than a minute through reactions with the soluble components in the water, while still completely removing many of the reactive micropollutants. This fast consumption of the oxidant in wastewater has been observed in previous studies by Andersen [11], Hey et al. [14], Lee and von Gunten [6] and Andersen et al. [15]. Based on ClO₂ reactivity in wastewater effluents, it has been suggested that ClO₂ could be used as an alternative to ozone for the removal of micropollutants. It is easy to introduce a ClO₂ dosing step in a WWTP since ClO₂ is produced as a solution in water by mixing aqueous solutions of the reactants in a simple reactor; furthermore, the ClO₂ stock solution is semi-storable. This is much simpler than treatment with ozone, which requires on-site delivery of dry oxygen and considerable electric power to run an expensive and complicated ozone generator which produces an ozone gas mixture with less than 20% ozone yield. Following the generation of ozone, the gas must be transferred to the water using a gas contact reactor, usually with 5–20 min hydraulic retention time [5,7,16].

* Corresponding author. Tel.: +46 46 222 8998; fax: +46 46 222 4526.
E-mail address: gerly.moradas@chemeng.lth.se (G. Hey).

When ClO_2 is used for oxidation of water with low NOM (natural organic matter), most of the ClO_2 is reduced to chlorite by reactions with the organic matter. Chlorate is also formed as a by-product, but at a much lower concentration than chlorite [17–19]. According to Korn [18] and Lee [19], the formation of chlorite and chlorate accounts for about 70% and 10%, respectively, of the chlorine dioxide applied. In drinking water with low NOM, chlorite reacts slowly with organic matter and is reduced to chloride, while in wastewater, significantly more NOM is available to reduce the chlorite. Toxicity derived from chlorite residuals after treatment may be problematic depending on the concentration and degradation rate [20]. ClO_2 differs from chlorine in that it produces very little chloro-organic by-products [11,15,21]. The formation of undesirable by-products can be controlled by minimizing the dose of ClO_2 and applying post-treatment using, for example, ferrous iron (Fe^{2+}) or sulfite (SO_3^{2-}), which reduces ClO_2 and chlorite residuals to chloride [22,23]. The removal of ClO_2 and chlorite residuals allows higher levels of ClO_2 to be used for treatment providing effective micropollutant removal.

In this study, the removal of 56 different APIs in biologically treated wastewater was investigated in both low- and high-COD effluents using different doses of chlorine dioxide. The APIs were chosen to represent different classes of pharmaceuticals commonly sold and used in Sweden, which will most likely end up in WWTP effluents due to their low sorption to sludge [24]. The effectiveness of the treatment was evaluated by monitoring the oxidant consumption and the amount of APIs oxidized. Oxidation by-products were not evaluated in this study as the aim was to determine the most suitable oxidant dose and identify which APIs can be removed. Once the relevant dose has been determined, attention can be turned toward investigating the ClO_2 by-products.

2. Materials and methods

2.1. Chemicals

All pharmaceutical reference standards were purchased as solids of analytical grade (>98%) from different suppliers. All APIs investigated are listed in Supplementary Information Table S1. Methanol and acetonitrile were of LC/MS grade (Merck, Darmstadt, Germany). Ultrapure water was prepared from deionized water using a Milli-Q Gradient system (Millipore, Billerica, MA), equipped with a UV radiation source. A stock solution of APIs was prepared in methanol at concentration of about 100 mg/L. Solutions for spiking and analysis were prepared by precise dilution of the stock solution. Chlorine dioxide was synthesized by adding equal volumes (25 mL each) of 9% HCl (Merck, Darmstadt, Germany) and 7.5% NaClO_2 (Sigma–Aldrich, Steinheim, Germany) to 400 mL deionized water. The solution was allowed to react in the dark for at least 10 h and then diluted to 1000 mL with water. This resulted in an approximately 1 g/L ClO_2 stock solution.

2.2. Analytical methods

The concentration of residual ClO_2 was quantified by reaction with DPD (N,N-diethyl-p-phenylenediamine) using an Alcon spectrophotometer (Aldos, GmbH, Germany) with a built-in calibration line for ClO_2 . The analysis of ClO_2 with DPD was performed according to the manufacturer's instructions.

For the analysis of the APIs, samples of 100 mL treated effluent were filtered using a 0.45 μm membrane filter (Millipore, Ireland) then acidified to pH 3 using sulfuric acid. Five ng of ^{13}C - and ^2H -labeled APIs was added as internal standards, to each sample (see Supplementary Table 1 for the complete list) before solid-phase extraction using Oasis HLB columns (200 mg, Waters). LC/MS/MS analysis of the extracts was carried out using a triple-stage quadrupole mass spectrometer (MS/MS TSQ Quantum Ultra EMR) coupled to an Accela LC pump (both from Thermo Fisher Scientific, San Jose, CA, USA) and a PAL HTC autosampler (CTC Analytics AG, Zwingen, Switzerland) with a Hypersil GOLD aQTM column (50 mm \times 2.1 mm ID \times 5 μm particles). Both heated electrospray and atmospheric pressure photoionization were used in positive and negative ion modes for the ionization of target compounds. Two MS/MS transitions were measured for each API. Samples were quantified using isotope dilution or internal standard methods. Six points calibration curve corresponding to concentration ranges 10–2500 ng/L were measured before, in the middle and at the end of sample analysis sequence to monitor response factor stability. Recoveries and the relative standard deviation of triplicate analyses of effluent from the Sjölanda WWTP spiked at 1 $\mu\text{g/L}$ are given in Supplementary Information Table S2. Maximum difference between results at quantification and qualification mass transition was set to 30% as criterion for positive identification of the analyte. The same method is used by Hörsing et al. [24] and Grabic et al. (unpublished results) [25].

2.3. Experimental setup

2.3.1. Wastewater effluents

Wastewater effluents were collected after secondary treatment from two WWTPs in southern Sweden. Effluent 1 was collected from Källby WWTP after the activated sludge system which is operated with extended nitrogen removal.

Effluent 2 was obtained from Sjölanda WWTP after a high loaded activated sludge process before nitrogen removal. This wastewater is typical of that in many Swedish WWTPs which are operated without nitrogen removal due to their location in the northern part of the country where the climate is colder. Sjölanda also employs full nitrogen removal but using a biofilm system after a highly loaded activated sludge plant. Nitrification is achieved in trickling filters and denitrification in moving bed biofilm reactors with the addition of external carbon.

Table 1 gives the characteristics of the effluents. The effluents were analyzed using standard Swedish methods for total suspended solids (SS-EN 872:2005), total P (SS-EN ISO 6878:2005) and total N (SS-EN ISO 11905-1), while COD was determined with the Dr. Lange LCK 114 kit. The effluents were classified as low COD (Effluent 1) or high COD effluent (Effluent 2) based on their COD levels.

2.3.2. Oxidation experiments

Effluent samples of 150 mL each were prepared in Schott Duran[®] bottles and spiked with mixed APIs to a final concentration of approx. 1 $\mu\text{g/L}$. ClO_2 was added to duplicate samples at concentrations ranging from 0 to 20 mg/L. All samples were stored in the dark and allowed to react overnight (approx. 18 h) at room temperature, after which the pH and oxidant concentration in the samples

Table 1
Effluent characteristics.

| | pH | COD (mg/L) | TSS (mg/L) | Total P (mg/L) | Total N (mg/L) |
|-----------------------|-----|------------|------------|----------------|----------------|
| Effluent 1 (Källby) | 6.8 | 35 | 5 | 0.26 | 7.5 |
| Effluent 2 (Sjölanda) | 7.2 | 55 | 8 | 0.28 | 8.0 |

were measured. Residual oxidants were removed by the addition of 50 mg/L sodium sulfite.

3. Results and discussion

Table 2 lists the APIs investigated, including information on the class of drug, arranged according to the ease with which they were oxidized by ClO₂ (based on Effluent 1).

No further pH adjustments were made during the entire experiment. The pH of the samples did not change significantly after treatment, even with the highest oxidant dose of 20 mg/L, where the sample remained slightly acidic (~pH 6.2–6.5). This slight decrease in pH is expected since the stock solutions of ClO₂ contain some residual HCl from the synthesis.


Fig. 1 shows the residual concentration of ClO₂ in the two effluents spiked with APIs as a function of the initial ClO₂ dose. It can be seen that the high COD effluent consumed more oxidant than the low COD effluent, especially when the dose was 8 mg/L ClO₂ and above.

Table 3 gives the number of APIs that can be effectively oxidized (i.e. by more than 90%) at each ClO₂ dose in both effluents. It can be seen that a dose of 8 mg/L ClO₂ to Effluent 1 was able to oxidize 38 of 56 APIs, and that only 1 more API was oxidized when the dose was increased to 20 mg/L. In Effluent 2, 33 APIs were oxidized with a dose of 8 mg/L ClO₂, and increasing the ClO₂ dose to 20 mg/L oxidized further 4 APIs. The remaining APIs (about one third) could not be degraded effectively (at least 90%) with a dose of 20 mg/L ClO₂.

Table 2

Name and chemical structure of the APIs investigated (www.fass.se). The therapeutic class, and in the case of the easily and moderately oxidizable APIs the reactive functional group are given in brackets.

Easily oxidized (0.5–1.25 mg/L ClO₂)



Moderately oxidized (2.5–5 mg/L ClO₂)




Table 2 (Continued)



Poorly oxidized (8–20 mg/L ClO₂)Fig. 1. Residual concentration of ClO₂ in the 2 effluents after treatment with different doses of the oxidant.

Table 3

The number of APIs tested (of a total of 56) that could be effectively oxidized (at least 90%) at each ClO₂ dose.

| ClO ₂ dose (mg/L) | No. of APIs oxidized by >90% | |
|------------------------------|------------------------------|--------------|
| | (Effluent 1) | (Effluent 2) |
| 0.5 | 4 | 0 |
| 1.25 | 11 | 4 |
| 2.5 | 15 | 8 |
| 3.75 | 24 | 12 |
| 5 | 31 | 18 |
| 8 | 38 | 33 |
| 10 | 38 | 36 |
| 20 | 39 | 37 |

Only few APIs were oxidized by more than 90% at the lowest dose of ClO₂ (0.5 mg/L), while high oxidative degradation was observed with higher doses (8–20 mg/L). The degree to which each API was oxidized at different ClO₂ doses is shown in Fig. 2A and B for Effluents 1 and 2, respectively. The vertical lines divide the APIs into easily, moderately, poorly (based on the ClO₂ dose required to




Fig. 2. Fraction of APIs oxidized in Effluent 1 (A) and Effluent 2 (B) at different ClO₂ doses. The vertical lines divide the APIs into groups according to their ease of oxidation.

achieve 90–100% degradation) and non-oxidizable APIs (less than 90% degradation with 20 mg/L ClO₂).

As shown for Effluent 1 (Fig. 2A and Table 2), 11 of the APIs from 8 different therapeutic classes could be oxidized by more than 90% with 0.5–1.25 mg/L ClO₂. These include all 3 hormones, 2 antibiotics, 1 antihistamine, and 1 narcotic analgesic, as well as the antiplatelet, antidiabetic, antiphlogistic and narcotic antagonist compounds. The common reactive and electron-rich functional groups in these APIs are aniline in diclofenac, phenol in hormones, buprenorphine, and naloxone, and tertiary amines in promethazine, clindamycin, dipyrindamole, repaglinide and ciprofloxacin. The high reactivity of ClO₂ with aniline, phenolic and tertiary amine functional groups has been reported in a number of studies [6,10,26]. The reactivity of ClO₂ with the piperazine ring of the antibiotic ciprofloxacin has also been reported by Wang et al. [13]. Similarly, Navalon et al. [12] also showed high reactivity of ciprofloxacin with ClO₂ in both surface water and wastewater effluent.

APIs requiring doses of 2.5–5 mg/L ClO₂ for oxidation are considered to be moderately oxidizable (Table 2). Most of the APIs from 13 of the different therapeutic classes belong to this category including 4 antidepressants, 2 antihistamines, 2 antiparkinson drugs, 2 narcotic analgesics, 2 anticholinergics, 1 antibiotic, 1 beta blocker, 1 sedative-hypnotic, 1 anxiolytic, and the representative compound from different classes, namely angiotensin converting enzyme (ACE) inhibitor, alpha blocker, antipsychotic and calcium antagonist. The most common functional group in this category of moderately oxidizable APIs is the tertiary amino group, which is also found in the structures of easily oxidizable APIs. However, despite belonging to the same therapeutic class, the behavior of the APIs differed significantly, depending largely on the reactivity

of electron-rich functional groups. The removal of pharmaceuticals at fairly low oxidant doses (1.25–3.75 mg/L ClO₂) has also been observed in previous studies on surface and drinking water [10] and in wastewater effluents [6,11].

The resistance of poorly and non-oxidizable APIs to oxidation by ClO₂ could be attributed to the presence of the electron-withdrawing functional groups such as the chloro (in clonazepam, bupropion, desloratidine, alprazolam, bezafibrate, and beclomethasone and budesonide), fluoro (in citalopram, flutamide, fluoxetine, flucanazole), nitro (in flutamide and clonazepam), olefin or C=C double bonds (in eprosartan and amitriptyline), amide carbonyl (in bezafibrate and finasteride) and keto group (in bupropion, beclomethasone and budesonide) [7,26–29]. The secondary amine-containing beta blockers, metoprolol and bisoprolol are also considered less susceptible to ClO₂ oxidation. Lee and von Gunten [6] reported the poor transformation of the beta blocker atenolol which has a secondary amine functional group. However, the oxidizability of the beta blocker sotalol can be explained by the presence of the ClO₂ reactive sulfonamide functional group in its structure. The same degree of API oxidation can be achieved in the high COD effluent (2) as in the low COD effluent (1), but higher ClO₂ doses are required. This is due to consumption of the ClO₂ competitively with the APIs by other organic components in the wastewater [6]. In addition, the presence of inorganic components in the wastewater also consumes some of the oxidant and this could affect the removal of the target micropollutants [6].

The results of this study showed that about 20 APIs cannot be oxidized effectively, even at the highest dose investigated (20 mg/L ClO₂), suggesting low reactivity between these APIs and ClO₂. In Effluent 1, 13 of these APIs (alprazolam, finasteride, fluoxetine, beclomethasone, desloratidine, maprotiline,

fluconazole, bezafibrate, flutamide, telmisartan, budesonide, bisoprolol, and clonazepam) were oxidized by 50–80%, while the remaining 4 APIs metoprolol, irbesartan, bupropion, and carbamazepine were degraded less (20–40%). On the other hand, in Effluent 2, most of these APIs were oxidized by less than 50%, while 3 APIs (the synthetic steroids beclomethasone and budesonide, and the antidepressant bupropion) did not show any degradation at all. Bezafibrate and carbamazepine have been shown in previous investigations to be recalcitrant to ClO₂ oxidation during water and wastewater treatment [6,10,28]. As mentioned above, the presence of electron-withdrawing functional groups results in low reactivity of some APIs to ClO₂ oxidation, and thus a much higher dose of ClO₂ would be needed for oxidation.

APIs such as diclofenac, sulfamethoxazole and estrogens have been found to be oxidized by more than 90% during ozonation of municipal wastewater effluents at O₃ doses of ≥2 mg/L, while a much higher O₃ dose was required for the effective removal of bezafibrate [30]. Ternes et al. [7] also found significant removal (>90%) of sulfamethoxazole, diclofenac, carbamazepine, and sotalol during treatment of municipal sewage effluent with 5 mg/L O₃, while a higher O₃ dose of 10–15 mg/L was required to effectively remove the beta blocker metoprolol, which also exhibits low reactivity to ClO₂. In the present study, ClO₂ was able to oxidize several APIs effectively at doses comparable to those of ozone. The reactivity of carbamazepine was very different since it could be removed by low ozone doses, while it is almost completely resistant to ClO₂.

The oxidation of APIs by ClO₂ is comparable to oxidation by molecular ozone as both are selective oxidants and are capable of transforming organic micropollutants based on the reactivity of the structure and the characteristics of the water matrix. These chemical oxidants react with electron-rich functional groups such as phenolic and amino groups, which can be found in the structures of most of the APIs investigated [6,10,31–33]. However, the reaction between ClO₂ and some APIs was much slower than ozonation, even with the same reactive functional group. Therefore, the usefulness of ClO₂ end-of-pipe treatment of WWTP effluents will depend on whether the micropollutants deemed to be critical for the receiving water are sensitive to ClO₂. Running costs must also be considered since ClO₂ is slightly more expensive to produce than ozone, while it is far simpler and less expensive to build both the generator and reaction chamber for ClO₂ treatment. The treatment perspective then is mainly to use ClO₂-treatment for small scale WWTP (<2000 person equivalent) effluents or where treatment is required only for a limited time.

Two of the APIs investigated here may be of considerable concern regarding the discharge of wastewater effluents into surface water. Both ethinyl estradiol, a pharmaceutical with a high endocrine-disrupting ability [34], and diclofenac, identified as a contaminant that causes direct toxic effects in the environment [35,36], were found to be very sensitive to ClO₂ oxidation. However, if other less reactive APIs, e.g. bezafibrate or carbamazepine, were found to be of concern regarding aquatic life in the receiving water body of the WWTP effluent, ClO₂ treatment would not be a suitable treatment option.

4. Conclusions

The results of this study show that ClO₂ can be used to treat wastewater effluents to oxidize various APIs belonging to different therapeutic classes. However, there was considerable variation in the reactivity of the investigated APIs to ClO₂. The degree of oxidation was found to be dependent on the type of wastewater; API removal is better from the low COD wastewater from the plant with extended nitrogen removal, than the one without (high COD wastewater), at the same oxidant dose. In addition, the reactivity

of the APIs depends on the reactive functional group present. APIs with electron-withdrawing functional groups appear to be more resistant to ClO₂ oxidation.

ClO₂ oxidation by-products and toxicity must be investigated before this method can be considered for application in wastewater treatment. The use of ClO₂ oxidation for the removal of pharmaceuticals may be beneficial in small wastewater treatment plants where ozonation could be too expensive and complicated.

Acknowledgement

The authors would like to thank the Swedish Foundation for Strategic Environmental Research through the MistraPharma programme for the full financial support of this study.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.cej.2012.01.093.

References

- [1] K. Kimura, H. Hara, Y. Watanabe, Removal of pharmaceutical compounds by submerged membrane bioreactors (MBRs), *Desalination* 178 (2005) 135–140.
- [2] N.M. Vieno, T. Tulkanen, L. Kronberg, Seasonal variation in the occurrence of pharmaceuticals in effluents from a sewage treatment plant and in the recipient water, *Environ. Sci. Technol.* 39 (2005) 8220–8226.
- [3] K. Fent, A.A. Weston, D. Caminada, *Ecotoxicology of human pharmaceuticals*, *Aquat. Toxicol.* 76 (2006) 122–159.
- [4] S.A. Snyder, Occurrence treatment, and toxicological relevance of EDCs and pharmaceuticals in water, *Ozone-Sci. Eng.* 30 (2008) 65–69.
- [5] K.M.S. Hansen, H.R. Andersen, A. Ledin, Ozonation of estrogenic chemicals in biologically treated sewage, *Water Sci. Technol.* 62 (2010) 649–657.
- [6] Y. Lee, U. von Gunten, Oxidative transformation of micropollutants during municipal wastewater treatment: comparison of kinetic aspects of selective (chlorine, chlorine dioxide, ferrate^{VI}, and ozone) and non-selective oxidants (hydroxyl radical), *Water Res.* 44 (2010) 555–566.
- [7] T.A. Ternes, J. Stuber, N. Herrmann, D. McDowell, A. Ried, M. Kampmann, B. Teiser, Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater? *Water Res.* 37 (2003) 1976–1982.
- [8] F.J. Benitez, J.L. Acero, F.J. Real, G. Roldan, F. Casas, Comparison of different chemical oxidation treatments for the removal of selected pharmaceuticals in water matrices, *Chem. Eng. J.* 168 (2011) 1149–1156.
- [9] T.A. Ternes, Occurrence of drugs in German sewage treatment plants and rivers, *Water Res.* 32 (1998) 3245–3260.
- [10] M.M. Huber, S. Korhonen, T.A. Ternes, U. von Gunten, Oxidation of pharmaceuticals during water treatment with chlorine dioxide, *Water Res.* 39 (2005) 3607–3617.
- [11] H.R. Andersen, Use of ClO₂ for removal of estrogenic substances in wastewater, Patent WO2010/023311, March 2010.
- [12] S. Navalon, M. Alvaro, H. Garcia, Reaction of chlorine dioxide with emergent water pollutants: product study of the reaction of three β-lactam antibiotics with ClO₂, *Water Res.* 42 (2008) 1935–1942.
- [13] P. Wang, Y. He, C. Huang, Oxidation of fluoroquinolone antibiotics and structurally related amines by chlorine dioxide: reaction kinetics, product and pathway evaluation, *Water Res.* 44 (2010) 5989–5998.
- [14] G. Hey, A. Ledin, J. la Cour Jansen, H.R. Andersen, Removal of pharmaceuticals in biologically treated wastewater by chlorine dioxide or peracetic acid, *Environ. Technol.* (2011), doi:10.1080/0959330.2011.606282.
- [15] H.R. Andersen, M. Lundsby, H.W. Vedel, E. Eriksson, A. Ledin, Estrogenic personal care products in a greywater reuse system, *Water Sci. Technol.* 56 (2007) 45–49.
- [16] A. Ried, J. Mielcke, A. Wieland, The potential use of ozone in municipal wastewater, *Ozone-Sci. Eng.* 31 (2009) 415–421.
- [17] V. Csordas, B. Bubnis, I. Fabian, G. Gordon, Kinetics and mechanism of catalytic decomposition and oxidation of chlorine dioxide by the hypochlorite ion, *Inorg. Chem.* 40 (8) (2001) 1833–1836.
- [18] C. Korn, R.C. Andrews, M.D. Escobar, Development of chlorine dioxide-related by-product models for drinking water treatment, *Water Res.* 36 (2002) 330–342.
- [19] Y. Lee, H. Kim, U. Lee, Formation of chlorite and chlorate from chlorine dioxide with Han river water, *Korean J. Chem. Eng.* 21 (3) (2004) 647–653.
- [20] D. Gates, G. Zigliio, K. Ozekin, *State of the Science of Chlorine Dioxide in Drinking Water*, American Water Research Foundation, 2011, ISBN: 9781605730509.
- [21] M.M. Huber, Elimination of pharmaceuticals during oxidative treatment of drinking water and wastewater: application of ozone and chlorine dioxide, Dissertation, Swiss Federal Institute of Technology Zurich, 2004.
- [22] A. Katz, N. Narkis, Removal of chlorine dioxide disinfection by-products by ferrous salts, *Water Res.* 35 (1) (2001) 101–108.

- [23] M.H. Griese, K. Hauser, M. Berkemeier, G. Gordon, Using reducing agents to eliminate chlorine dioxide and chlorite ion residuals in drinking water, *J. Am. Water Works Ass.* 83 (5) (1991) 56–61.
- [24] M. Hörsing, A. Ledin, R. Grabic, J. Fick, M. Tysklind, J. La Cour Jansen, H.R. Andersen, Determination of sorption of seventy-five pharmaceuticals in sewage sludge, *Water Res.* 45 (2011) 4470–4482.
- [25] R. Grabic, J. Fick, R.H. Lindberg, G. Fedorova, M. Tysklind, Multi-residue method for determination of trace levels of 100 pharmaceuticals in environmental samples using liquid chromatography coupled to triple quadrupole mass spectrometry, unpublished results.
- [26] J. Hoigné, H. Bader, Kinetics of reaction of chlorine dioxide (OClO) in water – I. Rate constants for inorganic and organic compounds, *Water Res.* 28 (1) (1994) 45–55.
- [27] B. Razavi, W. Song, W.J. Cooper, J. Greaves, J. Jeong, Free-radical-induced oxidative and reductive degradation of fibrate pharmaceuticals: kinetic studies and degradation mechanisms, *J. Phys. Chem. A* 113 (2009) 1287–1294.
- [28] T. Kosjek, H.R. Andersen, B. Kompare, A. Ledin, E. Heath, Fate of carbamazepine during water treatment, *Environ. Sci. Technol.* 43 (2009) 6256–6261.
- [29] A.B.C. Alvares, C. Diaper, S.A. Parsons, Partial oxidation by ozone to remove recalcitrance from wastewaters: a review, *Environ. Technol.* 22 (2010) 409–427.
- [30] M.M. Huber, A. Göbel, A. Joss, N. Hermann, D. Löffler, C.S. Mcardell, A. Ried, H. Siegrist, T.A. Ternes, U. von Gunten, Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: a pilot study, *Environ. Sci. Technol.* 39 (2005) 4290–4299.
- [31] M.O. Buffle, U. von Gunten, Phenols and amine induced HO[•] generation during the initial phase of natural water ozonation, *Environ. Sci. Technol.* 40 (2006) 3057–3063.
- [32] V.K. Sharma, Oxidative transformation of environmental pharmaceuticals by Cl₂, ClO₂, O₃ and Fe (VI): kinetics assessment, *Chemosphere* 73 (2008) 1379–1386.
- [33] D. Vogna, R. Marotta, A. Napolitano, R. Andreozzi, M. d'Ischia, Advanced oxidation of the pharmaceutical drug diclofenac with UV/H₂O₂ and ozone, *Water Res.* 38 (2004) 414–422.
- [34] A.O. Ifelebugu, The fate and behaviour of selective endocrine disrupting chemicals in full scale wastewater and sludge treatment unit processes, *Int. J. Environ. Sci. Technol.* 8 (2011) 245–254.
- [35] J.L. Oaks, M. Gilbert, M.Z. Virani, R.T. Watson, C.U. Meteyer, B.A. Rideout, H.L. Shivaprasad, S. Ahmed, M.J.I. Chaudry, M. Arshad, S. Mahmood, A. Ali, A.A. Khan, Diclofenac residues as the cause of vulture population decline in Pakistan, *Nature* 427 (2004) 630–633.
- [36] V. Naidoo, G.E. Swan, Diclofenac toxicity in Gyps vulture is associated with decreased uric acid excretion and not renal portal vasoconstriction, *Comp. Biochem. Phys. C* 149 (2009) 269–274.

Web reference

<http://www.fass.se/LIF/home/index.jsp> (accessed 22.07.11).

Paper III

Required ozone doses for removing pharmaceuticals from wastewater effluents

Maria G. Antoniou^{1,2}, Gerly Hey³, Sergio Rodríguez Vega⁴, Aikaterini Spiliotopoulou¹, Jerker Fick⁵, Mats Tysklind⁵, Anna Ledin³, Jes la Cour Jansen³, and Henrik Rasmus Andersen^{1,*}

¹Department of Environmental Engineering, Technical University of Denmark, Miljøvej, Building 113, 2800 Kongens Lyngby, Denmark

²Department of Environmental Science and Technology, Cyprus University of Technology, PO Box: 50329, 3603 Lemesos, Cyprus

³Water and Environmental Engineering at Department of Chemical Engineering, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden

⁴Departamento de Ingeniería Química, Facultad de Ciencias Químicas, Universidad Complutense Madrid, 28040 Madrid, Spain

⁵Department of Chemistry, Umeå University, SE-90187 Umeå, Sweden

Abstract

The aim of the present study was to investigate the ozone dosage required to remove active pharmaceutical ingredients (APIs) from biologically treated wastewater of varying quality originating from different raw wastewater and wastewater treatment processes. Secondary effluents from six Swedish wastewater treatment plants (WWTP) were spiked with 42 APIs (nominal concentration 1 µg/L) and treated with different O₃ doses (0.5-12.0 mg/L ozone) in bench- scale experiments.

In order to obtain a parameter to compare the sensitivity of APIs in each matrix the specific dose of ozone required to achieve one decade of removal of each investigated API (DDO₃) was determined for each effluent by fitting a first order equation to the remaining concentration of API at each applied ozone dose. Ozone dose requirements were found to vary significantly between effluents depending on their matrix characteristics.

The specific ozone dose was then normalized to the dissolved organic carbon (DOC) of each effluent. The DDO₃/DOC ratios were comparable for each API between the effluents. Seventeen of the 42 investigated APIs could be classified as easily degradable (DDO₃/DOC ≤ 0.7), while 17 were moderately degradable (0.7 < DDO₃/DOC ≤ 1.4) and 8 were recalcitrant towards O₃-treatment (DDO₃/DOC > 1.4). Furthermore, we predict that a reasonable estimate of the required ozone dose required to remove any of the investigated APIs may be attained by

multiplying the experimental average DDO_3/DOC obtained with the actual DOC of any effluent.

Keywords: matrix effects; ozonation; ozone dose, pharmaceuticals, wastewater.

Introduction

The modern life-style of developed countries involves daily usage of artificial compounds such as active pharmaceutical ingredients (API), personal care products, hormones, pesticides and other environmentally persistent chemicals. As a result residues of these compounds become micropollutants in wastewater (Fick et al., 2010; Hollender et al., 2009; Richardson, 2010; Gerrity and Snyder, 2011; Huber et al., 2005; Richardson, 2010). Of all groups of micropollutants the vast majority of research activities are currently focused on the fate of active pharmaceutical ingredients during wastewater treatments (Hollender et al., 2009; Huber et al., 2003; Huber et al., 2005; Lee and von Gunten, 2010; McDowell et al., 2005; Zimmermann et al., 2011). APIs by purpose are generally designed to illicit a specific biological action. Due to their use pattern release to the environment is mainly via sewage outlets into surface waters. APIs are usually found at concentrations ranging from pg/L - $\mu\text{g/L}$ in wastewater and surface waters influenced by wastewater outlets. However, in many cases chronic exposure of APIs to humans and wildlife even at these low concentrations is both of scientific and societal concern (Richardson, 2010). To address this problem many WWTPs consider incorporating an additional treatment process step to remove APIs from the effluent. Treatment with O_3 appears to be one of the most promising technologies for the removal of these compounds (Ternes et al., 2003; Hansen et al., 2010; Hollender et al., 2009; Huber et al., 2003; Huber et al., 2005; Lee and von Gunten, 2010; Zimmermann et al., 2011).

One of the first studies which showed the efficiency of ozonation for removal of micropollutants in biological treated wastewater was by Ternes et al. (2003). Ozonation was employed at 5.0 to 15.0 mg/L of O_3 to investigate the removal efficiency (Ternes et al., 2003) for selected APIs, personal care products and iodated X-ray contrast media. Pharmaceuticals and personal care products were removed sufficiently by only 5 mg/L of O_3 while the iodated X-ray contrast media were only partially removed by 15 mg/L of O_3 . However, as there is not much toxicological concern for iodated X-ray contrast media results were interpreted as promising and more optimised treatment studies were conducted which reported efficient removal of pharmaceuticals and hormones in wastewater at lower O_3 doses (2.0-3.5 mg/L) (Bahr et al., 2007; Hansen et al., 2010; Huber et al., 2005). Estimating the removal efficiencies of APIs from wastewater effluents in bench and pilot scale experiments, was the main focus of subsequent studies (Hollender et al., 2009; Huber et al., 2003; Zimmermann et al., 2011). For example, Hollender et al. (2009) studied the removal efficiencies of 220 pharmaceuticals in full scale

with conventional activated sludge sewage treatment followed by ozonation and sand filtration. Kinetic studies and modeling of ozonation based on reactor hydraulics, O₃ chemistry and reaction kinetics were also performed for a full scale municipal wastewater facility (Zimmermann et al., 2011).

Generally, APIs and other micropollutants are easy to degrade, i.e. can be removed with low ozone dosage, if they react reasonable fast with molecular ozone. If a micropollutant does not react well with ozone it will still degrade with higher applied ozone dosage via a secondary oxidation mechanism by which ozone in water is converted to the hydroxyl radical, HO[•], which is very reactive (non-selective) to most organic molecules.

Up to now, the parameter most commonly used by researchers to determine how well an API reacts with O₃, is the second order rate constant with O₃ ($k_{O_3,API}$, selective oxidation) and HO[•] ($k_{HO,API}$, non-selective oxidation) (Hollender et al., 2009; Huber et al., 2003; Zimmermann et al., 2011). According to these studies, compounds with $k_{O_3,API}$ greater than 10⁴ M⁻¹s⁻¹, require low delivered O₃ doses (easily degraded). Compounds with $k_{O_3,API} < 10^4$ M⁻¹s⁻¹, are more persistent to O₃ treatment and therefore their degradation occurs mainly via reaction with HO[•], the secondary degradation route of ozonation.

However, of the several hundred APIs which have been detected in WWTP effluents (Ternes et al., 1998; Kolpin et al., 2002; Hollender et al., 2009; Fick et al., 2011; Falås et al., 2012a) very few have had their respective $k_{O_3,API}$ and $k_{HO,API}$ determined (Benner and Ternes, 2009; Buffle et al., 2006a; Dodd et al., 2006; Huber et al., 2003; Huerta-Fontela et al., 2011). In fact, constants are available for less than 10% of the model APIs used in this study (Supplementary Information Table S1). Even when these two rate constants ($k_{O_3,API}$ and $k_{HO,API}$) are known for an API, an experiment to determine the ozone and HO exposure that results from an ozone dose in the specific wastewater is needed before the degradation of the API can be predicted (Huber et al., 2005; Buffle et al., 2006b).

With O₃ production being an energy intensive process (Kim and Tanaka, 2011), it is important for WWTPs to use optimum O₃ doses that achieve sufficient API degradation while maintaining low operational cost (Bahr et al., 2007; Hansen et al., 2010). APIs exhibit different susceptibilities to O₃ degradation which can vary up to 10 orders of magnitude (Hoigne and Bader, 1983; Hollender et al., 2009; Huber et al., 2003). They are also competing for O₃ degradation with the organic components found in the matrix of the WWTP effluent (Hollender et al., 2009) that vary in amount and quality depending on the treatment process and origin of wastewater. This makes it particularly difficult to predict the required O₃ dosage requirements (DO₃) for satisfactory API removal in WWTP effluents, which is crucial parameter in estimating treatment design and therefore cost.

This study investigated the delivered O₃ dose (0.5 mg/L ≤ DO₃ ≤ ~12 mg/L) needed to achieve one order of magnitude of removal of 42 APIs (at low

concentrations, $\mu\text{g/L}$, Table S1) from 6 Swedish WWTP effluents. These APIs are commonly found in the WWTP effluents of Sweden (Fick et al., 2011, 2012; Falås et al., 2012a) and have different susceptibilities to ozonation (Benner and Ternes, 2009; Buffle et al., 2006a; Dodd et al., 2006; Hoigne and Bader, 1983; Huber et al., 2003). Effluents used in the experiments were chosen to represent typical variations observed in the main traditional characteristics of effluent quality that would occur due to different treatment processes currently employed in Sweden and also variability in raw water, i.e. COD, alkalinity and $\text{NH}_4^+\text{-N}$ content (Table 1). Since APIs reacting with ozone also compete with the matrix components of the effluent, an attempt was made to correlate the DO_3 with the effluent characteristics.

Materials and Methods

Chemicals

All pharmaceutical reference standards were of analytical grade (> 98%) purchased from different suppliers (Table S2). A stock solution of the APIs was prepared in methanol (Merck, Darmstadt, Germany) at concentration of about 100 mg/L. An O_3 stock solution was prepared in Milli-Q water (Millipore, Billerica, MA) as described in Antoniou and Andersen (2011).

Wastewater effluents

Effluents from five WWTPs in Sweden, including Källby (Effluent 1&2), Björnstorp (Effluent 3), Oresundsverket (Effluent 4), Sjölunda (Effluent 5), and Nykvarnsverket (Effluent 6) were used in this study. Effluent 1 and Effluent 2 were from the same treatment plant but were collected on separate occasions with a 3-week time interval. Although Effluent 1 and Effluent 2 came from the same WWTP, they were treated as 2 different effluents due to the variability of their characteristics. This difference is attributed to the significant rainfall events which occurred following the first sampling round. These precipitation events most likely caused a sludge wash-out, reducing the biological treatment efficiency and increasing the COD value, while at the same time alkalinity reduced because of dilution with rain water. The characteristics and treatment processes that are performed at each WWTP are listed in Table 1 and extensively described in S.I., respectively.

Table 1. Source and characterization of the wastewater effluents.

| WWTP | Källby 1 | Källby 2 | Björnstorp | Öresundsv | Sjölunda | Nykvarnsv |
|--|-------------|-------------|------------|-----------|----------|-----------|
| | Eff 1 | Eff 2 | Eff 3 | Eff 4 | Eff 5 | Eff 6 |
| COD, mg/L | 29 | 51 | 30 | 36 | 90 | 44 |
| DOC, mg/L | 7.5 | 6.5 | 5.2 | 8.1 | 13.7 | 8.4 |
| Alkalinity, mg HCO ₃ ⁻ /L | 244 | 154 | 185 | 229 | 256 | 164 |
| pH | 6.6 | 6.7 | 7.0 | 7.2 | 6.7 | 6.8 |
| NH ₄ ⁺ -N, mg/L | 1.36 | 2.98 | 0.77 | 4.93 | 1.86 | 5.98 |

Experimental set-up

Effluent was spiked with the APIs standard to give a nominal concentration of 1 µg/L, and then transferred into borosilicate glass vials, where different volumes of O₃ stock solution were added (in triplicate) to give nominal concentrations between 0.5 and ~12 mg/L O₃ for a total volume of 150 mL. Vials were placed in a covered water bath at 15°C.

Analysis

DOC, pH, alkalinity (mg HCO₃⁻/L), COD, and NH₄⁺-N concentrations in the effluent were quantified based on standard methods. The DO₃ was measured with the colorimetric method of indigo ($\lambda = 600\text{nm}$), by preparing bottles with indigo trisulfonate solution in Milli-Q water in parallel with the treatment samples (Antoniou and Andersen, 2011; Bader and Hoigne, 1981). After SPE extraction, the APIs were quantified by LC/MS/MS using a triple-stage quadrupole mass spectrometer (MS/MS TSQ Quantum Ultra EMR) coupled to an Accela LC pump (both from Thermo Fisher Scientific, San Jose, CA, USA) and a PAL HTC autosampler (CTC Analytics AG, Zwingen, Switzerland) with a Hypersil GOLD aQTM column (50 mm x 2.1 mm ID x 5 µm particles). The same method was used to investigate the fate of APIs in wastewater treatment by Hörsing et al. (2011) and Hey et al. (2012) and a full method evaluation and detailed description of the method are given in Grabic et al. (2012).

Results and Discussion

Removal of APIs from 6 WWTP effluents: Effect of wastewater matrix

In this study, 42 APIs commonly found in WWTP effluents in Sweden were spiked in six different WWTP effluents and treated with O₃ to evaluate their removal efficiencies and the effect of the matrix. Figure 1 summarizes the contribution of each O₃ dose (0.5 to ~12.0 mg/L O₃) on the removal of the APIs in 2 (Effluent 1 and 5) of the six WWTP effluents. The two wastewaters represent the 2 distinct types of wastewaters in Sweden, where Effluent 1 represents activated sludge plants with extended nitrogen and phosphorous removal present in the Southern part of the country and Effluent 5 the high loaded activated sludge plants with only removal of organic matter and phosphorous, mainly can be found in the Northern part of Sweden where no nitrogen removal is needed. The same data is also shown in Figure S1 (for all effluents) and Figures S2 to S7 but plotted in a less condensed manner allowing representation of experimental variation. A general trend can be seen whereby increasing O₃ dosage increases API removal efficiency (Figure 1). However, great variability is observed in required O₃ dose to achieve removal of different APIs within the same effluent and for the same API between effluents.

For the lowest delivered O₃ dose (0.5-0.6 mg/L), Effluent 1 has the highest number of APIs exhibiting removal efficiencies between 50-100%, possibly due to its low COD values compared to other effluents. Low COD level reduces the competition for O₃ between the pharmaceuticals and the organic matrix of the wastewater. The high alkalinity value observed in this effluent (highest in the group, Table 1) did not seem to significantly affect the API removal. The APIs in Effluent 5 appear to be the most recalcitrant to O₃ treatment, with all exhibiting < 50% removal at the lowest delivered O₃ dosage. Increasing the O₃ dosage to ~8.9 mg/L has only little effect on API removal in this effluent, removing only 18 out of 42 by > 90%. Thus it can be noted that the high COD (~90 mg/L) level present in Effluent 5 contributed to inhibiting the API removal.

The APIs in the 3 effluents (Effluent 2, 3, and 6 and Figure S1) were removed by over 50% at the highest O₃ dosage. In Effluents 1 and 4, only 1 API had less than 50% removal while 7 of the APIs were poorly removed (< 50%) in Effluent 5 even with the highest O₃ dosage. Based on the results shown here, the susceptibility of the APIs to O₃ degradation appears to be highly dependent on the characteristics of the wastewaters studied, explaining the wide range of removal efficiencies that some APIs exhibited. Specifically, the synthetic steroid beclomethasone was removed between 0-98% in all effluents. Removal of fluconazole (antifungal) and flutamide (antiandrogen) ranged between 33-77% and 13-87%, respectively, inferring that the APIs were not effectively degraded (to reach the treatment goal of 90%) in any of the tested effluents with the applied O₃ doses.




Figure 1. Profiles of dose dependency for the removal of pharmaceuticals in the 2 investigated wastewaters.

Required ozone dose to achieve 90% removal of API in WWTP effluents

In order to determine the O_3 dosage that achieves 90% removal of each API in the effluent, the data shown on Figure 1 and also in Figure S1 were fitted with Equation 1 and the results summarized in Figures S2-S7. Equation 1 is an exponential formula that describes the remaining API concentration in relation to its initial concentration after a specific O_3 dose is delivered (DO_3). It is dependent on the fact that ozone's fate in the effluent is determined by the effluent's matrix and not significantly affected by the reaction with the APIs; therefore it is independent on the API concentration. The equation contains the O_3 dose required to remove 90% of the API as a constant (here noted as decadic dose of O_3 , DDO_3), allowing the determination of the standard error directly through curve fitting. The fitted parameter is named the decadic dose of O_3 , DDO_3 .

$$(Eq.1) \quad \log\left(\frac{C}{C_o}\right) = \frac{-DO_3}{DDO_3} \Leftrightarrow C = C_o \cdot 10^{-\left(\frac{DO_3}{DDO_3}\right)}$$

Equation 1 resembles the general formula used for the characterization of the effectiveness of energy intensive advanced treatment methods (Equation 2) recommended by IUPAC and described by Bolton et al. (2001). Equation 2 correlates the electrical energy dose (EED) with the residual concentration of the treatment target compound and uses the constant EEO which is the EED required to achieve 90% removal (Bolton et al., 2001).

$$(Eq.2) \quad \log\left(\frac{C}{C_o}\right) = \frac{-EED}{E_{EO}}$$

Equation 1 was suggested by Hansen et al., (2010) who used both Equations 1 and 2 to describe the effectiveness of O₃ treatment for estrogenic chemicals in WWTP effluents in terms of the O₃ and energy dosage applied. Based on the above, it was decided to use the same system of equations to describe the effectiveness of O₃-treatment for API removal from wastewater (Figures S2-S7).

In the present study, an apparent lag-phase towards degradation was observed at lower O₃ doses for some APIs and it wasn't until higher O₃ doses were applied that degradation occurred. Once the O₃ lag-phase dose was surpassed, a decrease in concentrations of the APIs with ozone dose was observed which is apparently similar to the curve shape (exponential decay) for the APIs which did not show this lag-phase. It is our belief, that the lag-phase is a result of the low reactivity of some APIs for direct reaction with O₃ in addition to competition with the wastewater matrix for O₃ degradation. Some of the matrix components react directly with O₃ and quickly consume the low O₃ doses, therefore reducing the chances of O₃ reacting with the target compounds. It is only when O₃ is added at higher doses, to satisfy the O₃ reactive part of the matrix, that enough O₃ remains for the APIs to be degraded either directly or through the secondary pathway which is mediated by HO• (O₃ + H₂O → 2HO• + O₂), assuming that O₃ remains in the wastewater long enough to break down to radical forms. To fit the concentration curves of the pharmaceuticals that showed an apparent lag of reactivity towards low O₃ doses, a variation of Equation 1 was developed and shown as Equation 3 (see Figure S8 for graphical representation).

$$(Eq.3) \quad \begin{aligned} IF : DO_3 < LagO_3 &\rightarrow C = C_o \\ IF : DO_3 > LagO_3 &\rightarrow C = C_o \cdot 10^{-\left(\frac{DO_3 - LagO_3}{D}\right)}; \quad DDO_3 = D + LagO_3 \end{aligned}$$

The resulting estimated DDO_3 values of each API in all the effluents are presented in Table 2. Significant variation is observed in the DDO_3 values of a specific API depending on the wastewater effluent matrix. For example, carbamazepine exhibited a low DDO_3 of ~ 2 mg/L in Effluent 3, compared to the high DDO_3 of ~ 10 mg/L in Effluent 5. This confirms the strong influence exerted by the wastewater matrix components on pharmaceuticals removal efficiencies with O_3 . This has also been observed by Benitez et al. (2009) during O_3 -treatment of pharmaceuticals (including metoprolol and naproxen) in surface and ground water and wastewater. Their results showed higher pharmaceutical removal in surface water (alkalinity= 30 mg CaCO_3/L) compared to groundwater (alkalinity= 388 mg CaCO_3/L), while the effluent containing the lowest DOC and alkalinity had the highest removal among the 3 secondary effluents tested (Benitez et al., 2009).

Based on the above, and in order to categorize the different pharmaceuticals into easily degradable, moderately degradable and recalcitrant towards O_3 degradation, the Specific DDO_3 value was calculated by dividing the DDO_3 with the effluent DOC [DDO_3/DOC]. The selection criterion for an API to be characterized as easily degraded was decided to be a [DDO_3/DOC] value of $= 0.7$. Seventeen out of 42 investigated APIs fulfilled this criterion including repaglinide (antidiabetic), trimethoprim (antibiotic), carbamazepine (antiepileptic) and diclofenac (antiphlogistic) and naproxen (antiphlogistics). Seventeen APIs fulfilled the moderately degradable criterion of $0.7 < [\text{DDO}_3/\text{DOC}] = 1.4$ including sulfamethoxazole (antibiotic), metoprolol and bisoprolol (beta blockers) and citalopram, amitriptyline, maprotiline, venlafaxine, fluoxetine, bupropion and sertraline (antidepressants). The remaining 8 APIs, such as beclomethasone and the antiphlogistics ketoprofen and ibuprofen, were considered O_3 -recalcitrant since they have [DDO_3/DOC] > 1.4 .

Hollender et al. (2009) and Bahr et al. (2010) have also used the O_3 dose in relation to the DOC value of the wastewater to describe the treatment efficiency. In a study conducted by Hollender et al. (2009) on the removal of organic micropollutants from wastewater with O_3 including 24 pharmaceuticals, the fast reacting APIs sulfamethoxazole, diclofenac, carbamazepine and trimethoprim were eliminated at a dose of 0.47 g O_3/g DOC (dissolved organic carbon). In our study we found that the same compounds require from 0.55 up to 0.77 g O_3/g DOC for 90% removal. Furthermore, Bahr et al., (2010) reported the complete removal of naproxen, diclofenac and carbamazepine at a specific ozone dose of 0.5 g O_3/g DOC during ozonation of secondary WWTP effluents. Our study predicts the dosage required for 90 % removal of these APIs to be in the order of 0.61 - 0.66 g O_3/g DOC. While for slow reacting compounds, such as ibuprofen and ketoprofen, a specific ozone dose > 1 g O_3/g DOC is required for $> 95\%$ removal according to Bahr et al., 2010. In comparison, our work showed the dosage of ozone required for 90 % removal to be 1.61 and 1.51 g O_3/g DOC, respectively, for these two APIs.

Table 2: Ozone dose for removal of the first decade of each pharmaceutical in the wastewater and the dose relative to the DOC with estimated 95% confidence intervals. (NA* = compound not quantified; NA** = out of range, either <<lowest dose or >> highest dose of ozone applied)

| API | DDO ₃ (ppm O ₃) | | | | | | [DDO ₃ /DOC] | | | | | | |
|---|--|-------|-------|-------|-------|-------|-------------------------|-------|-------|-------|-------|-------|------|
| | Eff 1 | Eff 2 | Eff 3 | Eff 4 | Eff 5 | Eff 6 | Eff 1 | Eff 2 | Eff 3 | Eff 4 | Eff 5 | Eff 6 | Ave |
| <i>Easily degradable</i> | | | | | | | | | | | | | |
| Repaglinide | 2.6 | 3.7 | 1.8 | 4.1 | 8.7 | 1.5 | 0.35 | 0.57 | 0.35 | 0.50 | 0.64 | 0.18 | 0.43 |
| Ezetimibe | 3.2 | 4.6 | 1.5 | 3.8 | 8.0 | 2.0 | 0.43 | 0.71 | 0.29 | 0.47 | 0.58 | 0.24 | 0.45 |
| Diltiazem | 3.6 | 3.7 | 2.2 | 4.3 | 8.0 | 3.9 | 0.48 | 0.57 | 0.42 | 0.53 | 0.58 | 0.47 | 0.51 |
| Verapamil | <0.5 | 5.4 | <0.5 | 5.0 | 10.5 | 7.5 | 0.07 | 0.84 | 0.10 | 0.61 | 0.77 | 0.90 | 0.55 |
| Eprosartan | 3.2 | 4.9 | 1.9 | 4.5 | 9.1 | 4.2 | 0.43 | 0.76 | 0.37 | 0.55 | 0.66 | 0.50 | 0.55 |
| Trimethoprim | 4.0 | 4.3 | 2.1 | 4.4 | 9.7 | 3.9 | 0.53 | 0.67 | 0.40 | 0.54 | 0.71 | 0.47 | 0.55 |
| Clomipramine | 2.3 | 7.3 | 2.4 | 3.7 | 7.5 | 4.2 | 0.31 | 1.13 | 0.46 | 0.45 | 0.55 | 0.50 | 0.57 |
| Risperidone | 3.5 | 4.7 | 0.9 | 5.5 | 12.1 | 5.0 | 0.47 | 0.73 | 0.17 | 0.68 | 0.88 | 0.60 | 0.59 |
| Hydroxyzine | 3.4 | 5.7 | 1.9 | 4.8 | 10 | 4.8 | 0.45 | 0.88 | 0.37 | 0.59 | 0.73 | 0.57 | 0.60 |
| Codeine | 4.2 | 4.9 | 2.4 | 4.6 | 9.2 | 5.4 | 0.56 | 0.76 | 0.46 | 0.57 | 0.67 | 0.65 | 0.61 |
| Carbamazepine | 5.1 | 5.4 | 2.2 | 4.3 | 10.8 | 3.5 | 0.68 | 0.84 | 0.42 | 0.53 | 0.79 | 0.42 | 0.61 |
| Loperamide | 2.0 | 4.5 | <0.5 | 5.7 | >12 | 8.7 | 0.27 | 0.70 | 0.10 | 0.70 | 0.97 | 1.04 | 0.63 |
| Naproxen | 5.7 | 5.0 | 2.5 | 6.4 | 10 | 3.7 | 0.76 | 0.77 | 0.48 | 0.79 | 0.73 | 0.44 | 0.66 |
| Fexofenadine | 5.2 | 5.8 | 3.0 | 6.5 | 9.1 | 2.9 | 0.69 | 0.90 | 0.58 | 0.80 | 0.66 | 0.35 | 0.66 |
| Orphenadrine | 4.5 | 5.0 | 3.4 | 4.8 | 12.1 | 4.0 | 0.60 | 0.77 | 0.65 | 0.59 | 0.88 | 0.48 | 0.66 |
| Diclofenac | 4.7 | 5.8 | NA* | 3.5 | 10 | NA* | 0.63 | 0.90 | NA* | 0.43 | 0.73 | NA* | 0.67 |
| Cilazapril | 4.5 | 7.1 | 2.7 | 5.7 | 11 | 4.0 | 0.60 | 1.10 | 0.52 | 0.70 | 0.80 | 0.48 | 0.70 |
| <i>Moderately degradable</i> | | | | | | | | | | | | | |
| Glimepiride | 7.0 | 7.6 | 3.6 | 6.7 | >12 | 0.6 | 0.93 | 1.18 | 0.69 | 0.82 | NA** | 0.07 | 0.74 |
| Rosuvastatin | 5.4 | 5.6 | 3.3 | 5 | >12 | 4.8 | 0.72 | 0.87 | 0.63 | 0.61 | 1.06 | 0.57 | 0.74 |
| Haloperidole | 4.8 | 7.8 | 1.5 | 6.3 | 11.8 | 5.9 | 0.64 | 1.21 | 0.29 | 0.77 | 0.86 | 0.71 | 0.75 |
| Sulfamethoxazole | 4.8 | 4.5 | 3.6 | 4.5 | >12 | NA* | 0.64 | 0.70 | 0.69 | 0.55 | 1.28 | NA* | 0.77 |
| Tramadol | 5.7 | 5.8 | 3.4 | 6.3 | >12 | 6.4 | 0.76 | 0.90 | 0.65 | 0.77 | 0.95 | 0.77 | 0.80 |
| Citalopram | 5.0 | 7.8 | 2.0 | 7.1 | >12 | 5.0 | 0.67 | 1.21 | 0.38 | 0.87 | 1.09 | 0.60 | 0.80 |
| Sertraline | 6.4 | 5.2 | 1.7 | 7.9 | 12 | 11.6 | 0.85 | 0.81 | 0.33 | 0.97 | 0.88 | 1.39 | 0.87 |
| Venlafaxine | 5.3 | 6.3 | 3.4 | 6.4 | >12 | 9.3 | 0.71 | 0.98 | 0.65 | 0.79 | 1.21 | 1.11 | 0.91 |
| Maprotiline | 7.3 | 6.9 | 4.1 | 8.3 | >12 | 7.2 | 0.97 | 1.07 | 0.79 | 1.02 | 0.99 | 0.86 | 0.95 |
| Bisoprolol | 7.2 | 6.0 | 3.3 | 7.3 | >12 | 7.2 | 0.96 | 0.93 | 0.63 | 0.90 | 1.53 | 0.86 | 0.97 |
| Amitriptyline | 7.3 | 9.4 | 3.6 | 8.3 | >12 | 7.3 | 0.97 | 1.46 | 0.69 | 1.02 | 0.99 | 0.87 | 1.00 |
| Metoprolol | 6.9 | 6.9 | 3.8 | 7.4 | >12 | 8.8 | 0.92 | 1.07 | 0.73 | 0.91 | 1.33 | 1.05 | 1.00 |
| Biperiden | 5.9 | 6.3 | 4.3 | 7.3 | >12 | 7.4 | 0.78 | 0.98 | 0.83 | 0.90 | 1.68 | 0.88 | 1.01 |
| Levonorgestrel | 6.7 | 7.3 | 6.6 | 6.0 | >12 | 6.5 | 0.89 | 1.13 | 1.27 | 0.74 | 1.33 | 0.78 | 1.02 |
| Fluoxetine | 6.6 | 6.8 | 3.1 | 7.7 | >12 | 11.3 | 0.88 | 1.05 | 0.60 | 0.95 | 1.46 | 1.35 | 1.05 |
| Irbesartan | 8.7 | 7.7 | 5.4 | 11.5 | >12 | 4.3 | 1.16 | 1.19 | 1.04 | 1.41 | 1.00 | 0.51 | 1.05 |
| Bupropion | 8.1 | 8.0 | 5.2 | 9.3 | >12 | 12.1 | 1.08 | 1.24 | 1.00 | 1.14 | NA** | 1.45 | 1.18 |
| <i>Recalcitrant towards ozone degradation</i> | | | | | | | | | | | | | |
| Oxazepam | 12.3 | 11.3 | 7.1 | >12 | 18.4 | 9.7 | 1.64 | 1.75 | 1.37 | 1.66 | 1.34 | 1.16 | 1.49 |
| Ketoprofen | 13.4 | 12.7 | 5.5 | >12 | 23.9 | 9.7 | 1.78 | 1.97 | 1.06 | 1.62 | 1.74 | 1.16 | 1.56 |
| Memantine | 11.4 | 12.8 | 7.8 | >12 | 21.3 | 10.2 | 1.52 | 1.98 | 1.50 | 1.78 | 1.55 | 1.22 | 1.59 |
| Ibuprofen | 11.5 | 10.9 | 7.3 | >12 | 27 | 10.4 | 1.53 | 1.69 | 1.40 | 1.81 | 1.97 | 1.24 | 1.61 |
| Beclomethasone | 20 | 18 | 5.8 | 12 | >12 | 9.2 | 2.66 | 2.79 | 1.12 | 1.47 | NA** | 1.10 | 1.83 |
| Atracurium | 3.7 | 6.2 | 4.4 | 11 | 11.1 | 3.9 | 0.49 | 3.13 | 0.85 | 1.35 | 0.81 | 0.47 | 1.18 |
| Flutamide | >12 | >12 | 11.7 | >12 | >12 | 9.4 | NA** | 3.87 | 2.25 | 2.20 | NA** | 1.12 | 2.36 |
| Fluconazole | 15.1 | >12 | 10.7 | 20 | >12 | >12 | 2.01 | 2.79 | 2.06 | 2.46 | NA** | 2.63 | 2.39 |

Some APIs follow first-order decay with the added O₃ dose such as carbamazepine and naproxen (Figure S2-S7) while APIs such as beclomethasone and memantine exhibits an apparent lag phase before any significant degradation occurred. In Figure S2-S7, the intersection of the horizontal line with the y-axis indicates the

DDO₃ of the APIs. It is evident that Effluent 5 has the most O₃-recalcitrant pharmaceuticals and requires higher DDO₃ compared to the other effluents (Figures 2A and 2B).

Based on the data shown in Table 2, the average [DDO₃/DOC] for the majority of the APIs is = 1.2, while only a few exhibit a [DDO₃/DOC] > 1.5. Thus, an O₃ dose of 1.4 g per g DOC should be sufficient to remove (by at least 90%) more than 80% of the APIs tested in this study. However, in order to remove the most O₃-recalcitrant APIs as well, a twice as high O₃ dose ([DDO₃/DOC] > 2.4 g O₃ per g DOC) is needed which results in a significantly more costly treatment process.

Effect of chemical structure of the APIs on O₃ reactivity

The chemical structure of each API and the functional groups comprising it determine whether an API would be easy or difficult to degrade with O₃. Due to its electronic configuration, O₃ can perform different types of reactions in water including oxidation reactions, cycloadditions and electrophilic substitution reactions (Beltrán, 2004). Easily degradable APIs (relatively low [DDO₃/DOC] values) are characterized by the presence of electron-rich functional groups and they mainly react readily with O₃ through electrophilic substitution. These functional groups include C=C double bonds (found in eprosartan, carbamazepine), tertiary amines (repaglinide, clomipramine), aniline (diclofenac), phenol (ezetimibe) and methoxy groups (trimethoprim, verapamil, diltiazem, naproxen) (Hoigne and Bader, 1976; Huber et al., 2003; Huber et al., 2005; Nakada et al., 2007, Hollender et al., 2009).

APIs which are poorly removed (relatively high [DDO₃/DOC] values) generally contain electron-withdrawing functional groups, such as fluoro (flutamide, fluconazole), nitro (flutamide), chloro (beclomethasone), amide (flutamide) and carboxyl (ketoprofen) (Hey et al., 2012; Nakada et al., 2007; Acero et al., 2000; Hollender et al., 2011). Electron withdrawing groups reduce electron (e⁻) density of the pharmaceutical structure inhibiting electrophilic substitution reactions to occur. In addition, the electronegative groups themselves are less likely to react with O₃ and thus cause a shielding effect.

Some easily degradable APIs such as carbamazepine and diclofenac also contain electron-withdrawing functional groups (amide in carbamazepine, chloro and carboxyl in diclofenac) but remain O₃-reactive, inferring the presence and position of the high e⁻ density functional groups in their structure (Nakada et al., 2007) and counteract the inhibitory effect. Ibuprofen possesses no electron-rich functional group and is recalcitrant towards O₃ treatment (Huber et al., 2005) however can be adequately removed through biological treatment (e.g. Falås et al., 2012b). In addition, effective oxidative removal of O₃-resistant APIs may be possible through

the hydroxyl radical pathway (Antoniou et al., 2008; von Sonntag and von Gunten, 2012).

Conclusions

- The effect of O₃ dose on the degradation of 42 APIs in different WWTP effluents was investigated with large variability between APIs and effluent characteristics. In order to evaluate the effect of O₃ dose on pharmaceutical degradation, the results of the remaining API concentrations were fitted with the corresponding O₃ dose and the decadic dose of O₃ (DDO₃) was determined from the resultant curve of the 42 pharmaceuticals. The DDO₃ of a specific API varied significantly among the effluents investigated.
- DDO₃ was correlated with the effluent DOC by calculating the DDO₃/DOC for each API in every effluent. This enabled ranking of the different APIs into easily degradable, moderately degradable and recalcitrant to O₃-treatment categories.
- Following this practice, the required O₃ dose can be predicted based on the target pharmaceutical and the matrix component of the wastewater (DOC) to be treated.
- An O₃ dose of 1.4 g per g DOC removed (by at least 90%) more than 80% of the pharmaceuticals investigated. To remove the most O₃-recalcitrant APIs, a dose in the order of 2.4 g O₃ per g DOC is required.

Acknowledgements

The authors would like to thank the Swedish Foundation for Strategic Environmental Research through the MistraPharma programme for the financial support of this study. We are also grateful to the staff and process engineers of the Swedish WWTPs of Källby, Björnstorp, Öresundsverket, Sjölanda, and Nykvarnsverket for the wastewater samples they provided.

References

- Acero, J.L., Stemmler, K., von Gunten, U., 2000. Degradation kinetics of atrazine and its degradation products with ozone and OH radicals: A predictive tool for drinking water treatment. *Environmental Science and Technology* 34, 591-597.
- Antoniou, M.G., Andersen, H.R., 2013. Evaluation of pre-treatments for inhibiting bromate formation during ozonation. *Environmental Technology*. 33(15), 1747-1753.

- Antoniou, M.G., Shoemaker, J.A., De La Cruz, A.A., Dionysiou, D.D., 2008. Unveiling new degradation intermediates/pathways from the photocatalytic degradation of microcystin-LR, *Environmental Science and Technology* 23, 8877-8883.
- Bader, H., Hoigne, J., 1981. Determination of ozone in water by the indigo method. *Water Research* 15(4), 449-456.
- Bahr, C., Schumacher, J., Ernst, M., Luck, F., Heinzmann, B., Jekel, M., 2007. SUVA as control parameter for the effective ozonation of organic pollutants in secondary effluent. *Water Science and Technology* 55(12), 267-274.
- Beltrán, F. J., 2004. Ozone reaction kinetics for water and wastewater systems, Lewis Publishers, CRC Press LLC.
- Benner, J., Ternes, T.A., 2009. Ozonation of metoprolol: Elucidation of oxidation pathways and major oxidation products. *Environmental Science and Technology* 43(14), 5472-5480.
- Benitez, F.J., Acero, J.L., Real, F.J., Roldan, G., 2009. Ozonation of pharmaceutical compounds: Rate constants and elimination in various water matrices. *Chemosphere* 77, 53-59.
- Bolton, J.R., Bircher, K.G., Tumas, W., Tolman, C.A., 2001. Figures-of-merit for the technical development and application of advanced oxidation technologies for both electric- and solar-driven systems. *Pure and Applied Chemistry* 73(4), 627-637.
- Buffle, M.O., Schumacher, J., Salhi, E., Jekel, M., von Gunten, U., 2006a. Measurement of the initial phase of ozone decomposition in water and wastewater by means of a continuous quench-flow system: Application to disinfection and pharmaceutical oxidation. *Water Research* 40(9), 1884-1894.
- Buffle, M.O., Schumacher, J., Meylan, S., Jekel, M., Von Gunten, U., 2006b. Ozonation and advanced oxidation of wastewater: Effect of O₃ dose, pH, DOM and HO₂⁻-scavengers on ozone decomposition and HO[•] generation. *Ozone: Science and Engineering* 28(4), 247-259.
- Dodd, M.C., Buffle, M.O., Von Gunten, U., 2006. Oxidation of antibacterial molecules by aqueous ozone: Moiety-specific reaction kinetics and application to ozone-based wastewater treatment. *Environmental Science and Technology* 40(6), 1969-1977.
- Falås, P., Andersen, H.R., Ledin, A., la Cour Jansen, J., 2012a. Occurrence and reduction of pharmaceuticals in the water phase at Swedish wastewater treatment plants. *Water Science and Technology*. 66(4) 783–791.

- Falås, P., Baillon-Dhumez, A., Andersen, H.R., Ledin, A., la Cour Jansen, J., 2012b. Suspended biofilm carrier and activated sludge removal of acidic pharmaceuticals. *Water Research* 46, 1167-1175.
- Fick, J., Lindberg, R.H., Tysklind, M., Larsson, D.G., 2010. Predicted critical environmental concentrations for 500 pharmaceuticals. *Regulatory toxicology and pharmacology: RTP* 58(3), 516-523.
- Fick, J., Lindberg, R.H., Kaj, L., Brorström-Lundén, E., 2011. Results from the Swedish National Screening Programme 2010. Subreport 3. Pharmaceuticals. (www.ivl.se, Can be ordered with e-mail to: publicationservice@ivl.se,))
- Gerrity, D., Snyder, S., 2011. Review of ozone for water reuse applications: Toxicity, regulations, and trace organic contaminant oxidation. *Ozone: Science and Engineering* 33(4), 253-266.
- Grabic, R., Fick, J., Lindberg, R.H., Fedorova, G., Tysklind, M., 2012. Multi-residue method for determination of trace levels of 100 pharmaceuticals in environmental samples using liquid chromatography coupled to triple quadrupole mass spectrometry. *Talanta*. Accepted for publication.
- Hansen, K.M.S., Andersen, H.R., Ledin, A., 2010. Ozonation of estrogenic chemicals in biologically treated sewage. *Water Science and Technology* 62(3), 649-657.
- Hey, G., Grabic, R., Ledin, A., la Cour Jansen, J., Andersen, H.R., 2012. Oxidation of pharmaceuticals by chlorine dioxide in biologically treated wastewater. *Chemical Engineering Journal* 185-186, 236-242.
- Hoigne, H., Bader, H., 1983. Rate constants of reactions of ozone with organic and inorganic compounds in water. II. Dissociating organic compounds. *Water Research* 17(2), 185-194.
- Hollender, J., Zimmermann, S.G., Koepke, S., Krauss, M., McArdell, C.S., Ort, C., Singer, H., Von Gunten, U., Siegrist, H., 2009. Elimination of organic micropollutants in a municipal wastewater treatment plant upgraded with a full-scale post-ozonation followed by sand filtration. *Environmental Science and Technology* 43(20), 7862-7869.
- Huber, M.M., Canonica, S., Park, G.Y., von Gunten, U., 2003. Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. *Environmental Science and Technology* 37(5), 1016-1024.
- Huber, M.M., Göbel, A., Joss, A., Hermann, N., Löffler, D., McArdell, C.S., Ried, A., Siegrist, H., Ternes, T.A., von Gunten, U., 2005. Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: A pilot study. *Environmental Science and Technology* 39(11), 4290-4299.

- Huerta-Fontela, M., Galceran, M.T., Ventura, F., 2011. Occurrence and removal of pharmaceuticals and hormones through drinking water treatment. *Water Research* 45(3), 1432-1442.
- Hörsing, M., Ledin, A., Grabic, R., Fick, J., Tysklind, M., la Cour Jansen, J., Andersen, H.R., 2011. Determination of sorption of seventy-five pharmaceuticals in sewage sludge. *Water Research* 45, 4470-4482.
- Kim, I., Tanaka, H., 2011. Energy consumption for PPCPs removal by O₃ and O₃/UV. *Ozone: Science and Engineering* 33(2), 150-157.
- Kolpin, D.W., Furlong, E.T., Meyer, M.T., Thurman, E.M., Zaugg, S.D., Barber, L.B., Buxton, H.T., 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. *Environmental Science and Technology* 36, 1202-1211.
- Lee, Y., von Gunten, U., 2010. Oxidative transformation of micropollutants during municipal wastewater treatment: Comparison of kinetic aspects of selective (chlorine, chlorine dioxide, ferrateVI, and ozone) and non-selective oxidants (hydroxyl radical). *Water Research* 44(2), 555-566.
- McDowell, D.C., Huber, M.M., Wagner, M., von Gunten, U., Ternes, T.A., 2005. Ozonation of carbamazepine in drinking water: Identification and kinetic study of major oxidation products. *Environmental Science and Technology* 39(20), 8014-8022.
- Nakada, N., Shinohara, H., Murata, A., Kiria, K., Managaki, S., Satoh, N., Takada, H., 2007. Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. *Water Research* 41, 4373-4382.
- Richardson, S.D., 2010. Environmental mass spectrometry: Emerging contaminants and current issues. *Analytical Chemistry* 82(12), 4742-4774.
- Richardson, S.D., 2010. Environmental mass spectrometry: Emerging contaminants and current issues. *Analytical Chemistry* 82(12), 4742-4774.
- Ternes, T.A., 1998. Occurrence of drugs in German sewage treatment plants and rivers, *Water Research* 32, 3245-3260.
- Ternes, T.A., Stüber, J., Herrmann, N., McDowell, D., Ried, A., Kampmann, M., Teiser, B., 2003. Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater? *Water Research* 37(8), 1976-1982.
- Von Sonntag, C. and von Gunten, U., 2012. *Chemistry of ozone in water and wastewater treatment*. IWA Publishing, UK.
- Zimmermann, S.G., Wittenwiler, M., Hollender, J., Krauss, M., Ort, C., Siegrist, H., von Gunten, U., 2011. Kinetic assessment and modeling of an ozonation step

for full-scale municipal wastewater treatment: Micropollutant oxidation, by-product formation and disinfection. *Water Research* 45(2), 605-617.

Supplementary Information (SI): Required ozone doses for removing pharmaceuticals from wastewater effluents

Text S1: Description of WWTPs

Källby WWTP in Lund receives mainly domestic wastewater from 80,000 people. Incoming wastewater has annual average concentrations of approximately 180 mg/L BOD₇ and 40 mg/L Total Nitrogen. The wastewater is treated mechanically (screening, grit removal, and sedimentation), followed by a low loaded activated sludge process operated with pre-denitrification and enhanced biological phosphorous removal. Side stream hydrolysis is also performed in order to provide an additional carbon source and therefore enhance the biological phosphorous removal. Post-precipitation is used as a complementary process in case of insufficient biological phosphorous removal.












Sjölunda WWTP in Malmö receives wastewater from 300,000 people and a wide range of industries. Incoming wastewater has annual average concentrations of approximately 220 mg/L BOD₇ and 40 mg/L Total Nitrogen. The wastewater is treated mechanically (screening, grit removal, and pre-precipitation) first. The subsequent, high loaded activated sludge process is operated for BOD removal but an anaerobic/anoxic zone at the inlet is created for denitrification of aerobically treated reject water from the sludge handling facilities. Nitrification takes place in a subsequent nitrifying trickling filter followed by a moving bed biofilm reactor (MBBR) for denitrification. Flotation makes up the final particle separation step. The samples for the present study are taken after the high loaded activated sludge plant.













Öresundsverket WWTP in Helsingborg receives wastewater from 120,000 people and various industries. Incoming wastewater has annual average concentrations of approximately 180 mg/L BOD₇ and 30 mg/L Total Nitrogen. The wastewater is treated mechanically (screening, grit removal, and sedimentation) first. The primary sedimentation tanks are operated with primary sludge hydrolysis for the production of carbon source for enhanced biological phosphorous removal. Nitrogen removal and enhanced biological phosphorous removal takes place in a traditional UCT process. No chemicals for phosphorus removal are used at the plant.













Björnstorp WWTP in Lund is a very small plant only receiving domestic wastewater from about 200 people. Incoming wastewater is diluted and has annual average concentrations of approximately 70 mg/L BOD₇ and 21 mg/L Total Nitrogen. The wastewater passes through a cutting pump prior to sedimentation in a pre-precipitation process; followed by activated sludge for BOD removal. The treated water is then soil infiltrated. In this study, samples were taken after activated sludge treatment.








Nykvarnsverket WWTP in Linköping receives wastewater from 135,000 people and several industries. Incoming wastewater has annual average concentrations of approximately 280 mg/L BOD₇ and 45 mg/L Total Nitrogen. The wastewater is treated mechanically (screening, grit removal, and pre-precipitation) first. Then a low loaded activated sludge plant with nitrification only follows. Part of the nitrified effluent is diverted into a post-denitrification unit (Moving Bed Biofilm Reactor) where ethanol is used as carbon source. Finally all wastewater is treated in a post-precipitation plant for final polishing. In this study, samples were taken after the final post-precipitation stage.

Table S1: Structures* of the pharmaceuticals and estimated second order rate constants with O₃ and HO•.

| Name | Structure | k _{O₃,API} (M ⁻¹ s ⁻¹) | k _{HO•,API} (M ⁻¹ s ⁻¹) | References |
|----------------|---|--|--|---------------|
| amitriptyline |  | | | - |
| atracurium |  | | | - |
| beclomethasone |  | | | - |
| biperiden |  | | | - |
| bisoprolol |  | | | - |
| bupropion |  | | | - |
| carbamazepine |  | 3·10 ⁵ | (8.8±1.2)·10 ⁹ | (Huber, 2003) |
| cilazapril |  | | | - |
| citalopram |  | | | - |
| clomipramine |  | | | - |
| codeine |  | | | - |

| | | | | |
|--------------|---|--------|----------------------------|-----------------------------|
| diclofenac |  | 10^6 | $(7.5 \pm 1.5) \cdot 10^9$ | (Buffle, 2006; Huber, 2003) |
| diltiazem |  | | | - |
| eprosartan |  | | | - |
| ezetimibe |  | | | - |
| fexofenadine |  | | | - |
| fluconazole |  | | | - |
| fluoxetine |  | | | - |
| flutamide |  | | | - |
| glimepiride |  | | | - |
| haloperidole |  | | | - |
| hydroxyzine |  | | | - |
| ibuprofen |  | 9.6 | $7.4 \cdot 10^9$ | Buffle et al., 2006 |

| | | | | |
|----------------|---|---------------------------|----------------------------|---|
| irbesartan |  | | | - |
| ketoprofen |  | 0.4±0.07 | | Real et al., 2009 |
| levonorgestrel |  | | | - |
| loperamide |  | | | - |
| maprotiline |  | | | - |
| memantine |  | | | - |
| metoprolol |  | $(20 \pm 0.6) \cdot 10^3$ | $(7.3 \pm 0.2) \cdot 10^9$ | (Benner, 2008; Benner and Ternes, 2009) |
| naproxen |  | $2.62 \cdot 10^4$ | $2.97 \cdot 10^5$ | Benitez et al., 2009 |
| orphenadrine |  | | | - |
| oxazepam |  | | | - |
| repaglinide |  | | | - |
| risperidone |  | | | - |

| | | | | |
|------------------|---|------------------|----------------------------|-----------------------------|
| rosuvastatin |  | | | - |
| sertraline |  | | | - |
| Sulfamethoxazole |  | $2.5 \cdot 10^6$ | $(5.5 \pm 0.7) \cdot 10^9$ | (Buffle, 2006; Huber, 2003) |
| tramadol |  | | | - |
| trimethoprim |  | $2.7 \cdot 10^5$ | $(6.5 \pm 0.2) \cdot 10^9$ | (Dodd, 2006) |
| venlafaxine |  | | | - |
| verapamil |  | | | - |

*Chemical structures of the investigated APIs were taken from www.fass.se

Table S2: List of suppliers for APIs and the corresponding internal standards used for quantification.

| APIs | Supplier | Internal standards | Supplier |
|----------------|--|--|---|
| Amitriptyline | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Atracurium | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Beclomethasone | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_5$ - Oxazepam | Sigma- Aldrich (Steinheim, Germany) |
| Biperiden | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Bisoprolol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Bupropion | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Carbamazepine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_{10}$ - Carbamazepine | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Cilazapril | LGC Standards (Middlesex, UK) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Citalopram | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |

| | | | |
|--------------|--|--|---|
| Clomipramine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Codeine | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Diclofenac | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Diltiazem | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Eprosartan | CHEMOS GmbH (Regenstauf, Germany) | $^2\text{H}_{10}$ - Carbamazepine | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Ezetimibe | CHEMOS GmbH (Regenstauf, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Fexofenadine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Fluconazole | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ - Trimethoprim | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Fluoxetine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_5$ - Fluoxetine | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Flutamide | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories |

| | | | |
|----------------|--|---|---|
| | | | (Andover, MA, USA) |
| Glimepiride | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_5$ - Oxazepam | Sigma-Aldrich (Steinheim, Germany) |
| Haloperidole | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Hydroxyzine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Ibuprofen | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ - Ibuprofen | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Irbesartan | CHEMOS GmbH (Regenstauf, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Ketoprofen | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ $^2\text{H}_3$ - Naproxen | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Levonorgestrel | LGC Standards (Middlesex, UK) | $^{13}\text{C}_2$ - Ethinyl estradiol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Loperamide | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Maprotiline | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Memantine | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope |

| | | | |
|------------------|--|--|---|
| | Germany) | | Laboratories (Andover, MA, USA) |
| Metoprolol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Naproxen | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3\ ^2\text{H}_3$ - Naproxen | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Orphenadrine | LGC Standards (Middlesex, UK) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Oxazepam | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_5$ - Oxazepam | Sigma- Aldrich (Steinheim, Germany) |
| Repaglinide | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Risperidone | LGC Standards (Middlesex, UK) | $^2\text{H}_4$ - Risperidone | Sigma- Aldrich (Steinheim, Germany) |
| Rosuvastatin | CHEMOS GmbH (Regenstauf, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Sertraline | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Sulfamethoxazole | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_6$ - Sulfamethoxazole | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Tramadol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope |

| | | | |
|--------------|--|--|---|
| | Germany) | | Laboratories (Andover, MA, USA) |
| Trimethoprim | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ - Trimethoprim | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Venlafaxine | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Verapamil | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |

Table S3: Ionization mode, recoveries, relative standard deviation (RSD) and limit of quantification (LOQ) of the APIs.

| API | Ionization mode | Recovery (average of | RSD | LOQ |
|----------------|-----------------|----------------------|------|------|
| | | triplicate) | | |
| | | % | % | ng/L |
| Amitryptiline | HESI | 83.3 | 7.5 | 5 |
| Atracurium | HESI | 85.8 | 7.2 | 0.5 |
| Beclomethasone | HESI | 25.2 | 12.9 | 10 |
| Biperiden | HESI | 106 | 8.4 | 0.1 |
| Bisoprolol | HESI | 83.1 | 5.1 | 0.1 |
| Bupropion | HESI | 96.3 | 4.7 | 0.1 |
| Carbamazepine | HESI | 101 | 15.1 | 1 |
| Cilazapril | HESI | 143 | 5.9 | 1 |
| Citalopram | HESI | 83.6 | 8.5 | 5 |
| Clomipramine | HESI | 72.7 | 11.4 | 0.5 |
| Codeine | HESI | 86.7 | 24.0 | 0.5 |
| Diclofenac | HESI | 42.1 | 4.4 | 10 |
| Diltiazem | HESI | 107 | 3.8 | 0.5 |
| Eprosartan | HESI | 62.3 | 4.3 | 5 |
| Ezetimibe | HESI | 18.5 | 18.6 | 50 |
| Fexofenadine | HESI | 81.1 | 7.1 | 5 |
| Fluconazole | HESI | 89.8 | 12.9 | 0.5 |
| Fluoxetine | HESI | 97.0 | 11.4 | 5 |
| Flutamide | HESI | 91.8 | 3.9 | 5 |
| Glimepiride | HESI | 45.6 | 18.5 | 10 |
| Haloperidole | HESI | 64.0 | 12.7 | 0.1 |
| Hydroxyzine | HESI | 94.5 | 14.2 | 0.5 |
| Ibuprofen | APPI | 62.4 | 7.4 | 10 |
| Irbesartan | HESI | 109 | 2.6 | 0.5 |
| Ketoprofen | APPI | 73.2 | 7.4 | 10 |
| Levonorgestrel | APPI | 99.5 | 3.0 | 10 |
| Loperamide | HESI | 61.6 | 15.7 | 0.5 |
| Maprotiline | HESI | 84.1 | 7.4 | 5 |
| Memantine | HESI | 85.7 | 7.7 | 0.5 |
| Metoprolol | HESI | 82.9 | 1.3 | 5 |
| Naproxen | APPI | 95.5 | 4.5 | 10 |
| Orphenadrine | HESI | 94.7 | 11.2 | 0.1 |
| Oxazepam | HESI | 97.4 | 1.1 | 5 |
| Repaglinide | HESI | 93.4 | 8.6 | 0.5 |
| Risperidone | HESI | 101 | 2.4 | 0.1 |
| Rosuvastatin | HESI | 147 | 6.4 | 10 |

| | | | | |
|------------------|------|------|------|-----|
| Sertraline | HESI | 71.2 | 16.5 | 10 |
| Sulfamethoxazole | HESI | 97.3 | 4.3 | 5 |
| Tramadol | HESI | 129 | 6.3 | 0.5 |
| Trimethoprim | HESI | 109 | 10.7 | 0.1 |
| Venlafaxine | HESI | 96.2 | 7.8 | 0.5 |
| Verapamil | HESI | 85.5 | 8.8 | 10 |








Figure S1: Profiles of dose dependency for the removal of pharmaceuticals in the 6 investigated wastewaters.




Figure S2: Fraction of remaining API concentrations (Y axis) and the corresponding ozone dose in WWTP Effluent 1. The T-bar indicates the standard error of the mean calculated from triplicate experiments performed at each ozone dose.




Figure S3: Fraction of remaining API concentrations (Y axis) and the corresponding ozone dose in WWTP Effluent 2. The T-bar indicates the standard error of the mean calculated from triplicate experiments performed at each ozone dose.




Figure S4: Fraction of remaining API concentrations (Y axis) and the corresponding ozone dose in WWTP Effluent 3. The T-bar indicates the standard error of the mean calculated from triplicate experiments performed at each ozone dose.




Figure S5: Fraction of remaining API concentrations (Y axis) and the corresponding ozone dose in WWTP Effluent 4. The T-bar indicates the standard error of the mean calculated from triplicate experiments performed at each ozone dose.




Figure S6: Fraction of remaining API concentrations (Y axis) and the corresponding ozone dose in WWTP Effluent 5. The T-bar indicates the standard error of the mean calculated from triplicate experiments performed at each ozone dose.




Figure S7: Fraction of remaining API concentrations (Y axis) and the corresponding ozone dose in WWTP Effluent 6. The T-bar indicates the standard error of the mean calculated from triplicate experiments performed at each ozone dose.




Figure S8: Graphical representation showing how the experimental data were fitted to predict the DDO3 based on Eqs. 3 and 4.

Paper IV

Removal of pharmaceuticals in WWTP effluents by ozone and hydrogen peroxide

G. Hey^a, S.R. Vega^b, J. Fick^c, M. Tysklind^c, A. Ledin^a, J. la Cour Jansen^{a,*}, H.R. Andersen^d

^a Water and Environmental Engineering at Department of Chemical Engineering, Lund University, P.O. Box 124, 221 00 Lund, Sweden

^b Departamento de Ingeniería Química, Facultad de Ciencias Químicas, Complutense University, Madrid, 28040 Spain

^c Department of Chemistry, Umeå University, 901 87 Umeå, Sweden

^d Department of Environmental Engineering, Technical University of Denmark, Miljøvej, Building 113, 2800 Kongens Lyngby, Denmark

*Corresponding author: Jes la Cour Jansen, Tel: +46 46 2228999; Fax: +46 462224526

Email: jes.la_cour_jansen@chemeng.lth.se

Abstract

The ozonation of wastewater effluents with pH values in the upper and lower part of the typical range for Swedish wastewater was investigated. The aim was to study the effects of differences in pH (6.0 and 8.0) and of small additions of H₂O₂ prior to ozone treatment on the removal of pharmaceuticals, and to evaluate the possibilities of promoting the decomposition of ozone to OH radicals and the effect this can have on the removal of pharmaceuticals. The effluents selected differed in their chemical characteristics, particularly in terms of alkalinity (65.3-427 mg HCO₃⁻/L), COD (18.2-41.8 mg/L), DOC (6.9-12.5 mg/L), ammonium (0.02-3.6 mg/L) and specific UV absorbance (1.78-2.76 L/mg×m). Lower ozone decomposition rates were observed at pH 6.0 than at pH 8.0. The addition of H₂O₂ at pH 6.0 increased the decomposition rate, indicating that production of OH radicals was promoted. When pH 8.0 effluents were ozonated, a higher degree of pharmaceutical removal occurred in those with a low than in those with a high specific UV absorbance. For pH 6.0 effluents, the removal of pharmaceuticals was most efficient in the effluent with low COD and in the same range as in the pH 8.0 effluent with low specific UV absorbance. The addition of H₂O₂ had no significant effect on the removal of pharmaceuticals but enhanced the ozone decomposition

rate. Thus, the addition of H₂O₂ can reduce the reactor volume needed for the ozonation of wastewater effluents.

Keywords: ozonation; pharmaceuticals; specific UV absorbance; wastewater effluents

Introduction

A number of pharmaceuticals of differing therapeutic class together with their metabolites have been detected in aquatic environments (Ternes 1998; Kolpin et al. 2002; Fent et al. 2006; Batt et al. 2006; Snyder 2008; Verlicchi et al. 2012). The major source of these pharmaceuticals is considered to be the discharge of effluents by wastewater treatment plants (WWTPs) that are not designed for removing trace organic pollutants in view of the recalcitrance of such pollutants to biodegradation and their limited biological activity, especially in cold climates. Accordingly, additional treatment following biological treatment is called for.

Ozonation is one of the most promising technologies for the removal of organic micropollutants contained in wastewater. The efficiency of ozone in removing pharmaceuticals and personal care products both from water generally and from wastewater has been tested in both laboratory- and pilot-scale experiments (Ternes et al. 2003; Huber et al. 2005; Buffle et al. 2006a,b; Bahr et al. 2007; Benner and Ternes 2009; Hollender et al. 2009; Hansen et al. 2010; Zimmermann et al. 2011). Ozone-based oxidation can be more energy-efficient than UV-based oxidation, especially when used for treatment of waters high in UV absorbance (Rosenfeldt et al. 2006; Hansen and Andersen 2012).

One of the benefits of using ozonation in aqueous solutions is that the hydroxyl (OH) radicals that are produced react non-selectively with pharmaceuticals that are difficult to degrade (Lee and von Gunten 2010). The OH radicals can be generated through the self-decomposition of ozone in water matrix at pH levels above 7, the hydroxide ions acting as initiators (Hoigne and Bader 1983). The addition of hydrogen peroxide (H₂O₂) catalyzes the decomposition of ozone promoting the production of OH radicals (von Gunten 2003). Non-selective oxidation by highly reactive radicals usually enhances the rate of oxidation of ozone-resistant compounds, reducing the treatment time required (Zwiener and Frimmel 2000; Huber et al. 2003). Balcioglu and Ötöker (2003) reported that adding H₂O₂ enhances both the UV absorbance (at 254 nm) and the COD removal of wastewater. The rapid reaction of OH radicals is preferable in practice since it reduces the reactor size needed for such treatment. The efficiency of ozone treatment for the removal of pharmaceuticals can also depend upon the reactivity of the wastewater matrix in general (Nöthe et al. 2009). Depending upon the wastewater characteristics, the removal of a large fraction of pharmaceuticals may

require a relatively large ozone dose, since ozone can be consumed by other organic compounds.

The present study aimed at investigating the impact of different pH levels on the removal of pharmaceuticals from wastewater effluents by the addition of ozone, and also at evaluating the extent to which the reactivity of ozone can be promoted by the addition of small amounts of H₂O₂ at low pH levels. Since the addition of H₂O₂ can be expected to catalyze the decomposition of ozone to OH radicals, it can be of interest to investigate the effect this has in the case of effluents with a pH below 7, where the reaction rate can be expected to be lower and the pharmaceutical removal rate lower due to the lack of hydroxide ions that promote the decomposition of ozone.

Materials and methods

Overall experimental setup

Two effluents of relatively high pH (pH 8.0) were treated with ozone, whereas two other effluents, low in pH (pH 6.0) were treated with ozone in combination with H₂O₂. Treatment was carried out at these pH levels since they correspond to the upper and the lower range of pH values typically found in Swedish WWTP effluents. The effluents selected are from plants with extended nitrogen and phosphorous removal. The difference in pH is due to the origin of the potable water (ground versus surface waters). Further, the effluents also differ with respect to other chemical parameters such as alkalinity and ammonium and organic matter content. The pharmaceuticals investigated represent different therapeutic classes commonly used in Sweden, most of them having been found to be present in WWTP effluents (Falås et al. 2012).

The production of OH radicals by ozone decomposition was followed indirectly through measuring the ozone concentration. The experiments were carried out initially in effluents with a pH range of between 5 and 8 with the aim to determine the minimum amount of H₂O₂ needed to increase the decomposition of ozone.

Chemicals

The H₂O₂ solution (30%) employed was purchased from Sigma-Aldrich, the NaOH and H₂SO₄ being purchased from Merck (Germany). The pharmaceutical reference standards were purchased from different suppliers as analytical grade (> 98%) solids (Supplementary Information Table S1). The stock solution of pharmaceuticals was prepared in methanol at a concentration of 100 mg/L. The ozone stock solution was prepared in purified water (Millipore-Billerica, MA) as described in Antoniou and Andersen (2012).

WWTP effluents

The biologically-treated wastewater effluents investigated, differing in their characteristics and representing the typical variations in alkalinity, pH, and organic matter and ammonium content, were taken from four municipal WWTPs in Sweden: Öresundsverket (Effluent 1), Klagshamn (Effluent 2), Uppsala (Effluent 3) and Käppala (Effluent 4). The effluent samples differed from one another in pH on the day of collection and were adjusted at the start of the experiment by use of either NaOH or H₂SO₄ so as to be exactly pH 6.0 or pH 8.0. Table 1 shows the quality parameters of the effluents.

Table 1. Quality parameters of the effluent wastewaters studied.

| WWTPs | Öresundsverket | Klagshamn | Uppsala | Käppala |
|---|----------------|------------|------------|------------|
| | Effluent 1 | Effluent 2 | Effluent 3 | Effluent 4 |
| | High pH | High pH | Low pH | Low pH |
| COD, mg/L | 41.8 | 32.4 | 18.2 | 35.4 |
| DOC, mg/L | 9.2 | 9.0 | 6.9 | 12.5 |
| Initial alkalinity, mg HCO ₃ ⁻ /L | 347.7 | 427 | 79.9 | 65.3 |
| NH ₄ ⁺ -N, mg/L | 0.04 | 0.29 | 0.02 | 3.6 |
| UV abs _{254nm} , m ⁻¹ | 16.4 | 24.8 | 16.0 | 29.5 |
| pH (initial) | 7.2 | 7.6 | 6.6 | 6.3 |
| pH (adjusted) | 8.0 | 8.0 | 6.0 | 6.0 |
| SUVA, L/mg-m | 1.78 | 2.76 | 2.31 | 2.36 |

Analysis

COD and NH₄⁺-N were determined by use of the Hach Lange test kits LCK 114 and LCK 304. To measure alkalinity, a 25 ml sample was titrated with 0.05 M HCl to a pH of 4.5, the alkalinity in mg HCO₃⁻/L being calculated then. DOC was measured on the basis of wet chemical oxidation, using a Shimadzu TOC-Vwp analyzer. The UV-absorbance at 254 nm was measured using a Varian CARY50 Bio UV-Vis spectrophotometer. The specific UV absorbance (SUVA), an indicator of the dissolved aromatic carbon that the wastewater contains, known to affect the reactivity of DOC to ozone, was determined by normalizing UV absorbance at 254 nm to the DOC concentration (Weishaar et al. 2003). The O₃ doses delivered were analyzed by the colorimetric method of indigo ($\lambda = 600$ nm)

through preparing bottles of indigo trisulfonate solution in Milli-Q water in parallel with the treatment samples (Bader and Hoigne 1981; Antoniou and Andersen 2012).

For pharmaceutical analysis, 100 ml samples of the treated effluent were filtered through a 0.45 μm membrane filter (Millipore) and were acidified to pH 3 by use of sulfuric acid. After SPE extraction, LC/MS/MS analysis of the extracts was carried out, using a triple-stage quadrupole MS/MS TSQ Quantum Ultra EMR (Thermo Fisher Scientific, USA) coupled with an Accela LC pump (Thermo Fisher Scientific, USA) and a PAL HTC autosampler (CTC Analytics AG, Switzerland) having a Hypersil GOLD aQTM column (50 mm x 2.1 mm ID x 5 μm particles, Thermo Fisher Scientific, USA). The method of analysing pharmaceuticals was used earlier by Hörsing et al. (2011) and Hey et al. (2012). A detailed description and a full method evaluation are presented in Grabic et al. (2012). The ionization mode, recoveries, relative standard deviations (RSD) and limit of quantification (LOQ) of the pharmaceuticals are given in the Supplementary Information Table S2.

Experimental setup

For the ozone consumption experiments carried out, the biologically-treated municipal wastewater was ozonated at different pH levels and O_3 to H_2O_2 ratios. Samples were taken at different reaction times for analysis of the O_3 content. For experiments involving pharmaceutical removal, the wastewater effluents from four WWTPs were spiked with pharmaceuticals so as to provide a nominal concentration of $\sim 1 \mu\text{g/L}$. The spiked effluents were transferred then into borosilicate glass bottles (Schott Duran[®]) to which different volumes of O_3 stock solution were added to provide, in each case, a nominal concentration of between 1.4 and 10.7 mg/L O_3 for a total sample volume of 150 mL. The bottles were covered with aluminum foil and were placed for 2 hours in a 15°C water bath. For the O_3 and H_2O_2 experiments that were conducted, the H_2O_2 was added just prior to the addition of ozone. All treatment tests conducted were run in triplicates, a relative standard deviation of up to 20% between replicates being considered for data treatment.

Results and discussion

Determination of ozone concentration profiles at different pH

At each of the pH levels (pH 5-8) tested, the ozone concentration in the effluents decreased rapidly during the first minute after the addition of ozone. Thereafter, the rate of ozone decomposition decreased gradually and stabilized. This relatively fast ozone consumption was to be expected, due to the matrix components of the

wastewater consuming the oxidant. In addition, as can be seen in Figure 1, the decomposition of ozone tended to proceed faster at the highest pH value (pH 8) than at the lowest value tested (pH 5), in accordance with the results of other studies, such as those of Hoigne and Bader (1981) concerning water spiked with organic compounds and of Elovitz et al. (2000) concerning different surface and ground waters.

When H_2O_2 was added to the effluents at H_2O_2/O_3 ratios ranging from 2 to 0.25 (Figure 1), the added ozone was almost completely consumed during the first minute. As could be expected, the effluent of high pH (pH 8) exhibited the fastest ozone decomposition rate (< 1 minute) (Figure 1B). To confirm this, an additional experiment was also carried out at pH 6.0, involving use of a rather high initial ozone dose and lower doses of H_2O_2 , this resulting in significantly lower H_2O_2/O_3 ratios of 0.05-0.10. As can be seen in Figure 1C, the differences between the samples in the ozone removal rate are most obvious in the first minute or so of treatment, the decomposition of ozone appearing to increase with an increase in the H_2O_2/O_3 ratio for around 2 minutes, after which nearly all of the ozone appeared to have been consumed.




Figure 1. Ozone consumption in the WWTP effluent at pH 5 (A), at pH 8 (B) and at pH 6 (C) for different doses of H_2O_2 .

O₃ concentration profiles in the WWTP effluents tested

On the basis of the findings, even the addition of relatively small amounts of H_2O_2 is able to change the ozone concentration profile appreciably. To investigate this further, a set of experiments was carried out using four different effluent wastewaters (Table 1), two having a relatively high pH and two a relatively low pH. The effluents, after pH adjustments to 8.0 and 6.0, respectively, were treated with ozone so as to follow its decomposition (Figures 2A and 2B). In the high pH effluents (Figure 2A), about half of the ozone was already consumed during the first minute, especially in the case of Effluent 2. The differences observed were found to be related to the higher SUVA content in Effluent 2 than in Effluent 1 (Table 1). The relatively high content of aromatic compounds, indicated by the

relatively high SUVA level, could explain the increased ozone consumption in the early stages of treatment, due to fast reactivity of aromatic compounds. Such was also observed by Westerhoff et al. (1999). At pH 6.0, in contrast, Effluent 3 appears to have a much lower ozone demand than Effluent 4 (Figure 2B), this probably being due to the lower organic content of Effluent 3, which is only about half that of Effluent 4. Similar to what can be seen above (Figure 1), the addition of H_2O_2 to the effluent led to an increased decomposition of ozone, measured as decline in ozone concentration.




Figure 2. Ozone consumption in WWTP effluents (A) at pH 8.0 without H_2O_2 and (B) at pH 6.0, both with H_2O_2 (at a H_2O_2/O_3 ratio of 0.10) and without.

These findings show it to be important, when employing ozonation, to investigate the initial ozone demand of the wastewater. The present findings also show that at low pH the combination of ozone and H_2O_2 reduces the reaction time, this also indicating it to be possible to reduce the size of the reaction tank employed for treatment.

Removal of pharmaceuticals by O_3 and H_2O_2

In ozonation of pH 8.0 effluents there was found to be significant reduction in the different pharmaceuticals especially in the case of Effluent 1 (Figure 3A), already at relatively low doses of ozone. At the lowest dose (1.5 mg/L O_3), 9 of the 40 pharmaceuticals (clomipramine, sulfamethoxazole, repaglinide, ethinyl estradiol, fexofenadine, codeine, naproxen, diltiazem and eprosartan) were already removed to 90-100%, only 8 of the pharmaceuticals (bupropion, oxazepam, levonorgestrel, memantine, fluconazole, flutamide, ketoprofen and ibuprofen) exhibiting < 50% removal. As the ozone dose was increased, most of the pharmaceuticals including the less reactive ones too were degraded.




Figure 3. The contribution of each level of ozone dose to the removal of pharmaceuticals in Effluent 1 (A) and in Effluent 2 (B) during ozonation at pH 8.0.

On the other hand, in Effluent 2 (Figure 3B) the pharmaceuticals were poorly removed, even when the O_3 dose was increased. This can be attributed to the high SUVA level (2.76 as compared with 1.78) of this effluent. The high ozone reactivity of the aromatic components of the DOC may have contributed to the decrease in pharmaceutical removal in Effluent 2. In contrast, in Effluent 1, for which COD is high and SUVA is low, the pharmaceuticals appear to be more susceptible to indirect ozone reaction, initiated by secondary oxidants such as OH radicals, produced by the reaction of ozone with the organic components of the wastewater. According to Huber et al. (2003), a high concentration of organic components in the wastewater can enhance the decomposition of ozone so as to produce more OH radicals, a matter that could have a positive effect on pharmaceutical removal. Also, as can be observed in Figure 3, some of the

pharmaceuticals in Effluent 1 exhibited a high level of removal in response to the lowest ozone dose but did not follow the same pattern of removal in Effluent 2. For example, both clomipramine and repaglinide showed a high degree of removal at the lowest ozone dose, yet when treated with the same O₃ dose in Effluent 2, it was only clomipramine for which the degree of removal was significant (~50%). This shows clearly that both the level of removal and the reactivity of pharmaceuticals can vary, depending upon the composition of the wastewater involved.

The efficiency of ozone in removing pharmaceuticals from pH 6.0 effluents (Figure 4A) showed that ozone alone could remove > 90% of half of the pharmaceuticals present in Effluent 3 at the lowest ozone dose (1.8 mg/L). When the dose was increased to 4.4 mg/L, all of the pharmaceuticals except for fluconazole were degraded by over 90%. A still further increase in the ozone dose resulted in over 99% removal of all of the pharmaceuticals, except for fluconazole (93%) and ibuprofen (96%). In contrast, the ozonation of Effluent 4 resulted in > 90% degradation of the pharmaceuticals when rather high doses of ozone (> 5 mg/L) were employed (Figure 4B).

Figure 5 illustrates the contribution that the addition of H₂O₂ can make to the removal of those pharmaceuticals that have been shown to have the lowest reactivity towards ozone. For fluconazole (Effluent 3), as can be seen, there was only a slight increase in removal after the addition of H₂O₂, whereas for ibuprofen no improvement in its removal occurred. Thus, the addition of H₂O₂ (at an H₂O₂/O₃ ratio of 0.08-0.13) to an initial ozone dose of 10 mg/L could not be expected to have any appreciable impact on the removal of pharmaceuticals. For Effluent 4, the addition of H₂O₂ was found to enhance the removal of ibuprofen, fluconazole, levonorgestrel, sulfamethoxazole and ketoprofen by 4-16% but it reduced naproxen removal by ~15%. The overall findings here show that the reaction time can be reduced when ozone is combined with small amounts of H₂O₂, this being advantageous when practical implementation of the technology takes place. For most pharmaceuticals, however, this addition has no impact on the removal efficiency, i.e. neither increasing nor decreasing removal.




Figure 4. The contribution of each level of ozone dose to the removal of pharmaceuticals in Effluent 3 (A) and in Effluent 4 (B) during ozonation at pH 6.0.




Figure 5. The contribution of the addition of H₂O₂ to the removal of pharmaceuticals less reactive to ozone in Effluent 3 and Effluent 4.

The majority of pharmaceuticals included in this study contained acidic and/or basic groups, their thus having different charges (positive, neutral or negative) and, as a result, their possibly also differing in their tertiary chemical structure as a function of pH. The pharmaceuticals that are acids are protolysed at pH 6, no further changes occurring then when pH is increased to 8. In contrast, those pharmaceuticals that are bases and thus have low pK_a values go from being unprotolysed at pH 6 to being protolysed at pH 8, the charge thus changing from positive to neutral, which can result in a change in the tertiary structure. Those pharmaceuticals having both acidic and basic groups may also undergo changes in the charge and in their tertiary structure. This can be thought to have an impact on the oxidation rate. It is not possible, however, on the basis of the experiments carried out here, to draw any final conclusions regarding this.

Table 2 provides an overview of the findings regarding removal efficiencies for the pharmaceuticals that were investigated. It can readily be seen that an ozone dose of around 5 mg/L is sufficient to remove over half of the target pharmaceuticals, except in the case of Effluent 2, in which a higher ozone dose may be required for removing a large fraction of the pharmaceuticals, this most likely being due to the higher SUVA level it possesses. At the same time, it appears that, in the case of wastewaters such as Effluent 3 that are low in pH, a reasonable dose of ozone for being able to remove over 90% of the pharmaceuticals is one of 5 mg/L.

Table 2. Pharmaceuticals for which at least 90% removal (✓) occurs in each of the effluents when treated with ~5 mg/L O₃. (NA = compound not quantified)

| Pharmaceuticals | (High pH) | | (Low pH) | | Pharmaceuticals | (High pH) | | (Low pH) | |
|-----------------|-----------|-------|----------|-------|-----------------|-----------|-------|----------|-------|
| | Eff 1 | Eff 2 | Eff 3 | Eff 4 | | Eff 1 | Eff 2 | Eff 3 | Eff 4 |
| Amitriptyline | ✓ | — | ✓ | ✓ | Hydroxyzine | ✓ | — | ✓ | ✓ |
| Atracurium | ✓ | NA | ✓ | ✓ | Ibuprofen | — | — | ✓ | |
| Beclomethasone | — | — | ✓ | — | Irbesartan | ✓ | — | ✓ | ✓ |
| Biperiden | — | — | ✓ | — | Ketoprofen | — | — | ✓ | — |
| Bisoprolol | — | — | ✓ | — | Levonorgestrel | — | — | ✓ | — |
| Bupropion | — | — | ✓ | — | Loperamide | NA | ✓ | ✓ | ✓ |
| Carbamazepine | ✓ | — | ✓ | ✓ | Maprotiline | ✓ | — | ✓ | ✓ |

| | | | | | | | | | |
|-------------------|---|----|---|----|------------------|---|---|---|---|
| Cilazapril | ✓ | — | ✓ | ✓ | Memantine | — | — | ✓ | — |
| Citalopram | ✓ | — | ✓ | ✓ | Metoprolol | — | — | ✓ | — |
| Clomipramine | ✓ | — | ✓ | ✓ | Naproxen | ✓ | — | ✓ | ✓ |
| Codeine | ✓ | — | ✓ | ✓ | Orphenadrine | ✓ | — | ✓ | ✓ |
| Diclofenac | ✓ | — | ✓ | ✓ | Oxazepam | — | — | ✓ | — |
| Diltiazem | ✓ | — | ✓ | ✓ | Repaglinide | ✓ | — | ✓ | ✓ |
| Eprosartan | ✓ | — | ✓ | ✓ | Risperidone | ✓ | — | ✓ | ✓ |
| Ethinyl estradiol | ✓ | NA | ✓ | NA | Rosuvastatin | ✓ | — | ✓ | ✓ |
| Fexofenadine | ✓ | — | ✓ | ✓ | Sertraline | ✓ | — | ✓ | ✓ |
| Fluconazole | — | — | — | — | Sulfamethoxazole | — | — | ✓ | — |
| Fluoxetine | ✓ | — | ✓ | ✓ | Tramadol | — | — | ✓ | — |
| Flutamide | ✓ | — | ✓ | ✓ | Trimethoprim | ✓ | — | ✓ | ✓ |
| Haloperidol | ✓ | — | ✓ | ✓ | Venlafaxine | ✓ | — | ✓ | — |

The oxidation of pharmaceuticals can lead to the production of by-products. Since these can be toxic to varying degree as compared with the mother compound, toxicity evaluation of a given technology should be performed before it is considered for implementation.

Conclusions

The following conclusions can be drawn on the basis of the results of the study:

- Ozonation can be employed as an additional treatment step to enable trace pharmaceuticals to be removed effectively from wastewater effluents.
- The amount of ozone required for the removal of pharmaceuticals is dependent upon the chemical composition of the wastewater, and on the target compounds, the content of organic matter in general and its aromaticity being of considerable importance here.
- Ozone decomposition can be stimulated by adding hydrogen peroxide at low pH. This reduces the treatment time and, accordingly, the reaction volume needed. Since the addition of hydrogen peroxide has only a limited impact on the removal of pharmaceuticals, it has no negative effects in terms of reducing the reactor volume.

Acknowledgements

The authors would like to thank the Swedish Foundation for Strategic Environmental Research through its MistraPharma programme for the financial support of this study. We also thank the staff and the process engineers of the WWTPs of Öresundsverket, Klagshamn, Uppsala and Käppala for the wastewater samples they provided.

References

- Antoniou, M.G. and Andersen, H.R. 2012a Evaluation of pre-treatments for inhibiting bromate formation during ozonation. *Environmental Technology*, **33**(15), 1747-1753.
- Bader, H. and Hoigne, J. 1981 Determination of ozone in water by the indigo method. *Water Research*, **15**(4), 449–456.
- Bahr, C., Schumacher, J., Ernst, M., Luck, F., Heinzmann, B. and Jekel, M. 2007 SUVA as control parameter for the effective ozonation of organic pollutants in secondary effluent. *Water Science and Technology*, **55**(12), 267-274.
- Balcioglu, I.A. and Ötker, M. 2003 Treatment of pharmaceutical wastewater containing antibiotics by O₃ and O₃/H₂O₂ processes. *Chemosphere*, **50**, 85-95.
- Batt, A.L., Snow, D.D. and Aga, D.S. 2006 Occurrence of sulfonamide antimicrobials in private water wells in Washington County, Idaho, USA. *Chemosphere*, **64**, 1963-1971.
- Benner, J. and Ternes, T.A. 2009 Ozonation of metoprolol: Elucidation of oxidation pathways and major oxidation products. *Environmental Science and Technology*, **43**(14), 5472-5480.
- Buffle, M.O., Schumacher, J., Salhi, E., Jekel, M. and von Gunten, U. 2006a Measurement of the initial phase of ozone decomposition in water and wastewater by means of a continuous quench-flow system: Application to disinfection and pharmaceutical oxidation. *Water Research*, **40**(9), 1884-1894.
- Buffle, M.O., Schumacher, J., Meylan, S., Jekel, M. and von Gunten, U. 2006b Ozonation and advanced oxidation of wastewater: Effect of O₃ dose, pH, DOM and HO[•]-scavengers on ozone decomposition and HO[•] generation. *Ozone Science and Engineering*, **28**(4), 247-259.
- Elovitz, M., von Gunten, U. and Kaiser, H.P. 2000 Hydroxyl radicals/ozone ratios during ozonation processes. II. The effect of temperature, pH, alkalinity, and DOM properties. *Ozone Science and Engineering*, **22**, 123-150.

- Falås, P., Andersen, H.R., Ledin, A., la Cour Jansen, J. 2012 Occurrence and reduction of pharmaceuticals in the water phase at Swedish wastewater treatment plants. *Water Science and Technology*, **66**(4), 783-791.
- Fent, K., Weston, A.A. and Caminada, D. 2006 Ecotoxicology of human pharmaceuticals. *Aquatic Toxicology*, **76**, 122-159.
- Grabic, R., Fick, J., Lindberg, R.H., Fedorova, G., Tysklind, M. 2012 Multi-residue method for trace level determination of pharmaceuticals in environmental samples using liquid chromatography coupled to triple quadrupole mass spectrometry. *Talanta*, **100**, 183-195.
- Hansen, K.M.S., Andersen, H.R. and Ledin, A. 2010 Ozonation of estrogenic chemicals in biologically treated sewage. *Water Science and Technology*, **62**, 649-657.
- Hansen, K.M.S and Andersen, H.R. 2012 Energy effectiveness of direct UV and UV/H₂O₂ treatment of estrogenic chemicals in biologically treated sewage. *International Journal of Photoenergy*, **2012** Doi: 10.1155/2012/27030.
- Hey, G., Grabic, R., Ledin, A., la Cour Jansen, J. and Andersen, H.R. 2012 Oxidation of pharmaceuticals by chlorine dioxide in biologically treated wastewater. *Chemical Engineering Journal*, **185-186**, 236-242.
- Hoigne, H. and Bader, H. 1983 Rate constants of reactions of ozone with organic and inorganic compounds in water. II. Dissociating organic compounds. *Water Research*, **17**(2), 185-194.
- Hollender, J., Zimmermann, S.G., Koepke, S., Krauss, M., McArdell, C.S., Ort, C., Singer, H., von Gunten, U. and Siegrist, H. 2009 Elimination of organic micropollutants in a municipal wastewater treatment plant upgraded with a full-scale post-ozonation followed by sand filtration. *Environmental Science and Technology*, **43**(20), 7862-7869.
- Huber, M.M., Canonica, S., Park, G.Y. and von Gunten, U. 2003 Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. *Environmental Science and Technology*, **37**(5), 1016-1024.
- Huber, M.M., Göbel, A., Joss, A., Hermann, N., Löffler, D., McArdell, C.S., Ried, A., Siegrist, H., Ternes, T.A. and von Gunten, U. 2005 Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: A pilot study. *Environmental Science and Technology*, **39**(11), 4290-4299.
- Hörsing, M., Ledin, A., Grabic, R., Fick, J., Tysklind, M., la Cour Jansen, J., and Andersen, H.R. 2011 Determination of sorption of seventy-five pharmaceuticals in sewage sludge. *Water Research*, **45**, 4470-4482.

- Kolpin, D.W., Furlong, E.T., Meyer, M.T., Thurman, E.M., Zaugg, S.D., Barber, L.B. and Buxton, H.T. 2002 Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. *Environmental Science and Technology*, **36**, 1202-1211.
- Lee, Y. and von Gunten, U. 2010 Oxidative transformation of micropollutants during municipal wastewater treatment: Comparison of kinetic aspects of selective (chlorine, chlorine dioxide, ferrateVI, and ozone) and non-selective oxidants (hydroxyl radical). *Water Research*, **44**(2), 555-566.
- Nöthe, T., Fahlenkamp, H. and von Sonntag, C. 2009 Ozonation of wastewater: Rate of ozone consumption and hydroxyl radical yield. *Environmental Science and Technology*, **43**, 5990-5995.
- Rosenfeldt, E.J., Linden, K.G., Canonica, S. and von Gunten, U. 2006 Comparison of the efficiency of $\cdot\text{OH}$ radical formation during ozonation and the advanced oxidation processes $\text{O}_3/\text{H}_2\text{O}_2$ and $\text{UV}/\text{H}_2\text{O}_2$. *Water Research*, **40**, 3695-3704.
- Snyder, S.A. 2008 Occurrence, treatment, and toxicological relevance of EDCs and pharmaceuticals in water. *Ozone Science and Engineering*, **30**, 65-69.
- Ternes, T.A. 1998 Occurrence of drugs in German sewage treatment plants and rivers. *Water Research*, **32**, 3245-3260.
- Ternes, T.A., Stüber, J., Herrmann, N., McDowell, D., Ried, A., Kampmann, M. and Teiser, B. 2003 Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater? *Water Research*, **37**(8), 1976-1982.
- Verlicchi, P., Al Aukidy, M. and Zambello, E. 2012 Occurrence of pharmaceutical compounds in urban wastewater: Removal, mass load and environmental risk after a secondary treatment—A review. *Science of the Total Environment*, **429**, 123–155.
- Von Gunten, U. 2003 Ozonation of drinking water: Part I. Oxidation kinetics and product formation. *Water Research*, **37**, 1443-1467
- Weishaar, J.L., Aiken, G.R., Bergamaschi, B., Fram, M.S., Fugii, R. and Mopper, K. 2003 Evaluation of specific ultraviolet absorbance as an indicator of the chemical composition and reactivity of dissolved organic carbon. *Environmental Science and Technology*, **37**, 4702-4708.
- Westerhoff, P., Aiken, G., Amy, G. and Debroux, J. 1999 Relationships between the structure of natural organic matter and its reactivity towards molecular ozone and hydroxyl radicals. *Water Research*, **33**(10), 2265-2276.
- Zimmermann, S.G., Wittenwiler, M., Hollender, J., Krauss, M., Ort, C., Siegrist, H. and von Gunten, U. 2011 Kinetic assessment and modeling of an ozonation

step for full-scale municipal wastewater treatment: Micropollutant oxidation, by-product formation and disinfection. *Water Research*, **45**(2), 605-617.

Zwiener, C. and Frimmel, F.H. 2000 Oxidative treatment of pharmaceuticals in water. *Water Research*, **34**(6), 1881-1885.

Supplementary Information: Removal of pharmaceuticals in WWTP effluents by ozone and hydrogen peroxide

Table S1: List of suppliers for pharmaceuticals and the corresponding internal standards used for quantification.

| Pharmaceuticals | Supplier | Internal standards | Supplier |
|-----------------|---------------------------------------|--|---|
| Amitriptyline | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Atracurium | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Beclomethasone | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_5$ - Oxazepam | Sigma-Aldrich (Steinheim, Germany) |
| Biperiden | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Bisoprolol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Bupropion | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Carbamazepine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_{10}$ Carbamazepine | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Cilazapril | LGC Standards | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge |

| | | | |
|-------------------|------------------------------------|--|---|
| | (Middlesex, UK) | | Isotope Laboratories (Andover, MA, USA) |
| Citalopram | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Clomipramine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Codeine | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Diclofenac | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Diltiazem | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Eprosartan | CHEMOS GmbH (Regenstauf, Germany) | $^2\text{H}_{10}$ - Carbamazepine | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Ethinyl estradiol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_2$ - Ethinyl estradiol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Fexofenadine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories |

| | | | |
|-------------|---------------------------------------|---|---|
| | | | (Andover, MA, USA) |
| Fluconazole | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ - Trimethoprim | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Fluoxetine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_5$ - Fluoxetine | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Flutamide | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Haloperidol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Hydroxyzine | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Ibuprofen | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ - Ibuprofen | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Irbesartan | CHEMOS GmbH (Regenstauf, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Ketoprofen | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ $^2\text{H}_3$ - Naproxen | Cambridge Isotope Laboratories (Andover, MA, USA) |

| | | | |
|----------------|---------------------------------------|---|---|
| Levonorgestrel | LGC Standards (Middlesex, UK) | $^{13}\text{C}_2$ – Ethinyl estradiol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Loperamide | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Maprotiline | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Memantine | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Metoprolol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Naproxen | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ $^2\text{H}_3$ - Naproxen | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Orphenadrine | LGC Standards (Middlesex, UK) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Oxazepam | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_5$ - Oxazepam | Sigma-Aldrich (Steinheim, Germany) |
| Repaglinide | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, |

| | | | |
|------------------|---------------------------------------|--|---|
| | | | USA) |
| Risperidone | LGC Standards (Middlesex, UK) | $^2\text{H}_4$ - Risperidone | Sigma-Aldrich (Steinheim, Germany) |
| Rosuvastatin | CHEMOS GmbH (Regenstauf, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Sertraline | Sigma-Aldrich (Steinheim, Germany) | $^2\text{H}_6$ - Amitriptyline | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Sulfamethoxazole | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_6$ - Sulfamethoxazole | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Tramadol | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Trimethoprim | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}_3$ - Trimethoprim | Cambridge Isotope Laboratories (Andover, MA, USA) |
| Venlafaxine | Sigma-Aldrich (Steinheim, Germany) | $^{13}\text{C}^2\text{H}_3$ - Tramadol | Cambridge Isotope Laboratories (Andover, MA, USA) |

Table S2: Ionization mode, recoveries, relative standard deviation (RSD) and limit of quantification (LOQ) of the pharmaceuticals.

| Pharmaceuticals | Ionization mode | Recovery (average of triplicate) | RSD | LOQ |
|-------------------|-----------------|----------------------------------|------|------|
| | | % | % | ng/L |
| Amitryptiline | HESI | 83.3 | 7.5 | 5 |
| Atracurium | HESI | 85.8 | 7.2 | 0.5 |
| Beclomethasone | HESI | 25.2 | 12.9 | 10 |
| Biperiden | HESI | 106 | 8.4 | 0.1 |
| Bisoprolol | HESI | 83.1 | 5.1 | 0.1 |
| Bupropion | HESI | 96.3 | 4.7 | 0.1 |
| Carbamazepine | HESI | 101 | 15.1 | 1 |
| Cilazapril | HESI | 143 | 5.9 | 1 |
| Citalopram | HESI | 83.6 | 8.5 | 5 |
| Clomipramine | HESI | 72.7 | 11.4 | 0.5 |
| Codeine | HESI | 86.7 | 24.0 | 0.5 |
| Diclofenac | HESI | 42.1 | 4.4 | 10 |
| Diltiazem | HESI | 107 | 3.8 | 0.5 |
| Eprosartan | HESI | 62.3 | 4.3 | 5 |
| Ethinyl estradiol | APPI | 85.7 | 4.1 | 10 |
| Fexofenadine | HESI | 81.1 | 7.1 | 5 |
| Fluconazole | HESI | 89.8 | 12.9 | 0.5 |
| Fluoxetine | HESI | 97.0 | 11.4 | 5 |
| Flutamide | HESI | 91.8 | 3.9 | 5 |
| Haloperidole | HESI | 64.0 | 12.7 | 0.1 |
| Hydroxyzine | HESI | 94.5 | 14.2 | 0.5 |
| Ibuprofen | APPI | 62.4 | 7.4 | 10 |
| Irbesartan | HESI | 109 | 2.6 | 0.5 |

| | | | | |
|------------------|------|------|------|-----|
| Ketoprofen | APPI | 73.2 | 7.4 | 10 |
| Levonorgestrel | APPI | 99.5 | 3.0 | 10 |
| Loperamide | HESI | 61.6 | 15.7 | 0.5 |
| Maprotiline | HESI | 84.1 | 7.4 | 5 |
| Memantine | HESI | 85.7 | 7.7 | 0.5 |
| Metoprolol | HESI | 82.9 | 1.3 | 5 |
| Naproxen | APPI | 95.5 | 4.5 | 10 |
| Orphenadrine | HESI | 94.7 | 11.2 | 0.1 |
| Oxazepam | HESI | 97.4 | 1.1 | 5 |
| Repaglinide | HESI | 93.4 | 8.6 | 0.5 |
| Risperidone | HESI | 101 | 2.4 | 0.1 |
| Rosuvastatin | HESI | 147 | 6.4 | 10 |
| Sertraline | HESI | 71.2 | 16.5 | 10 |
| Sulfamethoxazole | HESI | 97.3 | 4.3 | 5 |
| Tramadol | HESI | 129 | 6.3 | 0.5 |
| Trimethoprim | HESI | 109 | 10.7 | 0.1 |
| Venlafaxine | HESI | 96.2 | 7.8 | 0.5 |

